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General Introduction and 
Aim of this Thesis
G e n e r a l  in t r o d u c t io n  a n d  a im  o f  t h is  t h e s is
OSTEOARTHRITIS
I ntroduction
Osteoarthritis (OA) is the most prevalent disorder that affects diarthrodial joints 1 and 
the prevalence of OA based on radiographic evidence has been recorded as high as 
70% in people aged over 65 2. A major characteristic of OA is degradation of the 
articular cartilage (Figure 1). Other aspects of OA involve changes in the subchondral 
bone, ligaments, synovium, periarticular muscles and osteophyte formation (Figure 
1) 3. Clinically, OA is presented with joint pain and stiffness, restricted movement, 
joint instability and deformities of the joint 4. Certain joints are frequently affected by 
OA, whereas other joints are rarely affected. Examples of joints that are commonly 
affected are the hand, spine, hip and knee. Joints that are often spared are the 
ankle, wrist, elbow and shoulder 5. Although the etiology of OA is unknown, risk 
factors for OA are high age, sex (women more than men), obesity and genetic 
predisposition.
F i g u r e  1
D ia g r a m s  d e p ic t in g  th e  c h a n g e s  t h a t  ta k e  p la c e  in a  kn ee  jo in t  d u r in g  th e  O A  p r o c e s s . N o te  th e  th in n in g  a n d
SUBSEQUENT LOSS OF ARTICULAR CARTILAGE, THE INCREASED THICKENING OF THE SYNOVIAL LAYER AND THE INCREASED
fo r m a t io n  o f  o s t e o p h y t e s . (A d a p t e d : A r th r it is  R e s e a r c h  C a m p a ig n ).
Cartilage
A thin layer of articular cartilage covers the articulating ends of bone. The function of 
this articular cartilage is to provide frictionless and painless movement of the joint. 
Articular cartilage can be deviled in two zones, the un-calcified layer and calcified 
layer, which are separated by the "tidemark", a zone of enhanced calcification 
parallel to the articular surface. Chondrocytes are the sole cell type residing in 
articular cartilage and in humans make up about 0.4-2% of this tissue 6. Normal 
cartilage is a tightly organized structure made up by extracellular matrix components 
(ECM), such as collagens and proteoglycans (PGs).
During osteogenesis cartilage functions as the template for bone formation. 
Endochondral bone formation is initiated by chondrogenesis and subsequent 
chondrocyte differentiation, eventually leading to terminal differentiation 
(=hypertrophy) of the chondrocytes. In later stages this newly formed cartilage is 
turned into bone via calcification and ossification 7. Articular chondrocytes are a 
special type of chondrocytes because during chondrocyte differentiation they are 
arrested in a pre-hypertrophic state and therefore articular cartilage is not turned
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into bone. This arrest of chondrocyte differentiation is partly lost during OA, leading 
to terminal differentiation resulting in hypertrophic chondrocytes in the cartilage that 
have lost type II collagen expression but do express type X collagen 8,9
OA-mediated cartilage damage is regarded nowadays as the ultimate result of a 
predominantly chondrocyte-controlled misbalance between anabolic versus catabolic 
processes. The progression of OA can be described in four phases 10. In the initial or 
repair stage of OA, chondrocytes show increased metabolic activity that leads to an 
imbalance between synthesis and degradation of ECM components. Biochemically 
this stage is characterized by increased synthesis of ECM components such as PGs. 
During the next early stage of OA increased ECM degradation is observed that 
exceeds increased synthesis, ultimately resulting in net degradation. Other early OA 
features are chondrocyte proliferation and clustering. The articular cartilage shows 
disorganization of ECM components and fibrillation of the articular surface. Features 
of later intermediate stages of OA, include vertical cracks or fissures in the cartilage. 
During this stage, articular cartilage shows failing ECM production and the cartilage 
contains less ECM components as is reflected by the depletion of PGs from the 
cartilage. This stage also shows necrosis of chondrocytes. Late stage OA is 
characterized by extensive fissuring and erosion of the cartilage.
Osteophytes
Osteophytes are the hallmark of OA. In essence osteophytes are the formation of 
new bone on the joint edges. Osteophytes are thought to form through 
endochondral ossification and therefore osteophyte development starts with the 
induction of chondrogenesis of periosteal or synovial cells 11,12. Growth factors are 
thought of as the major players in the induction of chondrogenesis of these cells and 
subsequent regulators of chondrocyte differentiation resulting in a so-called 
chondrophyte 13. Eventually this chondrophyte calcifies and turns into a real 
osteophyte. After subsequent remodeling a structure forms existing of cortical and 
cancellous bone and bone marrow. At sites where osteophytes form near the joint 
surface, they become a sort extension of the articular surface. It is thought that 
hereby the total load bearing surface is enlarged, which leads to reduced pressure on 
the joint surface. Furthermore, osteophytes may contribute to the stabilization of the 
joint. Because of this, osteophytes can be regarded as an attempt at repair. On the 
other hand, it has been reported that osteophytes are a major source of pain in OA 
patients and the presence of osteophytes is strongly correlated with joint destruction 
14. Osteophytes are therefore often considered as an unwanted feature.
S ynovium
The synovium is a richly vascularized tissue that lines the recesses of the joint and in 
the normal situation the synovium never covers the articular surface. The two main 
functions of the synovium are the production of synovial fluid and the phagocytosis 
of particles in the joint space 15,16. The synovium exists of two zones: a synovial 
lining layer only a few cell layers thick and a deeper layer of supporting tissue. The 
two predominant cell types in the lining layer are macrophages and fibroblasts.
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During OA hyperplasia of the lining is observed with extensive fibrosis of the deeper 
layer initiated by an increased number of synovial fibroblasts 17.
TRANSFORMING GROWTH FACTOR-ß SUPERFAM ILY
Transforming Growth FACTOR-ß
Transforming Growth Factor-ß (TGF-ß) is the blueprint of a superfamily of growth 
factors that currently entails more than 30 members (Figure 2) 18. TGF-ß was 
originally identified and named based on the observation that TGF-ß stimulates the 
proliferation of fibroblasts 19,20. For TGF-ß three mammalian isoforms are described, 
called TGF-ß1, -ß2 and -ß3 21. TGF-ßs are homodimeric molecules containing 6 
cystine residues and have a molecular weight of 25 kDa. All three TGF-ß isoforms 
share a high degree of homology (84 - 92%) and control important biological 
functions such as proliferation, differentiation and stimulation of extracellular matrix 
production. Differential expression of the TGF-ß isoforms in several tissues have been 
observed.
F i g u r e  2 . P h y lo g e n e t ic  t r e e  o f  
r e p r e s e n ta t iv e  m em bers o f  th e  T G F -ß  
s u p e r fa m ily .  T h re e  s u b fa m ilie s  a re  s h o w n : 
th e  T G F -ß  s u b fa m ily ; th e  BM P  s u b fa m ily  a n d
THE ACTIVIN/INHIBIN SUBFAMILY.
TGF-ß is produced as a pro-peptide linked to the Latency Associated Peptide (LAP) 22. 
After secretion, the amino-terminal LAP remains non-covalently bound to the 
carboxy-terminal fragment constituting the growth factor. The function of LAP is to 
prevent TGF-ß from binding its receptor, therefore this complex is also referred to as 
the small latent complex 23,24. The LAP fragment can in turn covalently bind via 
disulfide bonds to a family of latent TGF-ß-binding proteins, thus creating the large 
latent complex 25. This complex may facilitate the secretion, storage, or activation of 
the TGF-ß-LAP complex 26.
The physiological mechanism of TGF-ß activation is poorly understood and is most 
likely a multistep process. Components involved in TGF-ß activation may involve the 
plasminogen activation cascade 27, and the mannose 6-phosphate receptor 22. 
Furthermore, the homotrimeric protein thrombospondin (TSP-1) has been shown to 
be important in TGF-ß activation 28-30. TGF-ß may also be activated via the proteolytic 
cleavage of LAP by MMP-3 and MMP-13 26,31.
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Bone Morphogenetic Pro teins (BMPs)
The subfamily of BMPs also belongs to the TGF-ß superfamily and consist of over 10 
family members 32. Originally BMPs have been described as proteins that can induce 
new bone formation when injected at ectopic sites. More recently it has become clear 
that besides the involvement in skeletal development, BMPs induce instructive signals 
guiding cell proliferation and differentiation, apoptosis, morphogenesis and 
organogenesis. BMP members for which regulation of chondrocyte growth and 
differentiation has been described are: BMP-2, -4, -6 and BMP-7 and -8 (also referred 
to as Osteogenic Protein (OP) -1 and -2, respectively)33. BMPs are secreted as 
homodimeric molecules and contain seven cystine residues. In contrast to TGF-ß, 
BMPs are in an active form when secreted. BMPs have shown to be crucial mediators 
in chondrogenesis and chondrocyte differentiation 34. Importantly, in contrast to TGF- 
ß, BMPs stimulate the terminal differentiation of chondrocytes 35.
SIGNALING b y  TGF-ß/BMP members
Signaling by members of the TGF-ß superfamily involves two distinct membrane 
serine/threonine kinase receptors, type I and type II 36. The ligand binds with high 
affinity to the type II receptor, which then recruits the type I receptor (Figure 3).
F i g u r e  3
Cytoplasm
T G F -ß  AND B M P  SIGNALING. UPON LIGAND-INDUCED HETEROMERIC COMPLEX FORMATION AND ACTIVATION OF TYPE I AND 
TYPE II RECEPTORS, R-SMADS ARE PHOSPHORYLATED AND FORM HETEROMERIC COMPLEXES WITH CO-SMADS THAT 
TRANSLOCATE INTO THE NUCLEUS, WHERE THEY CONTROL THE EXPRESSION OF TARGET GENES IN A CELL TYPE SPECIFIC 
MANNER. R - AND CO-SMADS APPEAR TO FORM PREFERENTIALLY TRIMERS CONSISTING OF ONE CO-SMAD AND TWO R-
Smads. N e g a tiv e  r e g u la t io n  o f  T G F -ß /B M P  s ig n a lin g  c a n  o c c u r  t h r o u g h  I-Sm ads t h a t  p re v e n t  a c t iv a t io n  o f  
R -Sm ads o r  c o m p e te  w i th  Smad4 FOR HETEROMERIC c o m p le x  fo rm a t io n  w ith  a c t iv a te d  R-Sm ads. I-Sm ads a re  
INDUCED BY T G F -ß  FAMILY MEMBERS AND THEY MAY THUS PARTICIPATE IN A NEGATIVE FEEDBACK LOOP. (ADAPTED FROM 
ITOH ET AL, EUR.J.BIOCHEM. 2 0 0 0 )
The current view is that two type II and two type I receptors are necessary for signal 
transduction. Following this complex formation, the constitutive active type II 
receptor trans-phosphorylates the type I receptor within the intracellular glycin-
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serine-rich (GS) domain, resulting in the activation of the type I receptor 37. The type 
I receptor then activates the intracellular mediators called Smad proteins. 
Functionally, this family of signaling molecules consists of three subclasses: receptor- 
associated Smads (R-Smads), common-mediator Smad (Co-Smad) and inhibitory 
Smads (I-Smads). Type I receptors for TGF-ß activate R-Smad2 and -3, whereas 
BMP type I receptors recognize Smadl, -5 and -8  38.
Smads are the major TGF-ß receptor substrates responsible for signal transduction. 
All Smads have two conserved domains separated by a linker region, the amino- 
terminal Mad Homology (MH) 1 and carboxy-terminal MH2 domains. The MH1 
domain is highly conserved between R- and Co-Smads but not in I-Smads, whereas 
all Smads have a conserved MH2 domain. Functionally, the MH1 domain has DNA- 
binding and transcriptional activity 39, whereas the MH2 domain drives nuclear 
translocation and binding of transcriptional activators or repressors 40. The linker 
region is important in protein degradation via ubiquitination.
In the absence of ligand, R-Smads are in an inactive state caused by an interaction 
of the MH1 and MH2 domains 41. Phosphorylation of R-Smads occurs at serine 
residues located in a conserved carboxy-terminal SSXS motif causing a 
conformational change. As a consequence of phosphorylation, R-Smads detach from 
the type I receptor and form homo-oligomers that quickly interact with the Co-Smad 
(Smad4) shared by TGF-ß and BMP signaling pathways 42-44. Upon trimerization the 
R-Smad/Co-Smad complex translocates to the nucleus after which up or down 
regulation of TGF-ß/BMP target genes occurs 45,46. It has been shown that R- 
Smad/Co-Smad complex has the ability to bind to certain specific DNA sequences 
called Smad-binding elements (SBE) 47. SBE are present in promoters of TGF-ß/BMP 
responsive genes such as: Plasminogen Activator Inhibitor-1 (PAI-1) 48,49, JunB 50, 
type VII collagen 51, Smad6 52 and -7 53,54.
The TGF-ß/BMP pathway can be inhibited by the I-Smads: Smad6 and Smad7. I- 
Smads interact efficiently with activated type I receptors by their MH2 domain, thus 
preventing the binding of R-Smads to the type I receptor 55-59. Smad6 can also 
compete with Smad4 for heteromeric complex formation with activated Smad1 and 
thus exert its inhibitory effect 60. I-Smads can also induce receptor degradation 
through recruitment of Smad ubiquitination regulatory factors (Smurfs). Smad6 has 
shown to inhibit preferentially BMP signaling 52,56,61, although in vitro some TGF-ß 
inhibitory effect has been shown 62-64. Smad7 acts as an inhibitor of both TGF-ßs and 
BMPs 55,57,59'62'65. It has been extensively shown that I-Smads are potently induced 
by members of the TGF-ß family, suggesting a role in negative feedback regulation. 
So, both BMP and TGF-ß induce the expression of Smad6 and -7 52,55-57,60,65. In 
addition, other stimuli such as Epidermal Growth Factor (EGF) and Interferon-y can 
induce I-Smad expression 65,66.
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GROWTH FACTORS DURING OA 
The Good, the B ad o r the Ugly
"Th e GOOD"
TGF-ß and BMPs are thought of as factors with a protective function in articular 
cartilage and therefore have significant therapeutic potential.
TGF-ß has shown to stimulate PG synthesis both in isolated chondrocytes and in 
chondrocytes present in articular cartilage 67-70. Interestingly, the effects of TGF-ß on 
PG synthesis are far stronger in osteoarthritic chondrocytes than in normal 
chondrocytes 71,72. When injected in a naive knee joint, a single dose of TGF-ß 
resulted in elevated PG synthesis in the articular cartilage for three weeks 73. More 
recently, experiments with transgenic mice have shown that interference of TGF-ß 
signaling by expression of a truncated, kinase defective TGF-ß type II receptor in 
skeletal tissue leads to OA due to abnormal terminal differentiation of chondrocytes 
74. Moreover, mice expressing a disfunctional Smad3 protein showed essentially the 
same characteristics 75. Importantly, TGF-ß is able to antagonize the adverse effects 
of Interleukin-1 (IL-1) on articular cartilage 76,77 and can even considerably stimulate 
articular cartilage PG synthesis during experimental arthritis 78. TGF-ß not only 
induces matrix synthesis but is also a potent inhibitor of matrix degradation. On the 
one hand TGF-ß downregulates the synthesis of several matrix metalloproteinases 
(MMPs) 79-81. On the other hand, TGF-ß stimulates the expression of natural 
inhibitors of MMPs, the TIMPs 80-85, and induces the expression of plasminogen 
activator inhibitor-1 (PAI-1) 86,87. The data summed up above are indicative of a 
protective function of TGF-ß on articular cartilage; stimulating PG synthesis and 
inhibiting matrix degradation.
BMPs are also very potent inducers of cartilage PG synthesis in  vitro and in  vivo 
73,88,89. A single i.a. injection of BMP-2 induced a much shorter but more impressive 
induction of PG synthesis than TGF-ß 73. In vitro data shows that BMP is able to 
inhibit IL-1 effects on chondrocyte PG synthesis 90,91. Additionally, several BMP 
isoforms have also shown to inhibit matrix degradation. BMP-7 can suppress mRNA 
expression of several MMPs isoforms induced by IL-1 and could counteract the IL-1 
induced suppression of TIMP 92. PG degradation of cartilage explants could be 
inhibited by BMP-3 and BMP-4 isoforms in  vitro 93. However, contrary to TGF-ß, in  
vivo experiments using BMP-2 could not show a counteraction of IL-1 mediated 
effects 94. Intra-articular injection of BMP-2 during full-blown arthritis was also 
unable to stimulate PG synthesis, in contrast to TGF-ß 78. So, BMPs seem to have a 
protective function on articular cartilage but if BMPs can induce this protective effect 
during pathology remains obscure.
In summary, since both TGF-ß and BMPs can stimulate chondrocyte matrix synthesis 
and inhibit matrix degradation, TGF-ß and BMPs are thought of as factors with a 
protective function on articular cartilage.
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"THE BAD and  the U G LY"
Besides the overall positive effects that TGF-ß and BMPs have on articular cartilage, 
evidence exists that these growth factors also induce unwanted OA-like features in 
the joint, such as osteophytes and fibrosis.
Osteophytes
Osteophytes are new bony structures at the joint edges, which are believed to 
originate from periosteal cells that have the potential to undergo chondrogenesis 
11,95. Both TGF-ß and BMPs have shown to be able to induce chondrogenesis of 
pluripotent periosteal cells 11,13,35,96-98. However, TGF-ß induces the expression of 
TGF-ß and BMPs in periosteal cells 35,99, whereas BMPs do not induce TGF-ß 
expression. TGF-ß also appears necessary to maintain BMP receptor mRNA 
expression 98. Chondrocytes present in periosteum and developing osteophytes 
clearly show TGF-ß and TGF-ß receptor mRNA expression together with enhanced 
TGF-ß protein levels 100-102. Although TGF-ß seems the initiator of chondrogenesis, 
BMP and BMP receptor expression have shown to be necessary in early stages of 
mesenchymal differentiation into chondrocytes 33,98,103.
Repeated i.a. injections of TGF-ß1, -ß2 and BMP-2 isoforms resulted in a very strong 
induction of osteophyte development 70,73,78,104,105. Interestingly, osteophytes induced 
by BMP-2 formed at different locations from osteophytes induced by TGF-ß 
injections. BMP-2-induced osteophytes mainly formed at sites were the growth plates 
meet the joint space, whereas TGF-ß-induced osteophytes formation was more 
independent from these locations 73. These results may be indicative of differential 
stimulation of different subtypes of mesenchymal precursor cells by TGF-ß and BMPs.
Taken together these data strongly point to a role for TGF-ß and BMPs in the 
initiation and progression of osteophytes formation as seen in natural occurring OA.
Fibr o sis
Under normal conditions of tissue remodeling the rate of synthesis of matrix proteins 
is balanced by protein degradation mediated by proteases such as MMPs and 
plasmin. TGF-ß is very well known for its capability to stimulate production of ECM 
components (especially types I and III collagen), and inhibit the degradation of these 
proteins 106-109. In essence this physiological reaction contributes to tissue repair 
eventually leading to restoration of normal tissue architecture. However, this process 
can escalate, leading to a pathologic excess of tissue components called fibrosis, 
which is also a feature of OA. In various other tissues such as liver, lung, skin and 
kidney, TGF-ß has shown to be the responsible factor for the induction of fibrosis 110­
113. TGF-ß induced fibrosis has shown to be mediated by Smad-proteins 114. When 
injected in joints, TGF-ß is able to induce massive fibrosis of the synovial lining 73,105, 
an observation that could be confirmed by overexpression of active TGF-ß in the
lining 104.
The role of BMPs in fibrosis is far less well understood and results seem to depend 
on the BMP isoform studied. Systemic treatment of rats with BMP-7 has shown to
14
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improve kidney fibrosis and restore kidney function 115. BMP-7 was also able to 
prevent infiltration of fibroblast in engineered cartilage 116. On the other hand during 
experimental wound healing BMP-2 induced considerable scar formation with 
increased deposition of irregular collagens 117. Additionally, tumors overexpressing 
BMP-6 were surrounded by extensive connective tissue reminiscent of fibrosis 118. 
Intra-articular injection of BMP-2 also resulted in hyperplasia and fibrosis of the 
synovial lining 73.
CARTILAGE PG DEPLETION
Unexpectedly, besides the "good" effects on cartilage, multiple high dose injections 
with TGF-ß have shown to induce PG depletion of the deep layer of non-calcified 
articular cartilage 105. In this study even cracks at the level of the tidemark were 
found after repeated injections of the growth factor. Also in other studies 
osteoarthritic changes of the cartilage have been described after exposure of knee 
joints of rats and mice to TGF-ß, supporting a role for TGF-ß in the pathogenesis of 
Oa  119,120. These effects on articular cartilage may be mediated by upregulation of 
MMP-13 by TGF-ß 121,122. The effect of TGF-ß on PG content may reflect a disbalance 
in matrix synthesis and degradation ultimately leading to a failure in the repair 
response.
The role of endogenous growth factors during OA
The major drawback of most studies studying the relation between growth factors 
and OA is that results are based on TGF-ß/BMP supplementation and therefore give 
no information about the physiological role of these growth factors released during 
diseases such as OA. In this thesis we set out to investigate the natural role of TGF-ß 
and BMP during experimental OA.
15
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a i m  a n d  s c o p e  o f  t h i s  t h e s i s
The aim of the research described in this thesis was to elucidate the role of 
endogenous growth factors during OA. This was done to study the function of TGF-ß 
and BMPs in the pathogenesis of OA and determine the deleterious and protective 
effects of naturally released growth factors during OA. Our results will give direction 
to therapeutic use of growth factors or growth factor inhibitors.
In c h a p te r  2 we investigated if a subtle age-related disbalance between anabolic 
and catabolic factors on articular cartilage could be a cause for OA. Comparing young 
and old mice, we studied the response of articular cartilage from these mice to TGF- 
ß, IL-1 and the combination TGF-ß/IL-1. Our results show that young and old mice 
have a comparable TGF-ß response, but that old mice have lost the ability to 
counteract IL-1 effects by TGF-ß on articular cartilage. This finding suggests that a 
subtle age-induced disbalance between anabolic versus catabolic factors can play a 
role in the initiation of the OA process.
In c h a p te r  3 we hypothesized that the loss of TGF-ß counteraction on IL-1 effects in 
old mice was due to either a decrease in TGF-ß signaling mediators or an increase in 
intracellular TGF-ß inhibitors. We investigated this via immunohistochemistry of 
receptor (R-) Smad-2, -3, -4 and inhibitory (I-) Smad-6 and -7  on total knee joint 
tissue sections of old and young mice. Surprisingly, we found a decrease in the 
expression of Smad7 in old mice, whereas the other Smads showed similar 
expression profiles to young mice. We conclude from this study that the loss of IL-1 
counteraction by TGF-ß is not due to a decrease of R-Smads or an increase in I- 
Smads.
A further goal was to study the role of endogenously released TGF-ß during OA and 
therefore we generated a specific TGF-ß antagonist called soluble type II receptor or 
solRII, of which the production and characterization is described in c h a p te r  4.
Next, we investigated the effect of TGF-ß inhibition during papain-induced OA by 
applying the solRII. In c h a p te r  5 we identified endogenous TGF-ß as the main 
inducer of osteophyte development. On the other hand, naturally released TGF-ß 
during OA showed to be a protective factor for articular cartilage. So, these results 
identify TGF-ß as a dualistic factor in the joint inducing both deleterious and positive 
effects.
In chapter 6 and 7 we switched to a different strategy to block TGF-ß signaling, 
involving the use of recombinant adenoviruses expressing inhibitory Smad-6 and -7 
and murine LAP1. In c h a p te r  6 we investigated if TGF-ß-mediated responses in 
cultured chondrocytes such as proliferation and PG synthesis were differentially 
regulated by adenoviral overexpression of Smad-6 and -7. Our results show that 
whereas Smad-7 is an extremely potent negative regulator of TGF-ß responses in 
chondrocytes, Smad-6 is at best a weak TGF-ß antagonist.
We continued to use adenoviruses expressing Smad-6 and -7  together with a virus 
expressing the murine form of LAP1 to block TGF-ß in  vivo as described in c h a p te r
16
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7. Transfection of the joint lining with these adenoviruses resulted in strong 
overexpression of the transgenes. Our result not only further proved endogenous 
TGF-ß to be a major contributor to osteophyte development and joint thickening but 
also, for the first time, determined a crucial role for naturally released BMPs in these 
OA-processes. The application of our own generated TGF-ß antagonist mLAP1 
confirmed results from chapter 5 that endogenous TGF-ß has a positive influence on 
articular cartilage but induces detrimental effects in the rest of the joint.
Because TGF-ß and BMP are strong inducers of cartilage matrix and inhibit cartilage 
degradation they have a strong therapeutic potential. We have indeed shown that 
endogenous TGF-ß released during experimental OA protects articular cartilage from 
PG loss. However, our studies also show that the same levels of these growth factors 
during the OA disease process are responsible for unwanted side-effects in the joint 
such as osteophyte formation and fibrosis. In order to apply TGF-ß or BMP as a 
therapeutic means to induce cartilage repair, the growth factors should be 
specifically targeted to the articular cartilage. Since osteophyte formation and fibrosis 
were blocked by Smad6 and -7  overexpression, one option to target TGF-ß/BMP to 
the articular cartilage only, could be the generation of a TGF-ß unresponsive joint 
lining by overexpression of these intracellular inhibitors.
17
GENERAL INTRODUCTION AND AIM OF THIS THESIS
REFERENCE LIST
1. Kelsey, J.L. and Hochberg, M.C. Epidemiology of chronic musculoskeletal disorders. Ann. Rev. 
Pub. Health 1988. 9:379-401.
2. Engel, A. Osteoarthritis and body measurements. Vital Health Stat. 1968. 11:1-37.
3. Pritzker, K.P.H. 1998. Pathology of osteoarthritis. In Osteoarthritis. Brandt, K.D., Doherty, D., 
and Lohmander, L.S., editors. Oxford University Press, Oxford. 50-61.
4. O'Reilly, S. and Doherty, D. 1998. Clinical features of osteoarthritis and standard approaches 
to the diagnosis. In Osteoarthritis. Brandt, K.D., Doherty, D., and Lohmander, L.S., editors. 
Oxford University Press, Oxford. 197-249.
5. Nelson, D.T. 1998. Epidemiology of osteoarthritis. In Osteoarthritis. Brandt, K.D., Doherty, 
M., and Lohmander, L.S., editors. Oxford University Press, Oxford. 13-22.
6. Stockwell, R.A. and Meachim, G. 1979. The chondrocytes. In Adult articular cartilage. 
Freeman, M.A., editor. Pitman Medical, Kent. 69-144.
7. Cancedda, R., Castagnola, P., Cancedda, F.D., Dozin, B., and Quarto, R. Developmental 
control of chondrogenesis and osteogenesis. Int. J. Dev. Biol. 2000. 44:707-714.
8. Karpouzas, G.A. and Terkeltaub, R.A. New developments in the pathogenesis of articular 
cartilage calcification. Curr. Rheumatol. Rep. 1999. 1:121-127.
9. Linsenmayer, T.F., Long, F., Nurminskaya, M., Chen, Q., and Schmid, T.M. Type X collagen 
and other up-regulated components of the avian hypertrophic cartilage program. Prog Nucleic 
Acid Res. Mol. Biol. 1998. 60:79-109.
10. Dijkgraaf, L.C., de Bont, L.G., Boering, G., and Liem, R.S. The structure, biochemistry, and 
metabolism of osteoarthritic cartilage: a review of the literature. J  Oral Maxiiiofac. Surg. 
1995. 53:1182-1192.
11. Gallay, S.H., Miura, Y., Commisso, C.N., Fitzsimmons, J.S., and O'Driscoll, S.W. Relationship of 
donor site to chondrogenic potential of periosteum in vitro. J  Orthop. Res. 1994. 12:515­
525.
12. O'Driscoll, S.W., Recklies, A.D., and Poole, A.R. Chondrogenesis in periosteal explants. An 
organ culture model for in vitro study. J  BoneJointSurg. Am. 1994. 76:1042-1051.
13. Miura, Y., Fitzsimmons, J.S., Commisso, C.N., Gallay, S.H., and O'Driscoll, S.W. Enhancement 
of periosteal chondrogenesis in vitro. Dose-response for transforming growth factor-beta 1 
(TGF-beta 1). Clin. Orthop. 1994. 301:271-280.
14. McCauley, T.R., Kornaat, P.R., and Jee, W.H. Central osteophytes in the knee: prevalence and 
association with cartilage defects on MR imaging. Am. J. Roentgenol. 2001. 176:359-364.
15. Unsworth, A., Dowson, D., and Wright, V. Some new evidence on human joint lubrication. 
Ann. Rheum .D is. 1975. 34:277-285.
16. Fell, H.B. Synoviocytes. J. Clin. Pathol. Suppl. 1978. 12:14-24.
17. Revell, P.A., Mayston, V., Lalor, P., and Mapp, P. The synovial membrane in osteoarthritis: a 
histological study including the characterisation of the cellular infiltrate present in 
inflammatory osteoarthritis using monoclonal antibodies. Ann. Rheum. Dis. 1988. 47:300­
307.
18. Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., 
Yandell, M., Evans, C.A., Holt, R.A. et al. The sequence of the human genome. Science 2001. 
291:1304-1351.
18
CHAPTER 1
19. Moses, H.L., Branum, E.L., Proper, J.A., and Robinson, R.A. Transforming growth factor 
production by chemically transformed cells. Cancer Res. 1981. 41:2842-2848.
20. Roberts, A.B., Anzano, M.A., Lamb, L.C., Smith, J.M., and Sporn, M.B. New class of 
transforming growth factors potentiated by epidermal growth factor: isolation from non­
neoplastic tissues. Proc. Natl. Acad. Sci. U. S. A 1981. 78:5339-5343.
21. Kingsley, D.M. The TGF-ß superfamily: new members, new receptors, and new genetic tests 
of function in different organisms. Genes Dev. 1994. 8:133-146.
22. Munger, J.S., Harpel, J.G., Gleizes, P.E., Mazzieri, R., Nunes, I., and Rifkin, D.B. Latent 
transforming growth factor-beta: structural features and mechanisms of activation. Kidney 
Int. 1997. 51:1376-1382.
23. Khalil, N. TGF-beta: from latent to active. Microbes. Infect. 1999. 1:1255-1263.
24. McMahon, G.A., Dignam, J.D., and Gentry, L.E. Structural characterization of the latent 
complex between transforming growth factor beta 1 and beta 1-latency-associated peptide. 
Biochem. J. 1996. 313:343-351.
25. Nunes, I., Munger, J.S., Harpel, J.G., Nagano, Y., Shapiro, R.L., Gleizes, P.E., and Rifkin, D.B. 
Structure and activation of the large latent transforming growth factor-beta complex. Int. J. 
Obes. 1996. 20:S4-S8.
26. Maeda, S., Dean, D.D., Gomez, R., Schwartz, Z., and Boyan, B.D. The first stage of 
transforming growth factor beta 1 activation is release of the large latent complex from the 
extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). 
Caicif. Tissue Int. 2002. 70:54-65.
27. Lyons, R.M., Gentry, L.E., Purchio, A.F., and Moses, H.L. Mechanism of activation of latent 
recombinant transforming growth factor beta 1 by plasmin. J. Cell Biol. 1990. 110:1361­
1367.
28. Crawford, S.E., Stellmach, V., Murphy-Ullrich, J.E., Ribeiro, S.M., Lawler, J., Hynes, R.O., 
Boivin, G.P., and Bouck, N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 
1998. 93:1159-1170.
29. Schultz, C.S., Chen, H., Mosher, D.F., Misenheimer, T.M., Krutzsch, H.C., Roberts, D.D., and 
Murphy-Ullrich, J.E. Regulation of transforming growth factor-beta activation by discrete 
sequences of thrombospondin 1. J. Biol. Chem. 1995. 270:7304-7310.
30. Schultz, C.S., Ribeiro, S., Gentry, L., and Murphy-Ullrich, J.E. Thrombospondin binds and 
activates the small and large forms of latent transforming growth factor-beta in a chemically 
defined system. J. Biol. Chem. 1994. 269:26775-26782.
31. D'Angelo, M., Billings, P.C., Pacifici, M., Leboy, P.S., and Kirsch, T. Authentic matrix vesicles 
contain active metalloproteases (MMP). a role for matrix vesicle-associated MMP-13 in 
activation of transforming growth factor-beta. J. Biol. Chem. 2001. 276:11347-11353.
32. Ducy, P. and Karsenty, G. The family of bone morphogenetic proteins. Kidney Int. 2000. 
57:2207-2214.
33. Hoffmann, A. and Gross, G. BMP signaling pathways in cartilage and bone formation. CritRev. 
Eukaryot. GeneExpr. 2001. 11:23-45.
34. Edwards, C.J. and Francis-West, P.H. Bone morphogenetic proteins in the development and 
healing of synovial joints. Semin. Arthritis Rheum. 2001. 31:33-42.
35. Mizuta, H., Sanyal, A., Fukumoto, T., Fitzsimmons, J.S., Matsui, N., Bolander, M.E., Oursler, 
M.J., and O'Driscoll, S.W. The spatiotemporal expression of TGF-beta1 and its receptors 
during periosteal chondrogenesis in vitro. J. Orthop. Res. 2002. 20:562-574.
19
GENERAL INTRODUCTION AND AIM OF THIS THESIS
36. Massague, J. TGF-beta signal transduction. Ann. Rev. Biochem 1998. 67:753-791.
37. Huse, M., Chen, Y.G., Massague, J., and Kuriyan, J. Crystal structure of the cytoplasmic 
domain of the type I TGF beta receptor in complex with FKBP12. Cell 1999. 96:425-436.
38. Moustakas, A., Souchelnytskyi, S., and Heldin, C.H. Smad regulation in TGF-beta signal 
transduction. J. Cell Sci. 2001. 114:4359-4369.
39. Itoh, S., Itoh, F., Goumans, M.J., and ten Dijke, P. Signaling of transforming growth factor­
beta family members through Smad proteins. Eur. J. Biochem. 2000. 267:6954-6967.
40. Massague, J. and Wotton, D. Transcriptional control by the TGF-beta/Smad signaling system. 
EMBO J. 2000. 19:1745-1754.
41. Hata, A., Lo, R.S., Wotton, D., Lagna, G., and Massague, J. Mutations increasing 
autoinhibition inactivate tumour suppressors Smad2 and Smad4 [see comments]. Nature
1997. 388:82-87.
42. Correia, J.J., Chacko, B.M., Lam, S.S., and Lin, K. Sedimentation studies reveal a direct role of 
phosphorylation in Smad3:Smad4 homo- and hetero-trimerization. Biochemistry 2001. 
40:1473-1482.
43. Chacko, B.M., Qin, B., Correia, J.J., Lam, S.S., de Caestecker, M.P., and Lin, K. The L3 loop 
and C-terminal phosphorylation jointly define Smad protein trimerization. Nat. Struct. Biol. 
2001. 8:248-253.
44. Jayaraman, L. and Massague, J. Distinct oligomeric states of SMAD proteins in the 
transforming growth factor-beta pathway. J. Biol. Chem. 2000. 275:40710-40717.
45. Xiao, Z., Watson, N., Rodriguez, C., and Lodish, H.F. Nucleocytoplasmic shuttling of Smad1 
conferred by its nuclear localization and nuclear export signals. J. Biol. Chem. 2001. 
276:39404-39410.
46. Xiao, Z., Liu, X., Henis, Y.I., and Lodish, H.F. A distinct nuclear localization signal in the N 
terminus of Smad 3 determines its ligand-induced nuclear translocation. Proc. Natl. Acad. Sci. 
U. S. A 2000. 97:7853-7858.
47. Zawel, L., Dai, J.L., Buckhaults, P., Zhou, S., Kinzler, K.W., Vogelstein, B., and Kern, S.E. 
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1998. 
1:611-617.
48. Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., and Gauthier, J.M. Direct binding of 
Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human 
plasminogen activator inhibitor- type 1 gene. EMBO J. 1998. 17:3091-3100.
49. Song, C.Z., Siok, T.E., and Gelehrter, T.D. Smad4/DPC4 and Smad3 mediate transforming 
growth factor-beta (TGF-beta) signaling through direct binding to a novel TGF-beta- 
responsive element in the human plasminogen activator inhibitor-1 promoter. J. Biol. Chem.
1998. 273:29287-29290.
50. Jonk, L.J., Itoh, S., Heldin, C.H., ten Dijke, P., and Kruijer, W. Identification and functional 
characterization of a Smad binding element (SBE) in the JunB promoter that acts as a 
transforming growth factor-beta, activin, and bone morphogenetic protein- inducible 
enhancer. J. Biol. Chem. 1998. 273:21145-21152.
51. Vindevoghel, L., Lechleider, R.J., Kon, A., de Caestecker, M.P., Uitto, J., Roberts, A.B., and 
Mauviel, A. SMAD3/4-dependent transcriptional activation of the human type VII collagen 
gene (COL7A1) promoter by transforming growth factor beta. Proc. Natl. Acad. Sci. U. S. A
1998. 95:14769-14774.
52. Ishida, W., Hamamoto, T., Kusanagi, K., Yagi, K., Kawabata, M., Takehara, K., Sampath, T.K., 
Kato, M., and Miyazono, K. Smad6 is a Smad1/5-induced smad inhibitor. Characterization of
20
CHAPTER 1
bone morphogenetic protein-responsive element in the mouse Smad6 promoter. J. Biol. 
Chem. 2000. 275:6075-6079.
53. Nagarajan, R.P., Zhang, J., Li, W., and Chen, Y. Regulation of Smad7 promoter by direct 
association with Smad3 and Smad4. J. Biol. Chem. 1999. 274:33412-33418.
54. von Gersdorff, G., Susztak, K., Rezvani, F., Bitzer, M., Liang, D., and Bottinger, E.P. Smad3 
and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming 
growth factor beta. J. Biol. Chem. 2000. 275:11320-11326.
55. Hayashi, H., Hayashi, H., Abdollah, S., Qiu, Y.B., Cai, J.X., Xu, Y.Y., Grinnell, B.W., 
Richardson, M.A., Topper, J.N., Gimbrone, M.A. et al. The MAD related protein SMAD7 
associates with the TGF-ß receptor and functions as an antagonist of TGF-ß signaling. Cell 
1997. 89:1165-1173.
56. Imamura, T., Takase, M., Nishihara, A., Oeda, E., Hanai, J., Kawabata, M., and Miyazono, K. 
Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997. 389:622-626.
57. Nakao, A., Afrakhte, M., Moren, A., Nakayama, T., Christian, J.L., Heuchel, R., Itoh, S., 
Kawabata, M., Heldin, N.E., Heldin, C.H. et al. Identification of Smad7, a TGFbeta-inducible 
antagonist of TGF- beta signalling. Nature 1997. 389:631-635.
58. Souchelnitskiy, S., Nakayama, T., Nakao, A., Moren, A., Heldin, C.H., Christian, J.L., and ten 
Dijke, P. Physical and functional interaction of murine and Xenopus Smad7 with bone 
morphogenetic protein receptors and transforming growth factor-beta receptors. J. Biol. 
Chem. 1998. 273:25364-25370.
59. Itoh, F., Asao, H., Sugamura, K., Heldin, C.H., ten Dijke, P., and Itoh, S. Promoting bone 
morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J.
2001. 20:4132-4142.
60. Hata, A., Lagna, G., Massague, J., and Hemmati Brivanlou, A. Smad6 inhibits BMP-Smad1 
signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev. 1998. 
12:186-197.
61. Ishisaki, A., Yamato, K., Hashimoto, S., Nakao, A., Tamaki, K., Nonaka, K., ten Dijke, P., 
Sugino, H., and Nishihara, T. Differential inhibition of Smad6 and Smad7 on Bone 
Morphogenetic Protein- and Activin-mediated growth arrest and apoptosis in B cells. J. Biol. 
Chem. 1999. 274:13637-13642.
62. Hanyu, A., Ishidou, Y., Ebisawa, T., Shimanuki, T., Imamura, T., and Miyazono, K. The N 
domain of Smad7 is essential for specific inhibition of transforming growth factor-beta 
signaling. J. Cell Biol. 2001. 155:1017-1027.
63. Topper, J.N., Cai, J., Qiu, Y., Anderson, K.R., Xu, Y.Y., Deeds, J.D., Feeley, R., Gimeno, C.J., 
Woolf, E.A., Tayber, O. et al. Vascular MADs; two novel MAD-related genes selectively 
inducible by flow in human vascular endothelium. Proc. Natl. Acad. Sci. U. S. A. 1997. 
94:9314-9319.
64. Kleeff, J., Maruyama, H., Friess, H., Buchler, M.W., Falb, D., and Korc, M. Smad6 suppresses 
TGF-beta-induced growth inhibition in COLO-357 pancreatic cells and is overexpressed in 
pancreatic cancer. Biochem. Biophys. Res. Commun. 1999. 255:268-273.
65. Afrakhte, M., Moren, A., Jossan, S., Itoh, S., Westermark, B., Heldin, C.H., Heldin, N.E., and 
ten Dijke, P. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. 
Biochem. Biophys. Res. Commun. 1998. 249:505-511.
66. Ulloa, L., Doody, J., and Massague, J. Inhibition of transforming growth factor-beta/SMAD 
signalling by the interferon-gamma/STAT pathway. Nature 1999. 397:710-713.
21
GENERAL INTRODUCTION AND AIM OF THIS THESIS
67. Redini, F., Galera, P., Mauviel, A., Loyau, G., and Pujol, J.P. Transforming growth factor beta 
stimulates collagen and glycosaminoglycan biosynthesis in cultured rabbit articular 
chondrocytes. FEBSLett. 1988. 234:172-176.
68. Morales, T.I. Transforming growth factor-beta 1 stimulates synthesis of proteoglycan 
aggregates in calf articular cartilage organ cultures. Arch. Biochem. Biophys. 1991. 286:99­
106.
69. Morales, T.I., Joyce, M.E., Sobel, M.E., Danielpour, D., and Roberts, A.B. Transforming growth 
factor-beta in calf articular cartilage organ cultures: synthesis and distribution. Arch. Biochem. 
Biophys. 1991. 288:397-405.
70. van Beuningen, H.M., van der Kraan, P.M., Arntz, O.J., and van den Berg, W.B. Transforming 
growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces 
osteophyte formation in the murine knee joint. Lab. Invest. 1994. 71:279-290.
71. Lafeber, F.P., van der Kraan, P.M., Huber, B.O., van den Berg, W.B., and Bijlsma, J.W. 
Osteoarthritic human cartilage is more sensitive to transforming growth factor beta than is 
normal cartilage. Br. J. Rheumatol. 1993. 32:281-286.
72. Lafeber, F.P., van Roy, H.L., van der Kraan, P.M., van den Berg, W.B., and Bijlsma, J.W. 
Transforming growth factor-beta predominantly stimulates phenotypical ly changed 
chondrocytes in osteoarthritic human cartilage. J. Rheumatol. 1997. 24:536-542.
73. van Beuningen, H.M., Glansbeek, H.L., van der Kraan, P.M., and van den Berg, W.B. 
Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage 
composition and osteophyte formation. Osteoarthritis. Cartilage 1998. 6:306-317.
74. Serra, R., Johnson, M., Filvaroff, E.H., Laborde, J., Sheehan, D.M., Derynck, R., and Moses, 
H.L. Expression of a truncated, kinase defective TGF-beta type II receptor in mouse skeletal 
tissue promotes terminal chondrocyte differentiation and osteoarthritis. J. Cell Biol. 1997. 
139:541-552.
75. Yang, X., Chen, L., Xu, X.L., Li, C.L., Huang, C.F., and Deng, C.X. TGF-beta/Smad3 signals 
repress chondrocyte hypertrophic differentiation and are required for maintaining articular 
cartilage. J .  C e ll B io l. 2001. 153:35-46.
76. van Beuningen, H.M., van der Kraan, P.M., Arntz, O.J., and van den Berg, W.B. Protection 
from interleukin 1 induced destruction of articular cartilage by transforming growth factor 
beta: studies in anatomically intact cartilage in vitro and in vivo. Ann. Rheum. Dis. 1993. 
52:185-191.
77. Rayan, V. and Hardingham, T. The recovery of articular cartilage in explant culture from 
interleukin-1 alpha: effects on proteoglycan synthesis and degradation. Matrix Biol. 1994. 
14:263-271.
78. Glansbeek, H.L., van Beuningen, H.M., Vitters, E.L., van der Kraan, P.M., and van den Berg, 
W.B. Stimulation of Articular Cartilage Repair in Established Arthritis by Local Administration of 
Transforming Growth Factor-beta into Murine Knee Joints. Lab. Invest. 1998. 78:133-142.
79. Chandrasekhar, S. and Harvey, A.K. Transforming growth factor-beta is a potent inhibitor of 
IL-1 induced protease activity and cartilage proteoglycan degradation. Biochem. Biophys. Res. 
Commun. 1988. 157:1352-1359.
80. Lum, Z.P., Hakala, B.E., Mort, J.S., and Recklies, A.D. Modulation of the catabolic effects of 
interleukin-1 beta on human articular chondrocytes by transforming growth factor-beta. J. Cell 
Physiol. 1996. 166:351-359.
81. Edwards, D.R., Murphy, G., Reynolds, J.J., Whitham, S.E., Docherty, A.J., Angel, P., and 
Heath, J.K. Transforming growth factor beta modulates the expression of collagenase and 
metalloproteinase inhibitor. EMBO J. 1987. 6:1899-1904.
22
CHAPTER 1
82. Gunther, M., Haubeck, H.D., van de Leur, E., Blaser, J., Bender, S., Gutgemann, I., Fischer, 
D.C., Tschesche, H., Greiling, H., and Heinrich, P.C. Transforming growth factor beta 1 
regulates tissue inhibitor of metalloproteinases-1 expression in differentiated human articular 
chondrocytes. Arthritis Rheum. 1994. 37:395-405.
83. Su, S., DiBattista, J.A., Sun, Y., Li, W.Q., and Zafarullah, M. Up-regulation of tissue inhibitor of 
metalloproteinases-3 gene expression by TGF-beta in articular chondrocytes is mediated by 
serine/threonine and tyrosine kinases. J. Cell Biochem. 1998. 70:517-527.
84. Su, S., Grover, J., Roughley, P.J., DiBattista, J.A., Martel-Pelletier, J., Pelletier, J.P., and 
Zafarullah, M. Expression of the tissue inhibitor of metalloproteinases (TIMP) gene family in 
normal and osteoarthritic joints. Rheumatol. Int. 1999. 18:183-191.
85. Cawston, T., Billington, C., Cleaver, C., Elliott, S., Hui, W., Koshy, P., Shingleton, B., and 
Rowan, A. The regulation of MMPs and TIMPs in cartilage turnover. Ann. N. Y. Acad. Sci.
1999. 30:878120-9.
86. Campbell, I.K., Wojta, J., Novak, U., and Hamilton, J.A. Cytokine modulation of plasminogen 
activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Down- 
regulation by tumor necrosis factor alpha and up-regulation by transforming growth factor-ß 
and basic fibroblast growth factor. bio 1994. 1226:277-285.
87. Laiho, M., Saksela, O., and Keski-Oja, J. Transforming growth factor-beta induction of type-1 
plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. 
J. Biol. Chem. 1987. 262:17467-17474.
88. Rosenzweig, B.L., Imamura, T., Okadome, T., Cox, G.N., Yamashita, H., Tendijke, P., Heldin, 
C.H., and Miyazono, K. Cloning and characterization of a human type II receptor for bone 
morphogenetic proteins. Proc. Natl. Acad. Sci. USA 1995. 92:7632-7636.
89. Morris, E. Differential effects of TGF-ß superfamily members on articular cartilage metabolism: 
stimulation by rhBMP-9 and rhBMP-2 and inhibition by TGF-ß. Trans Orthop Res Soc 1996. 
42:175.
90. Majumdar, M.K., Wang, E., and Morris, E.A. BMP-2 and BMP-9 promote chondrogenic 
differentiation of human multipotential mesenchymal cells and overcome the inhibitory effect 
of IL-1. J. Cell Physiol. 2001. 189:275-284.
91. Flechtenmacher, H.K., Schmid, T.M., Davies, S.D., Mollenhauer, J., Sampath, T.K., Kuettner, 
K.E., Thonar, E.J., and Aydelotte, M.B. Osteogenic protein 1 (OP-1) upregulates matrix 
synthesis by human articular chondrocytes cultured in the presence of serum and IL-1ß. Trans 
Orthop Res Soc 1995. 41:381.
92. Yao, J., Cole, A.A., Huch, K., and Kuettner, K.E. The effect of OP-1 on IL-1ß induced gene 
expressions of matrix metalloproteinases and TIMP in human articular chondrocytes. Trans 
Orthop Res Soc 1996. 42:305.
93. Luyten, F.P., Yu, Y.M., Yanagishita, M., Vukicevic, S., Hammonds, R.G., and Reddi, A.H. 
Natural bovine osteogenin and recombinant human bone morphogenetic protein-2B are 
equipotent in the maintenance of proteoglycans in bovine articular cartilage explant cultures. 
J .B io l. Chem. 1992. 267:3691-3695.
94. Glansbeek, H.L., van Beuningen, H.M., Vitters, E.L., Morris, E.A., van der Kraan, P.M., and van 
den Berg, W.B. Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan 
synthesis in vivo but does not counteract interleukin-1alpha effects on proteoglycan synthesis 
and content. Arthritis Rheum. 1997. 40:1020-1028.
95. O'Driscoll, S.W. Articular cartilage regeneration using periosteum. Clin. Orthop. 1999. S186- 
S203.
96. Iwasaki, M., Nakahara, H., Nakata, K., Nakase, T., Kimura, T., and Ono, K. Regulation of 
proliferation and osteochondrogenic differentiation of periosteum-derived cells by
23
GENERAL INTRODUCTION AND AIM OF THIS THESIS
transforming growth factor-beta and basic fibroblast growth factor. J. Bone Joint Surg. Am. 
1995. 77:543-554.
97. Iwasaki, M., Nakata, K., Nakahara, H., Nakase, T., Kimura, T., Kimata, K., Caplan, A.I., and 
Ono, K. Transforming growth factor-beta 1 stimulates chondrogenesis and inhibits 
osteogenesis in high density culture of periosteum-derived cells. Endocrinology 1993. 
132:1603-1608.
98. Sanyal, A., Oursler, M.J., Clemens, V.R., Fukumoto, T., Fitzsimmons, J.S., and O'Driscoll, S.W. 
Temporal expression patterns of BMP receptors and collagen II (B) during periosteal 
chondrogenesis. J. Orthop. Res. 2002. 20:58-65.
99. Sanyal, A., Sarkar, G., Saris, D.B.F., Fitzsimmons, J.S., Bolander, M.E., and O'Driscoll, S.W. 
Initial evidence for the involvement of bone morphogenetic protein-2 early during periosteal 
chondrogenesis. J. Orthop. Res. 1999. 17:926-934.
100. Horner, A., Kemp, P., Summers, C., Bord, S., Bishop, N.J., Kelsall, A.W., Coleman, N., and 
Compston, J.E. Expression and distribution of transforming growth factor-beta isoforms and 
their signaling receptors in growing human bone. Bone 1998. 23:95-102.
101. Dodds, R.A., Merry, K., Littlewood, A., and Gowen, M. Expression of mRNA for IL1 beta, IL6 
and tG f  beta 1 in developing human bone and cartilage. J. Histochem. Cytochem. 1994. 
42:733-744.
102. Kawakami, T., Hiraoka, B.Y., Kawai, T., Takei, N., Hasegawa, H., and Eda, S. Expression of 
transforming growth factor-beta peptide and its mRNA in chondrocytes in the early phase of 
BMP-induced heterotopic 'transchondroid bone formation'. Med. Sci. Res. 1999. 27:419-421.
103. Zou, H., Wieser, R., Massague, J., and Niswander, L. Distinct roles of type I bone 
morphogenetic protein receptors in the formation and differentiation of cartilage. Genes Dev. 
1997. 11:2191-2203.
104. Bakker, A.C., van de Loo, F.A.J., van Beuningen, H.M., Sime, P., van Lent, P.L.E.M., van der 
Kraan, P.M., Richards, C.D., and van den Berg, W.B. Overexpression of active TGF-beta-1 in 
the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation. 
Osteoarthritis. Cartilage 2002. 9:128-136.
105. van Beuningen, H.M., Glansbeek, H.L., van der Kraan, P.M., and van den Berg, W.B. 
Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming 
growth factor-beta injections. Osteoarthritis. Cartilage 2000. 8:25-33.
106. Kanzler, S., Lohse, A.W., Keil, A., Henninger, J., Dienes, H.P., Schirmacher, P., Rose-John, S., 
zum-Buschenfelde, K.H., and Blessing, M. TGF-beta1 in liver fibrosis: an inducible transgenic 
mouse model to study liver fibrogenesis. Am. J. Physiol 1999. 276:G1059-G1068.
107. Galera, P., Vivien, D., Pronost, S., Bonaventure, J., Redini, F., Loyau, G., and Pujol, J.P. 
Transforming growth factor-beta 1 (TGF-beta 1) up-regulation of collagen type II in primary 
cultures of rabbit articular chondrocytes (RAC) involves increased mRNA levels without 
affecting mRNA stability and procollagen processing. J. Cell Physiol 1992. 153:596-606.
108. Su, S., Grover, J., Roughley, P.J., DiBattista, J.A., Martel-Pelletier, J., Pelletier, J.P., and 
Zafarullah, M. Expression of the tissue inhibitor of metalloproteinases (TIMP) gene family in 
normal and osteoarthritic joints. Rheumatol. Int. 1999. 18:183-191.
109. Edwards, D.R., Leco, K.J., Beaudry, P.P., Atadja, P.W., Veillette, C., and Riabowol, K.T. 
Differential effects of transforming growth factor-beta 1 on the expression of matrix 
metalloproteinases and tissue inhibitors of metalloproteinases in young and old human 
fibroblasts. Exp. Gerontol. 1996. 31:207-223.
110. Gore-Hyer, E., Shegogue, D., Markiewicz, M., Lo, S., Hazen-Martin, D., Greene, E.L., 
Grotendorst, G., and Trojanowska, M. TGF-beta and CTGF have overlapping and distinct 
fibrogenic effects on human renal cells. Am. J. Physiol Renal Physiol 2002. 283:F707-F716.
24
CHAPTER 1
111. Nakamura, T., Sakata, R., Ueno, T., Sata, M., and Ueno, H. Inhibition of transforming growth 
factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in 
dimethylnitrosamine-treated rats. Hepatology2000. 32:247-255.
112. Zhao, J., Sime, P.J., Bringas, P., Gauldie, J., and Warburton, D. Adenovirus-mediated decorin 
gene transfer prevents TGF-beta-induced inhibition of lung morphogenesis. Am. J. Physiol.
1999. 277:L412-L422.
113. Border, W.A. and Noble, N.A. TGF-beta in kidney fibrosis: A target for gene therapy. Kidney 
Int. 1997. 51:1388-1396.
114. Verrecchia, F. and Mauviel, A. Transforming growth factor-beta signaling through the Smad 
pathway: role in extracellular matrix gene expression and regulation. J. Invest Dermatol.
2002. 118:211-215.
115. Morrissey, J., Hruska, K., Guo, G., Wang, S., Chen, Q., and Klahr, S. Bone morphogenetic 
protein-7 improves renal fibrosis and accelerates the return of renal function. J. Am. Soc. 
Nephrol. 2002. 13 Suppl 1:S14-S21.
116. Kaps, C., Bramlage, C., Smolian, H., Haisch, A., Ungethum, U., Burmester, G.R., Sittinger, M., 
Gross, G., and Haupl, T. Bone morphogenetic proteins promote cartilage differentiation and 
protect engineered artificial cartilage from fibroblast invasion and destruction. Arthritis 
Rheum. 2002. 46:149-162.
117. Stelnicki, E.J., Longaker, M.T., Holmes, D., Vanderwall, K., Harrison, M.R., Largman, C., and 
Hoffman, W.Y. Bone morphogenetic protein-2 induces scar formation and skin maturation in 
the second trimester fetus. Plast. Reconstr. Surg. 1998. 101:12-19.
118. Gitelman, S.E., Kobrin, M.S., Ye, J.Q., Lopez, A.R., Lee, A., and Derynck, R. Recombinant Vgr- 
1/BMP-6-expressing tumors induce fibrosis and endochondral bone formation in vivo. J. Cell 
Biol. 1994. 126:1595-1609.
119. Hulth, A., Johnell, O., Miyazono, K., Lindberg, L., Heinegard, D., and Heldin, C.H. Effect of 
transforming growth factor-beta and platelet-derived growth factor-BB on articular cartilage in 
rats. J. Orthop. Res. 1996. 14:547-553.
120. Itayem, R., Megarelli-Widholm, S., and Reinholt, F.P. The long-term effect of a short course of 
transforming growth factor-beta1 on articular cartilage. APMIS. 1999. 107:183-192.
121. Uria, J.A., Jimenez, M.G., Balbin, M., Freije, J.M.P., and Lopez Otin, C. Differential effects of 
transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in 
human fibroblasts. J. Biol. Chem. 1998. 273:9769-9777.
122. Tardif, G., Reboul, P., Dupuis, M., Geng, C., Duval, N., Pelletier, J.P., and Pelletier, J.M. 
Transforming Growth Factor-ß induced collagenase-3 production in human osteoarthritic 
chondrocytes is triggered by Smad proteins: cooperation between activator protein-1 and 
PEA-3 binding sites. J. Rheumatol. 2001. 28:1631-1639.
25

Loss of TGF-ß counteraction on IL-1- 
mediated effects in cartilage of old mice
A. Scharstuhl 
H. M. van Beuningen 
E L. Vitters 
P. M. van der Kraan 
W. B. van den Berg
Annals of the Rheumatic Diseases
2002. 61:1095-1098
CHAPTER 2
ABSTRACT
Ob je c t iv e . T o  investigate if  a difference exists between
YOUNG AND OLD MICE IN THE RESPONSE OF ARTICULAR 
CARTILAGE TO IL-1 AND TGF-ß ALONE OR IN COMBINATION.
M eth o d s. The in teraction  of IL-1 and TG F-ß  was
STUDIED IN CARTILAGE OF YOUNG (3 MONTHS) AND OLD MICE
(18 months) both in  v iv o  and in  v itr o . Therefore, IL-1 ,
TG F-ß  OR IL-1 TOGETHER WITH TGF-ß WAS INJECTED IN 
MURINE KNEE JOINTS ON DAYS 1, 3 AND 5 PRIOR TO HARVEST 
OF THE PATELLAE ON DAY 6. ALTERNATIVELY, ISOLATED 
PATELLAE WERE STIMULATED WITH IL-1 , TG F-ß  OR IL-1  
TOGETHER WITH TG F-ß  IN CULTURE FOR 48 HOURS. 
PROTEOGLYCAN (PG) SYNTHESIS AND NITRIC OXIDE (NO) 
PRODUCTION WERE MEASURED.
R e s u lt s . IL-1 inhibited PG synthesis and increased NO
PRODUCTION IN CARTILAGE OF BOTH YOUNG AND OLD MICE. ON 
THE OTHER HAND, TG F-ß  STIMULATED PG SYNTHESIS AND 
REDUCED NO PRODUCTION IN BOTH AGE GROUPS.
I mportantly, TG F-ß  was able t o  coun teract IL-1
MEDIATED EFFECTS ON PG SYNTHESIS AND NO PRODUCTION IN 
YOUNG MICE BUT NOT IN OLD.
Co n clu sio n s. C o n trary  to  the findings in young mice,
THE CARTILAGE OF OLD ANIMALS DO NOT ANTAGONIZE IL-1  
EFFECT VIA TGF-ß. THIS LOSS OF RESPONSIVENESS TO THE 
PIVOTAL CYTOKINE TGF-ß ON IL-1 EFFECTS CAN BE IMPORTANT 
IN THE INITIATION AND PROGRESSION OF OSTEOARTHRITIS
(OA).
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i n t r o d u c t i o n
OA is a joint disease with a high prevalence in the adult population 1i2. Although the 
etiology of OA is still unknown, increased age is a major risk factor, with up to 68% 
of women and 58% of men aged 65 years or older having radiological evidence of 
OA 3. Irrespective of the initiating event, OA is caused by an imbalance between 
anabolic and catabolic processes, which results in a slow but progressive destruction 
of articular cartilage.
Interleukin-1 (IL-1) is considered to be one of the most important catabolic factors in 
joint diseases 4-6. During OA large quantities of IL-1 are produced by chondrocytes, 
leading to the production of cartilage degrading matrix metalloproteinases (MMP's) 7­
10. Earlier studies have well documented the fact that IL-1 can inhibit cartilage 
proteoglycan (PG) synthesis and increase cartilage matrix breakdown 11-13. In old 
mice, IL-1 has shown to have a prolonged effect on articular cartilage compared to 
young individuals 14. An important second mediator stimulated by IL-1 is nitric oxide 
(NO) 15, which is also a very potent inhibitor of cartilage PG synthesis 16. Cartilage 
from OA patients produces significant amounts of NO 17.
A crucial anabolic factor to act on chondrocytes is Transforming Growth Factor-ß 
(TGF-ß). TGF-ß is stored in large amounts in articular cartilage and significant levels 
of active TGF-ß are found in the synovial fluid of OA patients 7 ,1 8 ,1 9  TGF-ß is thought 
to play an important role in articular cartilage homeostasis and during OA 20,21. We 
have previously shown that TGF-ß can enhance proteoglycan synthesis in vivo in 
both young and old individuals 13,22,23. Furthermore, MMP mediated cartilage 
degradation can be inhibited by TGF-ß via upregulation of tissue inhibitors of MMP's 
(TIMP's 1 and 3) 24,25. Recent studies show that abrogation of the TGF-ß signaling 
pathway in transgenic mice results in osteoarthritic changes of the articular cartilage, 
further implying a protective role for TGF-ß on articular cartilage 26,27. An important 
finding is that exogenous addition of TGF-ß in knee joints of young mice can 
counteract IL-1 induced cartilage PG depletion and breakdown 13,23,28. Moreover, PG 
synthesis was increased by TGF-ß in the presence of IL-1.
Since OA is a slowly progressive disease, a subtle imbalance between matrix 
breakdown (IL-1, NO) and matrix repair (TGF-ß) may be sufficient to initiate the 
osteoarthritic process. In this study, we compared IL-1 and TGF-ß responses 
between the cartilage of young and old mice. It was found that cartilage of old 
animals are still responsive to TGF-ß but are incapable of antagonizing IL-1 mediated 
effects via TGF-ß on NO production and cartilage PG synthesis. In contrast, in 
cartilage of young animals IL-1 mediated effects could be counteracted by TGF-ß.
m a t e r i a l s  & m e t h o d s
A n im als
Male C57Bl/6 mice aged 3-21 months were used. Mice were kept in filter top cages 
with a woodchip bedding under standard pathogen free conditions. They were fed a
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standard diet and tap water ad libitum. The local animal committee has approved 
this study.
In  vivo  P G  SYNTHESIS
Right knee joints of mice aged 3 or 18 months were injected with IL-1a (1 ng), TGF- 
ß1 (0.1 |ig, R&D systems Europe Ltd, Abingdon, UK) or the combination, in 6 |il PBS 
supplemented with 0.1% bovine serum albumin (BSA). Injections were done three 
times at alternate days (day 1, 3 and 5). The left knee joint was injected with PBS + 
0.1% BSA and served as an internal control.
PG synthesis was measured ex vivo, 1 day after the last injection. Therefore, mice 
were sacrificed and the patella with a standard amount of surrounding tissue was 
dissected as described earlier 29. Patellae were then pulse-labeled with 35S-sulfate (20 
|iCi, 2 hours, 37°C), which has previously shown to be a useful tool to specifically 
quantify chondrocyte PG synthesis 29,30. This was followed by washing the patellae 
extensively with physiological saline and fixing in 96% ethanol for 24 hours at room 
temperature. Patellae were decalcified in 5% formic acid for 4 hours at room 
temperature. Next, articular cartilage was stripped from the underlying bone and 
dissolved o/n in Lumasolve at 60°C (Lumac, Groningen, The Netherlands). Of every 
patella the incorporation of [35S] was measured separately using a liquid scintillation 
counter, which has shown to be a reliable method for the determination of patellar 
cartilage PG synthesis 30.
In  vitro  P G  SYNTHESIS
Mice were sacrificed at the age of 3-5 or 12-21 months. The patella with surrounding 
tissue was dissected in standardized fashion and placed in RPMI 1640 medium 
(Dutch modification, Flow laboratories, Irvine, UK). Patellae were divided into four 
treatment groups (minimal 6 patellae per group): no treatment, IL-1a (10 ng/ml), 
TGF-ß1 (10 ng/ml) or a combination of IL-1 and TGF-ß1. The tissue culture medium 
was changed every 24 hours. After 48 hours of treatment, patellae were labeled for 
2 hours with 20 |iCi radioactive sulfate in RPMI 1640 (Dutch modification) 
supplemented with gentamicine (50 mg/l), 2 mM l-glutamine at 37°C and 5% CO2. 
The rest of the labeling procedure was carried out as described above.
In total 30 "old" patellae and 20 "young" patellae were used in three independent 
experiments. All adsorbances and 35S incorporation levels were transformed to 
percentage compared to control treatment. Results were statistically analyzed via 
ANOVA.
M ea s u r e m e n t o fN O  lev els
NO levels in the culture media were measured on day 1 and 2. The medium 
concentration of NO2- (a stable breakdown product of NO) was determined by Griess 
reagent using NaNO2 standards. Griess reagent: 0.1% N-(1-naphtyl)-ethylenediamin 
dihydrochloride (Sigma Chemicals Co, St. Louis, MO, USA), 1:1 diluted with 1.0% 
sulfanilamide (p-aminobenzene-sulfanamide; Sigma Chemicals Co, St. Louis, MO, 
USA) in 5% H3PO4. In short, 100 |il of conditioned medium was mixed with 100 |il 
Griess reagent in a flat-bottom microtiter plate and adsorbance read at 545 nm using 
an ELISA plate reader (Titertek Multiscan MCC/340).
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R ESU LTS
In  VIVO PG SYNTHESIS
We investigated whether increased age influences the response of articular cartilage 
to anabolic and catabolic factors. Therefore, IL-1, TGF-ß1 or IL-1/TGF-ß1 were i.a. 
injected on day 1, 3 and 5 in young (3 months) and old (18 months) mice. One day 
later, the effect of these factors on the PG synthesis in isolated patellae was 
determined.
The used dose of TGF-ß1 (100 ng) has shown to induce maximal effects on PG 
synthesis in vivo as described earlier 13-15. The dose for IL-1 was based on earlier in 
vivo experiments 14,15. In these in vivo studies, the used IL-1 concentrations yielded 
maximal effects on inhibition of PG synthesis. We observed no influence of TGF-ß or 
IL-1 on the contralateral joint (results not shown).
As figure 1 shows, IL-1 induced a more severe suppression of PG synthesis in old 
than in young animals (56% versus 39%, respectively)(p<0.05). TGF-ß increased PG 
synthesis 2.5 to 2 fold in young and old animals respectively. Importantly, TGF-ß in 
combination with IL-1 reversed the inhibitory effects of IL-1 on PG synthesis to 
slightly higher than control levels in young mice but not in old. So, our results show 
that TGF-ß counteracts IL-1 induced suppression of PG synthesis in young mice only.
F ig u re  1 P a t e l l a r  c a r t il a g e  P G
SYNTHESIS IN OLD AND YOUNG MICE. RIGHT 
KNEE JOINTS OF YOUNG MICE (3 MONTHS) 
AND OLD MICE (18 MONTHS) WERE INJECTED 
ON DAY 1,3 AND 5 WITH T G F -ß  (0.1 jlG), IL- 
1 a  (1 NG) OR IL-1 + T G F -ß . L e f t  k n e e
JOINTS WERE INJECTED WITH VEHICLE AND 
SERVED AS INTERNAL CONTROLS (=100%).
O n  day  6, p a t e l la e  w e re  is o la t e d  and  
P G  s y n th e s is  w a s  m ea su red  e x  vivo  v ia  
35S - s u l f a t e  in c o rp o r a t io n  (2 HOURS, 
37°C). E a c h  v a lu e  r e p r e s e n t s  th e  mean 
P G  s y n th e s is  o f  5 p a te lla e .  R e s u l t s
WERE STATISTICALLY ANALYZED VIA A N O V A , 
** = p<0.001.
In  vitro  P G  sy n th esis
To gain more insight in the mechanistics behind the different responses of old and 
young individuals to IL-1 and TGF-ß, we turned to the in vitro situation. Isolated 
patellae from young and old mice were cultured for 48 hours with IL-1, TGF-ß1 or IL- 
1/TGF-ß and cartilage PG synthesis was studied.
The dose TGF-ß1 used for in vitro experiments has been shown to induce an 
optimum effect in cultured chondrocytes 13. Moreover, this dose seems 
physiologically relevant since comparable concentrations TGF-ß have been found in 
arthritic and osteoarthritic joints 19,31. The IL-1 dosage used induced maximal effects 
in vitro as described in earlier studies 13,15.
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In both age groups, TGF-ß only showed a slight increase in PG synthesis compared 
to controls, a difference that was not significant (figure 2). This loss of TGF-ß 
response, is probably due to the short exposure of the cartilage to TGF-ß in vitro 
compared to the repeated exposure to high TGF-ß concentrations via bolus injections 
in vivo. Despite the lack of response after TGF-ß addition alone, young mice showed 
a relative increase of 44% in PG synthesis in the IL-1/TGF-ß combination group 
compared to the IL-1 group (figure 2)(p<0.001). In contrast, old mice did not show 
a significant increase in PG synthesis in the IL-1/TGF-ß compared to IL-1 alone. 
These results show that TGF-ß was able to significantly reduce the IL-1-induced 
inhibition on PG synthesis in young mice, but that in old mice TGF-ß could not 
counteract the IL-1-induced suppression in PG synthesis.
F ig u re  2 In  vitro  P G  s y n th e s is  in p a t e l la r
CARTILAGE OF YOUNG (3-5 MONTHS) AND OLD
mice (12-21 m onths). P a t e l la e  w e re  
ISOLATED AND CULTURED IN R P M I 1640 
medium. P a t e l la e  w e re  t r e a t e d  48  h o u r s  
w ith  IL-1 a  (10 ng/m l), T G F - ß 1 (10ng/m l), a
COMBINATION OF IL-1 + TG F-ß1  OR WERE NOT
t r e a t e d . T h e  t is s u e  c u l t u r e  m e d iu m  w a s
CHANGED EVERY 24 HOURS. P G  SYNTHESIS WAS 
MEASURED VIA 35S-SULPHATE INCORPORATION (2
35
h o u r s , 37°C). S  in c o r p o r a t io n  l e v e l s
WERE TRANSFORMED TO PERCENTAGE 
COMPARED TO CONTROL TREATMENT (=100%).
R e s u l t s  w e r e  s t a t is t ic a l l y  a n a l y z e d  v ia  
A N O V A , ** = p <0.001.
young mice old mice
N O  SYNTHESIS
Nitric oxide is the most important second mediator of IL-1 in the inhibition of PG 
synthesis. TGF-ß is known to decrease NO synthesis. Therefore, the NO production 
was measured in media from control patellae and in patellae after stimulation with 
IL-1, TGF-ß and IL-1/TGF-ß. Patellae of young and old mice produced NO 
spontaneously (table 1).
T a b l e  1 In f l u e n c e  o f  IL-1 a n d  co m b in a tio n  IL-1/TGF-ß on  in v itr o  N O  p r o d u c t io n
(|lM) BY PATELLAR CARTILAGE OF YOUNG AND OLD MICE.
Y O U N G s d o l d s d
D a y  1 § S p o n t a n e o u s 7.81 ± 0.293 5.30 ± 0.175
IL-1 6.53 ± 0.463* 8.32 ± 0.496
TGF-ß/IL-1 5.12 ± 0.556 7.82 ± 0.436
A -28 % -6 %
D a y  2 § S p o n t a n e o u s 12.71 ± 0.390 10.82 ± 0.351
IL-1 18.10 ± 0.837* 20.82 ± 0.635
TGF-ß/IL-1 15.0 ± 0.814 20.13 ± 0.699
A -21 % -4 %
* = SIGNIFICANTLY DIFFERENT FROM IL-1 ALONE, § = SIGNIFICANTLY DIFFERENT FROM OLD MICE. A  =
D i f f e r e n c e  in p e r c e n t a g e  b e t w e e n  IL-1 t r e a t m e n t  a l o n e  a n d  T G F-ß /IL-1  c o m b in a t io n  
t r e a t m e n t .
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In young mice TGF-ß treatment alone resulted in significantly less NO production 
compared to no treatment, 50% on day 1 and 40% on day 2 (figure 3). In old mice 
a small but significant effect of TGF-ß was found on day 2 (14.4%, p<0.05), whereas 
no effect of TGF-ß alone was seen on day 1. Young mice displayed a considerably 
stronger effect of TGF-ß on the inhibition of NO production than old mice, 48% less 
NO on day 1 and 26% on day 2.
F ig u re  3 In  vitro  N O  p r o d u c t io n  a f t e r
T G F -ß  TREATMENT BY PATELLAR CARTILAGE OF 
YOUNG (3-5 MONTHS) AND OLD MICE (12-21 
MONTHS). PATELLAE WERE ISOLATED AND 
PLACED IN R P M I 1640 MEDIUM MEDIUM. 
PATELLAE WERE TREATED 48  HOURS WITH T G F -  
ß (10 NG/ML) OR WERE NOT TREATED. THE 
TISSUE CULTURE MEDIUM WAS CHANGED EVERY
24 HOURS. N O 2- IN THE MEDIUM WAS MEASURED 
AFTER 24  AND 48  HOURS VIA GRIESS REACTION. 
N O  PRODUCTION BY CONTROL TREATED 
PATELLAE WAS STATED AS 100% . RESULTS 
WERE STATISTICALLY ANALYZED VIA A N O V A , * = 
P<0.01 AND ** = P<0.001, SIGNIFICANTLY 
DIFFERENT FROM CONTROL TREATMENT.
In patellae of young mice, the combination treatment of IL-1/TGF-ß showed a 
counteractive effect of TGF-ß on IL-1-induced NO production (table 1). TGF-ß 
inhibited IL-1-induced NO production with 28% on day 1 (p<0.05) and 21% on day
2 (p<0.01). In old mice, TGF-ß had no significant effect on IL-1-induced NO 
synthesis.
D ISCU SSIO N
OA is a joint disease, which has high age as main risk factor. The determinant that 
initiates the process is still unknown but the general conception is that a disbalance 
between catabolic factors and anabolic factors targeting the articular cartilage plays a 
major role. Because the osteoarthritic process is slowly progressive, it is plausible 
that a subtle shift in the anabolic/catabolic balance is sufficient to start the process. 
The aim of this study was to identify differences between young and old cartilage 
concerning the influence of anabolic and catabolic factors.
We have previously observed that TGF-ß increases cartilage PG synthesis and 
content when injected i.a. in both young and old mice 13. Moreover, TGF-ß 
supplementation in young mice has shown to antagonize IL-1-mediated inhibition of 
PG synthesis 23. However, these studies did not provide any mechanistic information 
how TGF-ß counteracts IL-1 effects. The underlying in vivo and in vitro study shows 
that in young mice TGF-ß can antagonize IL-1 mediated effects on PG synthesis. In 
contrast, old animals have lost the ability to counteract IL-1 effects on PG synthesis 
via TGF-ß. We set out to further investigate how increased age influences the 
response to these cytokines. We hypothesized that the mechanistics behind the 
counteraction is NO mediated, since NO is the most important second mediator of IL- 
1 and TGF-ß is known to decrease NO synthesis 15,32,33. In addition, we have 
previously shown that i.a. injections of IL-1 in NO-deficient mice did not affect PG
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synthesis, proving that NO is necessary in mediating IL-1 effects 16. Here we 
compared responses of young and old mice on NO production after IL-1, TGF-ß and 
IL-1+TGF-ß stimulation. The results from the NO data show that old mice have lost 
the capability to block IL-1 induced NO production via TGF-ß, whereas young animals 
do have this capacity. This is probably not due to loss of the TGF-ß response because 
old animals still show a strong TGF-ß effect on PG synthesis in vivo. However, old 
mice show a very strong induction of NO production after IL-1 stimulation compared 
to young animals. The loss of IL-1 counteraction by one of the most potent anabolic 
factors on articular cartilage, together with a hypersensitivity to IL-1, could 
predispose the elderly to OA and can contribute to the progression of the disease.
The manner in which TGF-ß antagonizes IL-1 mediated PG synthesis is still unknown 
but can be based on various mechanisms. TGF-ß could cause downregulation of IL-1 
receptors or increase IL-receptor antagonist, the natural inhibitor of IL-1. However, 
since both cytokines are added simultaneously, the TGF-ß induced synthesis of IL-Ra 
will considerably lag behind the direct effect of IL-1. On the other hand, IL-1 could 
disturb the TGF-ß signaling pathway in old mice, resulting in loss of TGF-ß mediated 
inhibition of NO synthesis. Consequently, old mice will also be insensitive to 
endogenous TGF-ß, which otherwise would partly inhibit the IL-1 effect, as is the 
case in young animals. Loss of the response to endogenously produced TGF-ß could 
explain the high NO production after IL-1 stimulation, as observed in old mice but 
not in young. Abrogation of the TGF-ß pathway by IL-1 could potentially be based on 
upregulation of inhibitory molecules such as the recently described Smad-6 and -7 34­
. In addition, in old mice IL-1 might block essential secondary mediators in the 
TGF-ß signaling pathway like receptor associated Smad-2, -3 or the common 
mediator Smad-4 .
The results show a discrepancy between the in vivo and in vitro situation concerning 
the TGF-ß response on PG synthesis. Whereas in vivo TGF-ß greatly enhances PG 
synthesis in both age groups, no effect of TGF-ß addition was found in the in vitro 
situation. This difference is probably caused by the mode of TGF-ß administration: 
multiple high bolus concentrations in vivo versus a continuous relatively low dose in 
vitro. As we previously showed, TGF-ß has a slow response time in vivo, therefore, 
48 hours might be too early for the direct TGF-ß response on PG synthesis in the in 
vitro situation.
Our results indicate that in cartilage of young, but not old animals, TGF-ß is able to 
counteract the deleterious effects of IL-1 on PG synthesis and NO production. In 
contrast, chondrocytes from old animals appear to have lost the capacity to 
antagonize IL-1 effects via TGF-ß. Taken together, in old animals the balance 
between anabolic and catabolic factors seems to have shifted towards the catabolic 
side, a phenomenon that might be related to the initiation and progression of OA.
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ABSTRACT
O b je c t iv e . OA is co rre la ted  w ith high age and is
THOUGHT TO BE CAUSED BY A MISBALANCE BETWEEN ANABOLIC 
AND CATABOLIC FACTORS ACTING ON CHONDROCYTES.
T h erefo r e , w e in vestig ated  if  ch ondrocytes from young
AND OLD MICE SHOW DIFFERENCES IN THE EXPRESSION PROFILES 
OF VARIOUS SIGNALING MEDIATORS OF THE CRUCIAL ANABOLIC 
FACTOR TG F-ß  BEFORE AND AFTER IL-1 EXPOSURE.
Ma t er ia ls  & Meth o d s . The effect of in tra -a rt ic u la r  
IL-1 INJECTIONS (10 ng/ml) ON THE EXPRESSION OF THE 
TG F-ß  SIGNALING MEDIATORS SmAD2, -3, AND - 4  
(activating  m ediators), Smad-6 and - 7  (inhibiting  
mediators) and TG F-ß  type I and type I I  receptors was
STUDIED IN YOUNG (3 MONTHS) AND OLD MICE (2 YEARS).
Expressio n  pr o files  w ere  stu d ied  by immuno-
HISTOCHEMISTRY ON TOTAL KNEE JOINT SECTIONS. THE NUMBER 
OF CHONDROCYTES POSITIVE FOR THE VARIOUS SIGNALING 
PROTEINS WAS DETERMINED VIA AN IMAGE ANALYSIS SYSTEM 
AND CORRECTED FOR THE TOTAL NUMBER OF CHONDROCYTES.
R es u lt s . Exposure of a r t ic u la r  cartilag e  to  IL-1 did
NOT INDUCE SIGNIFICANTLY DIFFERENT EXPRESSION PROFILES IN 
BOTH YOUNG AND OLD MICE COMPARED TO NON-INJECTED KNEE
jo in ts . How ever , when comparing young w ith  old
ANIMALS, OLD MICE DISPLAYED RELATIVELY MORE TG F-ß-R I 
EXPRESSION (+ 8 0 % ), IN COMBINATION WITH A RELATIVELY 
LOWER EXPRESSION OF S mAD7 (-1 5 % ). THE EXPRESSION 
PROFILES OF THE OTHER SIGNALING MEDIATORS WERE SIMILAR 
IN YOUNG AND OLD MICE.
D is c u s s io n . Unexpectedly, o u r re su lts  point tow ard s
MORE ACTIVE TG F-ß  SIGNALING IN OLD ANIMALS. SO, THE HIGH 
INCIDENCE OF OA WITH INCREASED AGE CANNOT BE EXPLAINED 
BY DISTORTED TG F-ß  SIGNALING IN THE ELDERLY POPULATION.
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IN TR O D U CTIO N
OA is the most common rheumatologic disorder with a reported prevalence in the 
adult population of 70% 1. One of the main characteristics of OA is the destruction of 
articular cartilage. Although the exact etiology of OA is unknown, the incidence of OA 
is highly correlated with increased age. Because OA is a slowly progressive disease, 
OA may ultimately be the result of a subtle age-related disbalance in reaction to 
catabolic and anabolic factors acting on chondrocytes.
A very important catabolic cytokine involved in joint pathology is IL-1. In mice that 
readily develop OA and in OA patients chondrocytes demonstrate high IL-1 
expression, whereas mice that do not develop OA and non-arthritic patients showed 
limited expression of IL-1 2-4. Moreover, in knee joints of OA patients high levels of 
IL-1 are found 5. IL-1 has shown to inhibit cartilage PG synthesis and injection of IL- 
1 results in articular cartilage damage 5'6. IL-1 effects seem to be age dependent 
since IL-1-mediated inhibition of PG synthesis is prolonged in old mice compared to 
young mice 7. The destructive effect on articular cartilage by IL-1 is generally 
thought to be mediated by upregulation of matrix degrading enzymes (MMPs).
In contrast to IL-1, TGF-ß is a crucial anabolic factor for chondrocytes. Not only is 
TGF-ß one of the most potent inducers of chondrocyte proliferation but TGF-ß is also 
an important stimulator of cartilage PG and type II collagen synthesis in vivo and in 
vitro 8-11. TGF-ß downregulates the expression of cartilage degrading MMPs and 
upregulates the natural inhibitors of MMPs (TIMPs) 12.
Importantly, TGF-ß has been shown to antagonize IL-mediated effects in 
chondrocytes 13,14. IL-1-induced cartilage PG depletion and breakdown could be 
counteracted by TGF-ß 8,15-17 and TGF-ß was able to stimulate PG synthesis in the 
presence of IL-1 18. Additionally, IL-1-induced nitric oxide and protease production 
could be counteracted by TGF-ß 19,20. Interestingly, the counteractive ability of TGF-ß 
seems to be age dependent since old animals have lost this counteractive capability 
by TGF-ß as we have previously shown 20. This results in a shift to the catabolic side 
of the IL-1/TGF-ß balance in old animals that might be related to the initiation and 
progression of OA.
TGF-ß signaling starts with binding of TGF-ß to the type II receptor (TGF-ß-RII) 
followed by recruitment of the type I receptor (TGF-ß-RI). Intracellular TGF-ß 
signaling is mediated by three different classes of so-called Smad proteins. The TGF- 
ß pathway is activated by phosphorylation of receptor-associated (R-) Smad2 or -3 
by the activated TGF-ß-RI 21. Consequently, these R-Smads form a complex with the 
common-mediator (Co-) Smad4 and this complex translocates to the nucleus and 
regulates transcription of TGF-ß responsive genes 22. This activatory route can be 
negatively regulated via an auto-inhibitory feedback loop initiated by a third class of 
Smad proteins: the inhibitory (I-) Smad6 and -7 23,24.
Since OA is clearly associated with high age, we hypothesized that during aging TGF- 
ß signaling is altered, resulting in downregulation of receptor expression and/or the 
activatory R- and Co-Smads or rather an upregulation of I-Smads levels. Therefore,
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we investigated by immunohistochemical methods if intra-articular IL-1-injections 
resulted in altered TGF-ß-R or Smad expression levels between young and old 
animals. Unexpectedly, our results identified a significantly higher expression of TGF- 
ß-RI combined with a significantly lower expression of inhibitory Smad7 in old 
animals than in young. These data point to a more activated state of the TGF-ß 
signaling pathway, rather than decreased activity. Furthermore, the expression of 
Smad2, -3, -4 and -6 and also expression of type II receptors was similar in young 
and old mice. We conclude that the high occurrence of OA in the elderly population 
is not caused by a disfunctional TGF-ß signaling in old animals.
M A TER IA LS  & M ETH O D S
A n im als
Male C57Bl/6 mice aged 12 weeks (n=14) or 2 years (n=14) were used. Animals 
were kept in filter top cages with a woodchip bedding under standard pathogen free 
conditions. They were fed a standard diet and tap water ad libitum. The local animal 
committee has approved this study.
Exper im en tal Desig n
TGF-ß counteraction of IL-1 effects is most likely mediated by TGF-ß-RI, -RII and the 
intracellular Smad proteins. We investigated if young and old mice differ regarding 
expression of these TGF-ß signaling mediators before and after IL-1 exposure. 
Therefore, the right knee joints of mice were injected with 10 ng IL-1a (R&D 
systems), a dose that has shown to induce maximal effects in vivo 6,2S. The 
uninjected left knee joints served as internal controls. After 24 hours, mice were 
sacrificed; knee joints were isolated and prepared for histology.
Histo lo g y
For the different classes of Smads knee joints were decalcified for 14 days in 
EDTA/PVP and subsequently cryosections of total knee joints (7 |iM) were prepared 
and stored at -20°C. Before use, sections were airdried for 30 min and freshly 
prepared paraformaldehyde (4%, 5 min) was used to fixate the sections.
Immunohistochemistry for TGF-ß-RI and -R II was performed on paraffin sections 
from total knee joints. Knee joints were fixed in phosphate buffered formalin for 7 
days. Subsequently, knee joints were dehydrated using an automated tissue- 
processing apparatus (VIP) and embedded in paraffin. Tissue sections of 7 |im were 
prepared.
Im m u n o h isto ch em istr y
After washing the sections with PBS, endogenous peroxidase was blocked with 1% 
H2O2 in methanol for 30 min. Then, sections were blocked with 10% normal serum 
(in 1% BSA/PBS for 1 hr) of the species in which the secondary Ab was produced. 
Specific primary Ab against TGF-ß-RI and -R II (0.5 ng/ml), the R-Smad2 and -3, the 
Co-Smad4 (all 0.5 ng/ml) and the inhibitory Smad6 (1.0 ng/ml) and -7 (3.3 ng/ml) 
(All purchased from Santa Cruz Biotechnology Inc, Santa Cruz, USA, except Smad6, 
which was purchased from Zymed Laboratories Inc, San Francisco, USA) were
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incubated overnight at 4°C. As a negative control, the primary Ab was replaced with 
goat or rabbit IgG's. After extensive washing in PBS, the appropriate biotin labeled 
secondary Ab were used in a concentration of 2 ng/ml in 1% BSA/PBS for 2 hrs 
(Vector Laboratories. Inc, Burlingham, CA), followed by a biotin-streptavidine 
detection system according to the manufacturers protocol (Vector Laboratories). 
Bound complexes were visualized via reaction with 3',3'diaminobenzidine (Sigma 
Chemicals Co) and H2O2 resulting in a brown precipitate. Sections were briefly 
counterstained with haematoxylin and mounted with permount.
Q u an tifica tio n  o fp o s itiv e a r tic u la r  ch o n d ro cytes
For the different antigens the number of positive articular chondrocytes in the 
patellar cartilage was determined by a blinded observer. The microscopic image was 
displayed on a computer monitor using the Qwin image analysis system (Leica 
Imaging Systems Ltd. Cambridge, U.K.) and a Leica DC 300F digital camera. The 
area representing the non-calcified articular cartilage was selected by hand. For each 
antigen a threshold was set in such a manner that only chondrocytes were selected 
that were found positive (= brown cell) as judged by the observer. The computer 
program determined the number of positive cells in the cartilage for the different 
antigens. For each knee joint the expression of the different antigens was measured 
in at least 3 tissue sections. The intensity of the staining was not taken into account 
since no obvious differences were observed in staining intensities in the different 
experimental groups: young/old or -IL-1/+IL-1. The obtained values were averaged 
and the subsequent average per treatment group was determined. To correct for 
differences in cell number between young and old mice, the average number of 
chondrocytes in the non-calcified cartilage was determined in sections stained with 
haematoxylin only. This was based on a similar selection procedure as described 
above with the exception that selection of chondrocytes was based on the blue 
staining from haematoxylin instead of brown staining. The percentage of positive 
chondrocytes based on the total number of chondrocytes was determined. Results 
were analyzed by ANOVA.
R ESU LTS
Ch o n d r o cyte cell n um ber
The number of positive cells for the different signaling proteins was expressed in 
percentages of total chondrocyte number. Therefore, for young and old mice the 
average chondrocyte number present in the patellar cartilage was determined in 
non-stimulated and IL-1 stimulated knee joints. Table 1 shows that patellar cartilage 
from non-injected knee joints of both young and old mice demonstrate an identical 
number of chondrocytes. The injection of IL-1 did not significantly alter the number 
of chondrocytes in the articular cartilage in both age groups.
IL-1  EFFECTS ON TGF-ß SIGNALING MEDIATORS
First, we investigated if IL-1 induced differences in TGF-ß receptor expression and if 
such a difference was age-dependent. Figure 2 shows that IL-1 had no significant 
effect on TGF-ß-RI expression in articular chondrocytes of both young and old 
animals compared to control cartilage. However, it can be observed from figure 1
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A+B (see Chapter 9) and figure 2 that in control cartilage of old mice chondrocytes 
express far more TGF-ß-RI than control cartilage of young animals, 88% and 38%, 
respectively and p<0.01. After stimulation with IL-1, no significant difference 
between young and old mice could be observed (p=0.147). Expression of the TGF-ß- 
RII was not significantly affected by IL-1 treatment and furthermore, the expression 
did not show any age dependency (figure 1 C+D (Ch. 9) and figure 2).
T a b l e  1 Q u a n tific atio n  o f  c h o n d r o c y t e  n u m b e r  in c a r t il a g e  f r o m  y o u n g  a n d  o ld  m ic e .
T r e a t m e n t Y o u n g  m i c e O L D  MICE
A v e r a g e * SEM A v e r a g e * SEM
- IL-1 74.6 3.7 77.2 4.0
+ IL-1 76.8 3.4 69.5 2.1
* Right knee joints of young (3 months, n=14) and old (2 years, n=14) mice were injected with IL-1 (10 
ng/ml), left knee joints served as controls. 24 Hours later knee joints were prepared for histology. 3 semi 
serial haematoxylin stained sections were analyzed for the presence of chondrocytes via a computer aide< 
image analysis system. The number of positive chondrocytes as stained by haematoxylin is shown.
We also studied if IL-1 had effect on the expression of activating TGF-ß signaling 
mediators (Smad2, -3 and -4) in articular chondrocytes and investigated if there was 
a difference between young and old mice. As figure 1 E+F (Ch. 9) and 3 show, 
approximately 40% of the articular chondrocytes show detectable Smad2 expression, 
whereas approximately 30% of the chondrocytes was Smad3 positive. IL-1 had no 
significant effects on the expression of Smad2 and -3 in young and old mice. On the 
other hand, IL-1 seemed to reduce the relative expression of Smad4 in young mice 
by 31%. In old mice, IL-1 even reduced Smad4 expression by 50% (figure 1 G-I (Ch. 
9)). However, this effect of IL-1 on Smad4 expression did not reach statistical 
significance in both young and old animals, p=0.345 and p=0.130, respectively.
F ig u re  2. Q u a n t if ic a t io n  o f  T G F -ß  r e c e p t o r s  
t y p e  I a n d  - II. R ig h t  k n e e  jo in t s  o f  y o u n g  (3 
MONTHS, N=14) AND OLD (2 YEARS, N=14) MICE 
w e r e  in je c t e d  w ith  IL-1 (10 n g /m l ) a n d  l e f t
KNEE JOINTS SERVED AS INTERNAL CONTROLS. 24
H o u r s  l a t e r  k n e e  jo in t s  w e r e  is o l a t e d  a n d  
p r e p a r e d  f o r  h is t o l o g y . T G F -ß -R I  a n d  -RII 
w e r e  d e t e c t e d  v ia  im m u n o h is t o c h e m is t r y  o n
TOTAL KNEE JOINT SECTIONS. THREE SEMI-SERIAL
s e c t io n s  w e r e  a n a l y z e d  b y  a  b l in d e d  o b s e r v e r  
f o r  t h e  p r e s e n c e  o f  p o s it iv e  c h o n d r o c y t e s  v ia  
a  c o m p u t e r  a id e d  im a g e  a n a l y s is  s y s t e m . T h e  
n u m b e r  o f  p o s it iv e  c h o n d r o c y t e s  w a s  
e x p r e s s e d  a s  t h e  p e r c e n t a g e  o f  t o t a l  
c h o n d r o c y t e s . * = P < 0.005.
The influence of IL-1 on the expression of the inhibitory Smad6 and -7 was also 
investigated. Figure 1 J-L and figure 4 show that, whereas only 10% of the articular 
chondrocytes showed detectable Smad6 expression, more than 70% of the cells are 
positive for Smad7. The injection of IL-1 had no effect on I-Smad expression in 
young and old mice compared to unstimulated cartilage. In addition, we did not 
observe obvious differences in staining intensities for the various signaling mediators 
between different treatment groups.
42
S h ifte d  e x p r e s s io n  pr o file s  of TG F-ß  s ig n a lin g  m e d ia to r s  in y o u n g  c o m p a r e d  to  o ld  mice
When comparing young with old animals also no significant differences were 
observed, although a trend could be observed that chondrocytes from old animals 
express less Smad7 than young.
F ig u re  3. Q u a n t if ic a t io n  o f  a c t iv a t in g
INTRACELLULAR T G F -ß  SIGNALING MEDIATORS.
R ig h t  k n e e  jo in t s  o f  y o u n g  (3 m o n t h s , n =14) 
AND OLD (2 y e a r s , N=14) MICE WERE INJECTED 
WITH IL-1 (10 n g /m l ) a n d  l e f t  k n e e  jo in t s  s e r v e d  
a s  in t e r n a l  c o n t r o l s . 24  H o u r s  l a t e r  k n e e  
jo in t s  w e r e  is o l a t e d  a n d  p r e p a r e d  f o r  
h is t o l o g y . A c t iv a t in g  S m a d 2, -3 a n d  -4 w e r e
DETECTED VIA IMMUNOHISTOCHEMISTRY ON TOTAL 
KNEE JOINT SECTIONS. THREE SEMI-SERIAL SECTIONS 
WERE ANALYZED BY A BLINDED OBSERVER FOR THE 
PRESENCE OF p o s it iv e  c h o n d r o c y t e s  VIA A 
COMPUTER AIDED IMAGE ANALYSIS SYSTEM. THE 
NUMBER OF POSITIVE CHONDROCYTES WAS 
e x p r e s s e d  AS THE PERCENTAGE OF TOTAL 
c h o n d r o c y t e s .
Yo un g  ver su s o ld
Since no significant effect of IL-1 injections was observed on the expression of any of 
the TGF-ß signaling proteins in young or old mice, the data from -  IL-1 and + IL-1 
were combined. This allowed for a more powerful statistical analysis between young 
and old animals. This procedure resulted in statistical differences regarding type I 
receptor and Smad7 expression (Figure 5). The relative expression of type I receptor 
was increased by 78.6% in old mice compared to young mice (p<0.01). Moreover, 
the relative Smad7 expression was decreased by 15%, in old versus young mice 
(p<0.05). No statistical differences between young and old animals were observed 
regarding expression of Smad2, -3, -4, -6 and TGFß-RII in articular chondrocytes 
(data not shown). These results point to a more active TGF-ß signaling pathway in 
old mice than in young animals.
F ig u re  4. Q u a n t if ic a t io n  o f  inhibiting
INTRACELLULAR T G F -ß  SIGNALING MEDIATORS.
R ig h t  k n e e  jo in t s  o f  y o u n g  (3 m o n t h s , n =14) 
AND OLD (2 y e a r s , N=14) MICE WERE INJECTED 
WITH IL-1 (10 n g /m l ) a n d  l e f t  k n e e  jo in t s  s e r v e d  
a s  in t e r n a l  c o n t r o l s . 24  H o u r s  l a t e r  k n e e  
jo in t s  w e r e  is o l a t e d  a n d  p r e p a r e d  fo r  
h is t o l o g y . In hib it in g  S m a d 6 a n d  -7 w e r e
DETECTED VIA IMMUNOHISTOCHEMISTRY ON TOTAL 
KNEE JOINT SECTIONS. THREE SEMI-SERIAL SECTIONS 
WERE ANALYZED BY A BLINDED OBSERVER FOR THE 
PRESENCE OF p o s it iv e  c h o n d r o c y t e s  VIA A 
COMPUTER AIDED IMAGE ANALYSIS SYSTEM. THE 
NUMBER OF POSITIVE CHONDROCYTES WAS 
e x p r e s s e d  AS THE PERCENTAGE OF TOTAL 
c h o n d r o c y t e s .
D ISCU SSIO N
OA is the most common joint disorder in the adult population and although the 
initiating factor that causes OA is unknown, an imbalance between anabolic and 
catabolic factors may be the underlying cause of OA. Additionally, the prevalence of 
OA strongly correlates with increased age. Nevertheless, the relation between
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increased age and altered cytokine responses or changed expression levels of 
cytokine signaling mediators have received little attention. Therefore, we investigated 
the effect of IL-1 exposure on the expression profile of TGF-ß receptors and the 
intracellular mediators, the Smad proteins.
Exposure of knee joints to IL-1 did not induce significant changes regarding 
expression of TGF-ß receptors or the different classes of Smads in articular 
chondrocytes. However, Smad4 expression was decreased in both young and old 
animals. Especially the 50% reduction of positive chondrocytes for Smad4 after IL-1 
exposure in old animals could be important. Since Smad4 is the pivotal mediator 
involved in TGF-ß and Bone Morphogenetic Protein signaling, this reduction could 
have pronounced effects on the TGF-ß counteraction on IL-1 effects in chondrocytes. 
Increased group size could lead to significant results of IL-1 regarding Smad4 
expression, however, we were hampered by a limited number of old mice.
FIGURE 5. R e l a t iv e  e x p r e s s io n  o f  TGF-ß-RI
AND S mAD7 IN YOUNG AND OLD MICE. KNEE JOINTS 
WERE ISOLATED AND PREPARED FOR HISTOLOGY.
TGF-ß-RI a n d  S m a d 7 w e r e  d e t e c t e d  via
IMMUNOHISTOCHEMISTRY ON TOTAL KNEE JOINT
s e c t io n s . T h r e e  s e m i -s e r ia l  s e c t io n s  w e r e
ANALYZED BY A BLINDED OBSERVER FOR THE 
PRESENCE OF POSITIVE CHONDROCYTES VIA A 
COMPUTER AIDED IMAGE ANALYSIS SYSTEM. THE 
NUMBER OF POSITIVE CHONDROCYTES WAS 
EXPRESSED AS THE PERCENTAGE OF TOTAL 
CHONDROCYTES. THE PERCENTAGE OF POSITIVE 
CHONDROCYTES IN YOUNG MICE WAS STATED AS
-> 100% . T h e  r e l a t iv e  e x p r e s s io n  is s h o w n .
Strikingly, our results point towards a more active TGF-ß signaling pathway in old 
mice compared to young. We not only identified significantly more TGF-ß-RI positive 
chondrocytes in old than in young animals, the number of chondrocytes expressing 
the inhibitory Smad7 was decreased in old compared to young animals. It has been 
reported that TGF-ß-induced chondrocyte proliferation decreases with increased age 
26,27. On the other hand, TGF-ß-stimulated production of inorganic pyrophosphate, a 
factor involved in the induction of joint pathology, increases with age 27,28. This latter 
observation is in line with our data pointing to more active TGF-ß signaling. However, 
the described loss of TGF-ß counteraction of IL-1 effects in old mice as we published 
previously 20, is unlikely to be caused by a less active TGF-ß signaling in these old 
animals.
Our data show a strong discrepancy between the percentage of chondrocytes 
positive for the different signaling proteins; ~10% for Smad6 and ~80% for Smad7 
and TGF-ß-RI. Although this makes it tempting to speculate about the occurrence of 
subpopulations of chondrocytes expressing different TGF-ß signaling mediators, the 
detected differences can also be explained by different antibody affinities. 
Furthermore, physiological concentrations of antigens can be below threshold level of 
the immunological methods used. So, the percentages of positive chondrocytes 
identified do not necessarily represent the definitive number of chondrocytes 
expressing the signaling proteins. Additionally, we observed no relation with
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increased age or effect of IL-1 treatment on the staining intensity of the different 
signaling molecules. Therefore, the amount of protein detected per chondrocyte is 
probably similar in the different experimental groups.
Our hypothesis was that old mice had a less active TGF-ß signaling due to shifted 
expression of TGF-ß signaling mediators to a more silent state compared to young. It 
has been described that responses of chondrocytes to other growth factors decrease 
with higher age. For epidermal growth factor (eGF) it has been demonstrated that 
chondrocytes from old animals display less EGF receptors 29. Furthermore, the 
decrease in response to platelet derived growth factor (PDGF) was significantly 
correlated with increased age 26. Nevertheless, our results point towards a more 
active TGF-ß signaling state of "old" chondrocytes. Alternatively, altered IL-1 
signaling in old versus young animals could explain our previously published results. 
Indeed chondrocytes from old mice have shown to exhibit a stronger and prolonged 
IL-1 effect on PG synthesis than young mice 6. Moreover, OA chondrocytes have 
demonstrated increased levels of IL-1 receptors compared to normal chondrocytes 30. 
Taken together, it seems that in old compared to young animals, both the TGF-ß and 
IL-1 signaling pathways are in a more active state. However, the net balance 
between these more active anabolic (TGF-ß) and catabolic (IL-1) pathways in old 
animals is probably shifted towards the catabolic side, which might explain the strong 
correlation of OA with increased age.
In conclusion, the observation that TGF-ß counteraction of IL-1 effects is lost in old 
animals cannot be explained by less active TGF-ß signaling.
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ABSTRACT
T o  study the (patho)physiological ro le  of Transform ing  
G row th FACTOR-ß (TG F-ß), potent and selective  
INHIBITORS ARE NECESSARY. SINCE TG F-ß  SIGNALING IS 
INITIATED BY THE HIGH AFFINITY BINDING TO THE TYPE II  
RECEPTOR (R II) , THE EXTRACELLULAR PART OF R II (SOLRII) 
CAN FUNCTION AS A TGF-ß ANTAGONIST. SOLRII WAS CLONED 
AND LARGE-SCALE PROTEIN SYNTHESIS WAS PERFORMED IN THE 
YEAST PlCHIA PASTORIS EXPRESSION SYSTEM. OUR RESULTS 
INDICATE THAT VIA THIS SYSTEM HIGH LEVELS OF PURE 
CONCENTRATED SOLRII CAN BE OBTAINED. MOREOVER,
pu rified  so lR II is  an a ctiv e  protein  as shown by ELISA
AND BIOASSAY. IN CONCLUSION, OUR LARGE-SCALE PROTEIN 
EXPRESSION PROCEDURE RESULTS IN HIGH QUANTITIES OF
pu rified  so lR II, which  is  a pow erful to o l  to  study th e  
NATURAL ROLE OF TGF-ß.
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LARGE SCALE PROTEIN PRODUCTION OF THE TG F-ß  TYPE II RECEPTOR
IN TR O D U CTIO N
TGF-ß is an important regulator of cell proliferation/differentiation and matrix 
synthesis. Disregulation of TGF-ß signaling has been implicated in several 
pathologies, such as the joint disease osteoarthritis (OA) 1i2. OA is mainly 
characterized by cartilage loss and the formation of new bone at the joint edges, so 
called osteophytes. We have previously described that exogenous added TGF-ß 
induced OA-like side effects such as osteophytes and fibrosis 3-5. On the other hand, 
exogenous addition of TGF-ß into the knee joint of mice had a protective effect on 
the articular cartilage 6'7. Despite extensive research on the subject it is still unclear 
what the role of endogenously released TGF-ß during OA is. To study the role of 
endogenous TGF-ß during disease, potent and specific TGF-ß inhibitors are 
necessary.
The first step in the TGF-ß signaling pathway is the binding of TGF-ß to its type II 
receptor, an interaction of high affinity 8. The soluble, extracellular domain of RII 
(solRII) has been shown to antagonize TGF-ß 9,1°. We expressed the complete 
extracellular domain of the human TGF-ß type II receptor in combination with a His6- 
tag and the Saccharomyces cerevisiae a-factor secretion signal peptide in order to 
obtain a small (25 kDa), and potent soluble TGF-ß antagonist. We made use of the 
Pichia pastoris protein expression system because of the advantages of eukaryotic 
protein processing, protein folding and posttranslational modifications. Moreover, the 
P. pastoris system is an easy and cheap system with the benefit of high expression 
levels of recombinant protein. High-level protein production was initiated by the 
addition of methanol in a large-scale fermentation protocol using a 5 liter tabletop 
bioreactor. The His6-tagged solRII was purified from the yeast supernatant using a 
Ni2+-charged streamline-chelating column and molecular weight filters. Our results 
show that the obtained solRII protein is a heterogeneously glycosylated protein of 
25-40 kDa with a pi of 7. The purified solRII was very potent in blocking TGF-ß 
activity on a TGF-ß responsive cell line. in conclusion, the large scale production of 
solRII via the P. pastoris protein expression system will enable us to study the role of 
endogenous TGF-ß during joint diseases such as OA.
M A TER IA LS  & M ETH O D S
Co n str u ctio n  o f  th e yea st  ex pr essio n  vector  a n d  Tr an sfo r m atio n  o f  Pich ia  
pa sto r is
Construction of the yeast expression vector and screening of solRII expressing clones 
are described elsewhere 11. in short, the complete extracellular domain of human 
type i i  receptor was obtained via PCR. The 5' primer used in the cloning procedure 
introduced a Xhol restriction site and the sequence encoding the cleavage signal of 
the Saccharomyces cerevisiae a-factor secretion signal peptide. Via the 3' primer the 
sequence coding for six consecutive histidine residues (6x his-tag), a termination 
signal and an EcoRI restriction site were introduced. The PCR fragment was first 
cloned in the pCR-Script tm SK(+) plasmid (Stratagene, La Jolla, CA, USA), 
whereafter via XhoI/EcoRI digestion the solRII fragment was ligated in the pPic-9 
expression plasmid (Invitrogen Corporation, San Diego, CA, USA). The constructed 
vector (pPic-9/solRII) thus contains an open reading frame coding for the
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Saccharomyces cerevisiae a-factor secretion signal peptide and the complete 
sequence of the extracellular domain of the TGF-ß type i i  receptor.
P. pastoris strain GS115 was transformed using the spheroblast-method according to 
the manufacturers protocol (Invitrogen Corporation, San Diego, CA, USA). Briefly, the 
Bglii-linearized pPic9/solRII construct was incubated with spheroblasts. His+ 
transformants were selected by their capability to grow on media lacking L-histidine.
Pr o d u ctio n  a n d  pu r ifica  tio n  o f  so lR II
Pichia pastoris inoculum was prepared as followed. Baffled flasks containing 10% of 
the initial fermentation volume of Buffered Minimal Glycerol-complex medium 
(BMGY; 1% yeast extract, 2% peptone, 1.34% yeast nitrogen base, 4-10-5% biotin, 
100 mM potassium phosphate buffer, pH 6.0) were inoculated from a frozen glycerol 
stock. The yeast cells were grown at 30°C, agitated at 250 rpm for 16-20 hours until 
the OD600 was >5. The Bioflow 3000 benchtop fermenter (New Brunswick Scientific, 
New Jersey, USA) containing 2.5-3.5Í of fermentation basal salts medium (26.7 ml/l 
phosphoric acid 85%; 0.93 g/l calcium sulfate-2H2Ü; 18.2 g/l potassium sulfate; 14.9 
g/l magnesium sulfate-7H2O; 4.13 g/l potassium hydroxide; 40.0 g/l glycerol) was 
sterilized. Temperature was set to 30°C, agitation at 500 rpm and aeration at 0.9 
vvm. The pH of the fermentation basal salts medium was adjusted at pH 5.0 with 
28% ammonium hydroxide. The dissolved oxygen was maintained at 30%. 4.35 ml 
PTM1 trace salts (6.0 g/l cupric sulfate-5H2Ü; 80 mg/l sodium iodide; 3.0 g/l 
manganese sulfate-H2O; sodium molybdate-2H2O; 20 mg/l boric acid; 500 mg/l 
cobalt chloride; 20.0 g/l zinc chloride; 65.0 g/l ferrous sulfate-7H2O; 200 mg/l biotin;
5.0 ml/l sulfuric acid) per liter fermentation basal salts medium were aseptically 
added to the fermenter. The fermenter was inoculated with the overnight culture 
from the baffled flasks. After complete consumption of the glycerol (approximately 
24 hours), indicated by an increase of the DÜ to 100%, a 50% w/v glycerol feed 
containing 12 ml PTMi trace salts/l was started at a rate of 18.15 ml/l/initial 
fermentation volume. The glycerol feed was continued for 16 hours. Then, a 100% 
methanol feed containing 12 ml PTM1 trace salts/l was started at a rate of 3.6 
ml/l/initial fermentation volume. This feeding rate was gradually increased to a final 
rate of 10.9 ml/l/initial fermentation volume, which was maintained for approximately 
100 hours.
After completing the fermentation process, the yeast cells were separated from the 
medium by centrifugation for 20 min at 5000 x g. The pH of the supernatant was 
adjusted to 7.8 with sodium hydroxide and sodium chloride was added to an end 
concentration of 0.5 M. The supernatant was further purified by filtration over a 0.2 
|im membrane filter (Schleicher&Schull, Dassel, Germany).
The recombinant solRII was purified from the supernatant by means of a 6x his-tag, 
which has a very high affinity for nickel. To reduce non-specific binding to the 
column, 7.5 mM imidazole was added to the supernatant. The supernatant was 
applied to a 150 ml Ni2+-charged Streamline Chelating column (Amersham 
Biosciences, Roosendaal, The Netherlands) in a continuous fashion for 16 hours at a 
flow rate of 3 ml/min. Subsequently, the column was washed with 50 mM sodium 
phosphate, 300 mM sodium chloride, 10% glycerol and 10 mM imidazole. Bound 
protein was eluted from the column with 300 mM imidazole in washbuffer and
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collected in 15 ml fractions. imidazole was removed from the protein solution via a 
HiPrep 26/10 desalting column (Amersham Biosciences, Roosendaal, The 
Netherlands) using a 50 mM sodium phosphate and 150 mM NaCl buffer. The protein 
was further purified and concentrated using MW cut-off 100,000 and MW cut-off
10,000 Centriplus centrifugal filters (Amicon, Millipore, Bedford, USA) to a final 
concentration of ~60 mg/ml. The endotoxin level of purified protein was analyzed via 
the endochrome endotoxin detection kit (Charles River Endosafe, Ltd, Kent, UK). 
Yeast supernatant contained an unknown interfering substance that confounded test 
results (results not shown).
S D S -P A G E a n d  Wes ter n b lo tp r o c ed u r es
SDS-PAGE analysis was performed on a 12% polyacrylamide gel under denaturating 
conditions. Proteins were stained using a standard Silverstaining protocol. A 10 kDA 
protein ladder was used as a molecular mass marker.
For Western blot analysis, a benchmark 10 kDA protein ladder was used as a 
molecular mass marker. The SDS-PAGE gel, the blotting membrane and the 
Whatman paper were all equilibrated in transfer buffer (39 mM Tris, 48 mM glycin). 
The solRII protein was blotted on a PVDF membrane (Amersham Biosciences, 
Roosendaal, The Netherlands) using a semi-dry blotting system during 2 hours at 70 
mA. Next, the PVDF membrane was blocked 1 hour with TBS/5% milk powder. After 
washing three times 10 minutes with TBS/Tween 0.02%, the membrane was 
incubated o/n at 4°C with an antibody against the extracellular part of the TGF-ß 
type i i  receptor (R&D Systems, Minneapolis, USA)(1:5000) in TBS/Tween 0.02% and 
3% milk powder. Then, the membrane was washed three times 10 minutes with 
TBS/Tween 0.02%, followed by incubation with the secondary rabbit anti-goat biotin 
labeled Ab (1:800) in TBS/Tween 0.02% and 3% milk powder for two hours. 
Subsequently, a biotin-streptavidine detection system (ABC-Kit) was used according 
to the manufacturers recommendations (Vector Laboratories, Burlingame, CA, USA). 
Bound complexes were detected by reaction with 3',3' diaminobenzidine (Sigma- 
Aldrich, Zwijndrecht, The Netherlands) in 15 ml PBS and 30% H2O2.
D eg lyco sylatio n  o f  so lR II
Purified solRII was dialyzed against deglycosylation buffer (50 mM EDTA, 1% ß- 
mercaptoethanol, 1% n-octylglucoside, 0.2% SDS, 50 mM potassium phosphate, pH 
6.0), whereafter protein was denaturated by heating to 100°C. N-glycosidase F 
(Roche, Basel, Switzerland) was added (2 U/mg protein) and the sample was 
incubated over night at 37°C. Samples were analyzed via SDS-PAGE.
Iso elec tr ic  fo cu ssin g  (IEF)
Phastgels IEF 3-9 (Amersham Biosciences, Roosendaal, The Netherlands) were used 
for IEF analysis. Proteins were visualized by silverstaining followed by isoelectric 
point (pi) determination of the recombinant protein using IEF standards ranging 
from pi 4.5-9.6 (Bio-Rad Laboratories B.V., Veenendaal, The Netherlands)
Blo c k in g  c a p a c ity  o f  so lR II
The blocking capacity of the recombinant solRII was determined via a TGF-ß 
competition ELISA using solRII as a capture agent. in short, ELISA plates were 
coated with solRII (3 |ig/ml; R&D systems, Minneapolis, USA) by overnight
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incubation at 4°C in a sodium carbonate buffer (pH 9.6; 0.1 M). Non-specific binding 
sites were blocked with 1% gelatin/PBS for 2 hours at 37°C. TGF-ß1 was used as a 
standard in a concentration of 10 pg/ml-2500 pg/ml (R&D systems, Minneapolis, 
USA). Samples of recombinant solRII were mixed with TGF-ß1 in a ratio of 1000:1 - 
8000:1. Standards or samples were applied and incubated for 1-3 hours at 37°C. 
Plates were then incubated with the primary antibody (Ab), anti-TGF-ß1-Ab (1:5000 
in 0.5% gelatin PBS/Tween, (R&D systems, Minneapolis, USA) for 2 hours at 37°C. 
Subsequently, the secondary biotinylated Ab, anti-chicken IgY (1:5000 in 0,5% 
gelatin PBS/Tween, (Jackson immunochemicals, Brunschwig Chemie, Amsterdam, 
The Netherlands) was incubated for 1 hour at 37°C followed by incubation with 
streptavidine-poly-peroxidase conjugate for 45 minutes at 37°C. Bound complexes 
were detected by reaction with orthophenylenediamine (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) and H2O2. Adsorbance was read at 492 nm using an ELISA plate 
reader (Titertek Multiscan MCC/340).
Bio lo g ic A c t iv it y o f s o lR II
Now that we demonstrated that solRII can block TGF-ß binding to immobilized 
solRII, we studied if solRII also inhibits biologic activity of different TGF-ß isoforms. 
Therefore, we used a modified bioassay for IL-1 12. in this assay we made use of the 
fact that TGF-ß inhibits the IL-1 dependent production of IL-2 in NÜB cells. The 
production of IL-2 was studied via the IL-2 induced proliferation of CTLL cells, 
present in the same culture as the NÜB cells. in short, 2.5-104 NÜB cells and 4-103 
CTLL cells were plated in microtiter plates in RPMI medium supplemented with 5% 
fetal calf serum (Invitrogen Life Technologies, Breda, The Netherlands). IL-1ß was 
added (12.5 pg) and standards (TGF-ß) (R&D systems, Minneapolis, USA) or samples 
(1.5 ng/ml TGF-ß1, -ß2 or -ß3 together with 30 |ig/ml solRII or 30 |ig/ml bovine 
serum albumin) were added. Cells were then cultured o/n at 37°C and 5% CO2 
before 1 |iCi/ml 3H-thymidine was added. Cells were cultured for another 4 hours, 
after which the cells were harvested and the incorporated radioactivity was 
measured using a liquid scintillation counter. All values were normalized to controls 
to which no TGF-ß was added.
R ESU LTS
Pr o tein  pro d uctio n/ pu r ifica  tio n
To study the natural role of TGF-ß during disease the extracellular part of the type ii 
receptor can be used as a TGF-ß antagonist. For these studies large amounts of 
highly purified solRII in high concentrations are necessary. Here we describe the 
large scale production of a secreted protein in the Pichia pastoris expression system. 
Via a one step purification protocol using a Ni2+-Streamline Chelating column and 
one further concentration step, we were able to concentrate the sol Rii from the 
initial 5 L to approximately 1 mL. Per 5L fermentation yeast culture ~100 mg pure 
protein was obtained.
S D S -P A G E a n d  Wes ter n b lo tp r o c ed u r es
We characterized the recombinant solRII as produced by Pichia pastoris. Therefore, 
purified solRII was analyzed via SDS-PAGE. Recombinant solRII showed a pattern of 
protein bands ranging from about 25 kDA to 40 kDa (figure 1a). The faint high
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molecular mass bands are most likely alcohol oxidase, a native Pichia pastoris 
protein, which is strongly upregulated by the methanol, added during protein 
production.
Western blot analysis using a specific antibody against the extracellular domain of 
the TGF-ß type II receptor, shows a similar staining pattern of 25 kDA to 40 kDa, 
demonstrating that the purity of the produced recombinant solRII is approximately 
95% (figure 1b). The antibody used did not cross react with a BSA preparation 
contaminated with other proteins.
FIGURE 1. S D S - P A G E  a n d  W e s t e r n  b l o t  
a n a l y s is  o f  r e c o m b in a n t  s o l RII p r o d u c e d  b y
P. PASTORIS.
A )  S D S - P A G E  a n a l y s is  w a s  p e r f o r m e d  o n  a  
12%  p o l y a c r y l a m id e  g e l  u n d e r  d e n a t u r a t in g  
c o n d it io n s . P r o t e in s  w e r e  v is u a l iz e d  v ia  a  
s t a n d a r d  s il v e r s t a in in g . A  10 k D a  p r o t e in
LADDER WAS USED AS A MOLECULAR MASS 
MARKER.
B ) W e s t e r n b l o t t in g  w a s  p e r f o r m e d  o n  P V D F
MEMBRANE USING A SEMI-DRY BLOTTING SYSTEM.
S o l RII w a s  d e t e c t e d  u s in g  a n  a n t ib o d y  
a g a in s t  t h e  e x t r a c e l l u l a r  p a r t  o f  t h e  T G F -ß
TYPE II RECEPTOR. VISUALIZATION OF BOUND
co m p le x e s  w a s  d one  by  r e a c t io n  w ith  3 ',3 ' 
DIAMI NOBENZIDINE AND H 2O 2 . A  BENCHMARK 10 
kD a  p r o te in  la d d e r  w a s  u sed  a s  a  m o le c u la r  
m ass m a rke r.
As shown by the SDS-PAGE and Western blot the recombinant solRII as produced by 
Pichia pastoris did not result in a distinct band but a smear of 25-40 kDa was 
observed. To investigate if this smear was the result of heterogeneous glycosylation 
we treated solRII with N-glycosidase F. As figure 2 shows, deglycosylation resulted in 
one distinct band of 22 kDa, indicating that solRII produced by Pichia pastoris is a 
heterogeneously glycosylated protein. The observed molecular mass of 22 kDa is in 
line with the expected molecular mass based on amino acid sequence. IEF analysis of 
purified solRII showed that the pi of the protein was 7.0 (results not shown).
F ig u re  2. s d s - p a g e  a n a ly s is  o f  
re c o m b in a n t  s o lR I I  p ro d u c e d  by  P.
PASTORIS BEFORE (LANE 1) AND AFTER (LANE
2) d e g l y c o s y l a t io n  w ith  N -g l y c o s id a s e  
F. S D S - P A G E  a n a l y s is  w a s  p e r f o r m e d  
ON A 12%  p o l y a c r y l a m id e  g e l  u n d e r  
DENATURATING CONDITIONS. PROTEINS 
WERE VISUALIZED VIA A STANDARD
s il v e r s t a in in g . A  10 k Da  p r o t e in  l a d d e r  
w a s  u s e d  a s  a  m o l e c u l a r  m a s s  m a r k e r .
60 kDa- 
40 kDa-
M 1 2
20 kDa-
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B lo ck in g  capa c ity  o fs o lR II
We proceeded to determine the blocking capacity of solRII with a competition ELISA. 
A 1000- to 8000-fold excess of solRII was used to block 2.5 ng/ml TGF-ß. To 
completely neutralize TGF-ß, an 8000 fold excess of solRII was required, as is shown 
in figure 3. SolRII in excess of 4000 and 2000 fold prevented detection of TGF-ß in 
the order of 96% and 84%, respectively. A 1000 fold excess of solRII was still able 
to neutralize 68% of TGF-ß.
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Bio lo g ic  a c tiv ity  o fs o lR II
As can be seen in figure 4, solRII was able to fully inhibit TGF-ß1 and -ß3 activity in 
the bioassay. In contrast, solRII was unable to antagonize TGF-ß2 activity. BSA had 
no inhibitory effect on TGF-ß isoform mediated inhibition of proliferation.
F ig u re  4. D e t e r m in a t io n  o f  s o l RII
BIOACTIVITY IN NEUTRALIZING T G F - ß 1 , -ß2 
a n d  -ß3. S a m p l e s  c o n t a in in g  1.5 n g /m l  
T G F - ß w e r e  in c u b a t e d  in t h e  p r e s e n c e  
o f  30  jig /m l  s o l RII o r  B S A  a s  a  
c o n t r o l . T h e  N O B /C T L L  b io a s s a y  
w a s  u s e d  a n d  t h e  3H -t h y m id in e  
in c o r p o r a t io n  w h ic h  is in h ib ited  b y  
T G F - ß w a s  m e a s u r e d  u s in g  a  liquid  
sc in t illa t io n  c o u n t e r . T h e  3H - 
t h y m id in e  in c o r p o r a t io n  in t h e  
a b s e n c e  o f  T G F -ß  is s t a t e d  a s  100% .
d i s c u s s i o n
Disregulation of the TGF-ß pathway has been described in many different pathologies 
such as RA and OA. In order to investigate the endogenous role of TGF-ß during 
joint disease, potent and specific inhibitors are necessary. The soluble, extracellular 
domain of the TGF-ß type II receptor (solRII) has been shown to bind TGF-ß and 
neutralize TGF-ß activity 9,1°. Not only does solRII bind TGF-ß with high affinity but 
due to its small size solRII is able to penetrate dense matrixes such as cartilage.
The systemic blocking of endogenous TGF-ß during experimental OA will require 
large quantities of protein. Therefore, we opted for large scale fermentation in
F ig u re  3. D e t e r m in a t io n  o f  s o l RII a c t iv it y . 
T h e  a c t iv it y  o f  f r e s h l y  p r o d u c e d  s o l RII w a s  
d e t e r m in e d  w ith  a  c o m p e t it io n  E L IS A . E L IS A  
p l a t e s  w e r e  c o a t e d  w ith  s o l RII. S a m p l e s  
CONTAINING 2 .5  NG/ML T G F -ß  WERE MIXED WITH 
2 .5 -20  jig /m l  s o l RII a n d  a p p l ie d  t o  t h e  p l a t e . 
T h e  T G F -ß  b o u n d  t o  t h e  c o a t e d  s o l RII w a s  
v is u a l iz e d  v ia  a n  AN T i-TG F-ß  A b . T h e  
PERCENTAGE OF BLOCKED T G F -ß  IS SHOWN.
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combination with the Pichia pastoris protein expression system to obtain large 
amounts of pure protein. Since yeast is an eukaryotic organism the expression 
system has all the benefits of eukaryotic post translational modifications such as 
protein folding and glycosylation as compared to prokaryotic systems.
Through the introduction of the His6-tag the solRII could easily be purified via a one 
step affinity chromatography using a Ni2+-charged streamline chelating column. We 
opted for a wide column filled with a relative high ratio of column material to protein, 
in order to purify all His-tagged protein in one run. During the fermentation process, 
protein synthesis was induced by the addition of methanol, which also caused the 
strong upregulation of alcohol oxidase, a native Pichia protein. Despite stringent 
washing with imidazole the solRII protein sample was still contaminated with AOX. 
We made use of the difference in MW between AOX (100 kDa) and solRII (25 kDa) 
to separate the two proteins. After extreme concentration to ~60 mg/ml our results 
show that only very little AOX was present in the sample (< 5%). From one 
fermentation run we were able to purify approximately 100 mg pure solRII protein.
Our results indicate that solRII produced by Pichia pastoris is a heterogeneously 
glycosylated protein, which is in line with earlier reports 9,1°. The solRII we produced 
via the Pichia pastoris expression system has neutralizing activity. A 4000 fold excess 
of recombinant solRII to TGF-ß was able to neutralize 96% of TGF-ß activity as 
determined via ELISA. This is well in range with other studies in which 1,600 to
20,000 fold excess of solRII was needed to fully inhibit TGF-ß activity 10,13. The 
results from the bioassay show that solRII is a potent inhibitor of TGF-ß1 and -ß3 
activity. In contrast, solRII was unable to antagonize TGF-ß2 activity, a finding also 
described by others 9 ,1 0 ,1 4  This is probably due to the high homology in protein 
structure between TGF-ß1 and ß3 as compared to TGF-ß2 15,16. Moreover, for TGF-ß2 
to bind RII and to be biologically active the presence of the type III receptor is 
required 14.
Here we describe the large scale production of solRII, a potent and specific TGF-ß 
antagonist. The P . pastoris expression system combined with an optimal 
fermentation process resulted in the production of high levels of solRII. The effective 
purification procedure enabled us to obtain solRII in extremely high concentrations. 
SolRII can now be used to study the role of endogenous TGF-ß during disease.
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CHAPTER 5
a b s t r a c t
O steo a r th ritis  (OA) has as main ch a ra cteristics  th e
DEGRADATION OF ARTICULAR CARTILAGE AND THE FORMATION 
OF NEW BONE AT THE JOINT EDGES, SO CALLED OSTEOPHYTES.
I n t h is  study enhanced expression  of TGF-ß1 and -ß3
WAS DETECTED IN DEVELOPING OSTEOPHYTES AND ARTICULAR 
CARTILAGE DURING MURINE EXPERIMENTAL OA. TO DETERMINE 
THE ROLE OF ENDOGENOUS TG F-ß  ON OSTEOPHYTE FORMATION 
AND ARTICULAR CARTILAGE, TG F-ß  ACTIVITY WAS BLOCKED VIA 
A SCAVENGING SOLUBLE T G F-ß -R II (SOLRII). OUR RESULTS 
CLEARLY SHOW THAT INHIBITION OF ENDOGENOUS TGF-ß  
NEARLY COMPLETELY PREVENTED OSTEOPHYTE FORMATION. IN 
CONTRAST, TREATMENT WITH RECOMBINANT SOLRII MARKEDLY 
ENHANCED ARTICULAR CARTILAGE PROTEOGLYCAN (PG) LOSS 
AND REDUCED THE THICKNESS OF ARTICULAR CARTILAGE. IN 
CONCLUSION, WE SHOW FOR THE FIRST TIME THAT ENDOGENOUS 
TG F-ß  IS A CRUCIAL FACTOR IN THE PROCESS OF OSTEOPHYTE 
FORMATION AND HAS AN IMPORTANT FUNCTION IN PROTECTION 
AGAINST CARTILAGE LOSS.
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i n t r o d u c t i o n
OA is a joint disease that is characterized by degradation of articular cartilage and 
the formation of new bone at the joint margins, so called osteophytes. Articular 
cartilage PG loss and fibrillation of the articular surface are early events in the OA 
process. At later stages clefts are formed in the cartilage, while end stage OA shows 
erosion of the articular cartilage.
TGF-ß is a multifunctional cytokine involved in crucial biological processes such as: 
development, extracellular matrix synthesis, cell proliferation/differentiation and 
tissue repair. So far, three mammalian isoforms have been described: TGF-ß1, -ß2 
and -ß3. TGF-ß is produced in a latent form, associated with the latency associated 
peptide (LAP). TGF-ß can be activated after dissociation of LAP from the mature 
protein 1. TGF-ß signaling starts with binding of TGF-ß to TGF-ß-RII, a constitutively 
active seri ne/threon ine kinase 2. After transphosphorylation of TGF-ß-RI by TGF-ß- 
RII the signal is further propagated involving smad proteins 3'4.
TGF-ß has been suggested as an important factor in the pathogenesis of OA. One 
indication is the significant levels of active TGF-ß in the synovial fluid of OA patients 
5'6. Indeed, OA changes of the cartilage have been described after exposure of knee 
joints to TGF-ß, supporting a role for TGF-ß in the pathogenesis of OA 7'8. Local 
administration of TGF-ß in the knee joint also induced inflammation and fibrosis 7'9. 
Another remarkable finding was the formation of osteophytes after multiple intra- 
articular (i.a.) injections of TGF-ß protein or adenoviral overexpression of TGF-ß1 in 
the knee joint 7,8,10. Osteophytes are newly formed bony structures located at the 
joint margins, which occurrence is strongly associated with OA. Osteophytes 
originate from activated periosteum leading to new cartilaginous outgrowths that 
eventually ossify into osteophytes via the process of endochondral ossification. In 
developing osteophytes, mRNA's for TGF-ß and TGF-ß protein expression are 
strongly upregulated 11-13. These data suggest that TGF-ß induces osteophyte 
formation.
Although TGF-ß seems implicated in pathology, TGF-ß has also been suggested as a 
beneficial factor in cartilage repair. We have previously shown that injection of TGF-ß 
in naive murine knee joints results in an increase in PG synthesis and PG content of 
articular cartilage 14. Moreover, i.a. injection of TGF-ß during experimental arthritis 
resulted in protection from PG loss 15. Also effects of IL-1, such as inhibition of 
cartilage PG synthesis and release of cartilage PG content, could be blocked by local 
application of TGF-ß 16,17. This demonstrates that TGF-ß is able to counteract the 
deleterious effects of IL-1, a cytokine considered to be a key mediator during erosive 
joint diseases. Taken together, these experiments suggest a protective function for 
TGF-ß in articular cartilage.
As can be concluded from the discussion above, TGF-ß appears to have a dualistic 
role in OA; protection against cartilage damage but induction of osteophyte 
formation. Experiments carried out to investigate the role of TGF-ß in joint diseases 
are mainly based on TGF-ß supplementation. In this study, we aimed to determine 
the role of endogenous TGF-ß during experimental OA. We selectively blocked
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endogenous TGF-ß via systemic treatment with solRII; the cloned scavenging 
extracellular domain of the TGF-ß-RII, an approach that to our knowledge has never 
been previously used in OA. SolRII has a very high affinity for TGF-ß1 and -ß3, the 
two most abundant isoforms of TGF-ß in the knee joint. Moreover, due to the small 
size of solRII it can penetrate the articular cartilage and affect chondrocytes. We 
show for the first time that inhibition of endogenous TGF-ß during experimental OA 
dramatically decreases osteophyte size, but enhances PG loss. Our study implies a 
crucial role for endogenous TGF-ß in osteophyte formation and cartilage 
maintenance.
M ATER IAL & M ETH O D S
Im m u n o h isto ch em istr y
The expression of TGF-ß1, -ß2 and -ß3 was studied during papain-induced OA. The 
papain model is characterized by PG depletion of articular cartilage, which is followed 
by attempted replenishment of the articular cartilage with PG's at approximately day 
10 18. The right knee joints of mice were injected with 1 U papain solution, the left 
knee joints served as internal controls. Knee joints were dissected at day 7 and 14. 
Immunohistochemistry was performed on cryosections with specific Ab against TGF- 
ß1, -ß2 and -ß3 (R&D Systems Europe Ltd, Abingdon, UK). As a negative control, the 
primary Ab was replaced with chicken IgY's or goat IgG's. Biotin labeled secondary 
Ab were used (Vector Laboratories. Inc, Burlingham, CA), followed by a biotin- 
streptavidine detection system (Vectra elite kit, Vector Laboratories. Inc, Burlingham, 
CA). Bound complexes were visualized via reaction with 3',3'diaminobenzidine (Sigma 
Chemicals Co, St. Louis, MO, USA) and H2O2. Sections were briefly counterstained 
with haematoxylin and mounted with permount.
Q u an tifica tio n  o f  TGF-ß1 a n d  TG F-ß3 iso fo r m s
Since TGF-ß1 and -ß3 were detected by immunohistochemistry, TGF-ß1 and -ß3 
levels in knee joints were quantified via ELISA. Therefore, 1 U papain was injected in 
the right knee joints of mice (n=6), uninjected left knee joints served as internal 
controls. After 3 days, patellae were isolated and placed in RPMI medium/0.1% BSA. 
After 2 or 10 hours of culturing, the medium was analyzed for the presence of TGF- 
ß1 and -ß3 via ELISA. In short, ELISA plates were coated with solRII (R&D Systems 
Europe Ltd, Abingdon, UK). TGF-ß1 or -ß3 standards (R&D Systems Europe Ltd, 
Abingdon, UK) or samples were applied and subsequently incubated with anti-TGF- 
ß1 - or -ß3 Ab. The appropriate secondary biotinylated Ab were used, followed by 
incubation with streptavidine-poly-peroxidase conjugate. Bound complexes were 
detected by reaction with orthophenylenediamine (Sigma Chemicals Co, St. Louis, 
MO, USA) and H2O2. Absorbance was read at 492 nm using an ELISA plate reader 
(Titertek Multiscan MCC/340).
Co n str u ctio n  o f  th e yea stex pr essio n  vector
Construction of the yeast expression vector and screening of solRII expressing clones 
are described elsewhere 19. In short, the complete extracellular domain of human 
TGF-ß type II receptor was cloned in the pPic-9 expression plasmid (Invitrogen 
Corporation, San Diego, CA, USA). During the cloning procedure the cleavage signal
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of the Saccharomyces cerevisiae a-factor secretion signal peptide and a sequence 
coding for six consecutive histidine residues (6x his-tag) were introduced via PCR.
Pr o d u ctio n  a n d  pu r ifica  tio n  o f  so lR II
For the production of solRII the Pichia pastoris expression system (Invitrogen 
Corporation, San Diego, CA, USA) was used. P. pastoris was cultured in the Bioflow 
3000 table top fermenter (New Brunswick Scientific Co., NJ, USA). In essence, the 
fermentation process was carried out as described elsewhere 20. Yeast culture 
supernatant was filtered through a 0.2 |im filter (Schleicher&Schull, Dassel, 
Germany). SolRII was purified from the supernatant by means of a 6x his-tag and a 
Ni-NTA column (Qiagen, Leusden, The Netherlands). Bound protein was eluted from 
the column with 300 mM imidazole in washbuffer. Imidazole was removed via a 
HiPrep 26/10 desalting column (Amersham Pharmacia Biotech, Buckinghamshire, 
England). The protein was subsequently further purified and concentrated using 
m.w. cut-off 100,000 and 10,000 filters (Millipore b.v., Etten-Leur, The Netherlands) 
to a final concentration of ~60 mg/ml. Although yeast cells do not contain LPS, the 
endotoxin level of purified protein was analyzed via the endosafe Kinetic 
turbidimetric assay (Charles River Endosafe, Kent, England). However, yeast 
supernatant contained an unknown interfering substance that confounded test 
results (results not shown). Therefore, an endotoxin inhibitor, polymyxin B (PMB; 
Sigma Chemicals Co, St. Louis, MO, USA), was added prior to implantation as a 
precautionary measure.
SD S-PA G E  a n d  Wester n  b lo ttin g  pr o ced u r es
SDS-PAGE analysis of recombinant solRII was performed on a 12% gel under 
denaturating conditions. Proteins were visualized via a standard silverstaining 
procedure.
For Western blotting analysis, solRII protein was blotted on a polyvinylidene 
difluoride (PVDF) membrane (Amersham Pharmacia Biotech, Buckinghamshire, 
England). SolRII protein was detected by an Ab against the extracellular part of the 
TGF-ß-RII (R&D Systems Europe Ltd, Abingdon, UK) in combination with the 
appropriate secondary biotin labeled Ab (Vector Laboratories Inc, Burlingham, CA). 
Bound complexes were detected by the ECL Plus detection reagents (Amersham 
Pharmacia Biotech, Buckinghamshire, England).
A c tiv ity  o f  so lR II
The blocking capacity of the recombinant solRII was determined via a TGF-ß 
competition ELISA using solRII as a capture agent. To assure the stability of the 
solRII for the duration of the implantation period, the used osmotic pumps were 
retrieved at the end of the experiment and flushed with 200 |il PBS. The diluted 
samples were also tested via ELISA. Samples of recombinant solRII were mixed with 
TGF-ß1 in a molar ratio of 1000:1 - 8000:1. The TGF-ß1 ELISA was performed as 
described under header: quantification of TGF-ß isoforms.
A n im als
Male C57Bl/6 mice aged 12 weeks were used. Animals were kept in filter top cages 
with a woodchip bedding. They were fed a standard diet and tap water ad libitum.
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Exper im en tal d esig n  a n d  His to lo g y
Alzet osmotic pumps (model 1007D and 2002, Alza corporation, Palo Alto, CA) were 
filled with the solution containing solRII (60 mg/ml)/PMB (2.63 mg/ml) or PMB alone 
and as a control empty pumps were used. 1 Day after i.p. implantation of the 
osmotic pumps, 1 U papain solution was injected into the right knee joint. We aimed 
to induce a relatively mild OA in order to allow for diminished and increased PG loss 
of the cartilage due to the treatment with solRII. Left knee joints served as internal 
controls for the systemic treatment with solRII/PMB and PMB. In order to administer 
solRII for 3 weeks, first an osmotic pump model 2002 was implanted i.p., which after 
14 days was replaced by a model 1007D pump. After 7, 14 or 21 days mice were 
sacrificed and whole knee joints were dissected and fixed for 4 days in 4% formalin. 
Subsequently, knee joints were decalcified in 5% formic acid and processed for 
paraffin embedding. Tissue sections (7 |im) were stained with Safranin O/fast red.
[35S]-sulfate incorporation was studied by i.p. injection of radiolabeled sulfate (75 
|iCi), 4 hours before dissection of the knee joints. After histological processing, 7 |im 
tissue sections were dipped in K5 emulsion (Ilford, Basildon, Essex, U.K.) and 
exposed for three to five weeks. Then, the slides were developed and stained with 
H&E. All findings are the result of two independent experiments.
Im a g ea n a ly s is  o f  h isto lo g y
The surface area of the osteophytes was measured using the Qwin image analysis 
system (Leica Imaging Systems Ltd. Cambridge, U.K.), using a JVC 3-CCD color video 
camera. The size of the osteophytes was determined by manual selection of the 
surface area of the osteophyte in five semi-serial sections per knee, spaced ~50 |im 
apart. Measurements of 8 knees per group were averaged.
The PG content of articular cartilage was also measured using an image analysis 
system as described elsewhere 21. The non-calcified layer of the patellar- and femoral 
cartilage and cartilage of both the lateral- and medial sides of the tibia-femur plateau 
was selected by hand. Loss of red staining (= loss of PG's) was calculated by 
measuring the amount of blue light passing through the tissue section. Of each knee 
joint, three sections per cartilage compartment were measured and the average was 
taken. Of each compartment the most severe depletion was considered as maximal 
PG loss. The non-calcified cartilage of the control left knees were also measured and 
averaged and the PG content was stated as being 100%. All measurements were 
expressed on a scale of 0 to 100% PG content as measured by Saf-O staining.
We also noted a thinning of the articular cartilage, which resulted in a decrease in 
the thickness of the cartilage. This loss of non-calcified articular cartilage of the 
patella and femur was measured in three sections, spaced ~50 |im apart by manual 
selection of the non-calcified cartilage, the surface area was determined and values 
were averaged.
M M P & A D A M -TS  & TIM P m RNA ex pr essio n
Treatment with solRII during experimental OA increases PG loss compared to 
untreated animals. We investigated whether solRII had an effect on the mRNA 
expression of MMP-3, -13, -14, ADAMTS-4, -5, TIMP-1 and -3. Therefore, papain (1
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U) was injected in the right knee joints of mice (n=6 per group). Uninjected left knee 
joints served as internal controls. After 3 days, patellae were isolated and placed in 
200 |il RPMI 1640 (Dutch modification) medium (Life Technologies B.V., Breda, The 
Netherlands) for 24 hours as described previously 22,23. Patellae were treated with 
solRII (10 |ig/ml) or IL-1 (10 ng/ml) as a positive control or were not treated. Next, 
RNA was isolated and treated with reverse transcriptase (Life Technologies BV, 
Breda, The Netherlands). The RT-PCR protocol started with 1 minute denaturation at 
92°C, followed by annealing at 60°C for 1 minute (58°C for TIMP-3) and 1 minute 
extension at 72°C for 1 minute. PCR products were subjected to electrophoresis in a 
1% low melting agarose gel (Seaplaque, SanverTech) containing ethidium bromide. 
For each primer set, the cycle number at which the PCR product was first detected 
on the agarose gel was identified. It was determined that in this phase the PCR 
reaction still performs linearly. The PCR products were excised from the gel. PCR 
products were quantified using PicoGreen, a fluorescent dye that selectively stains 
dsDNA, according to the manufacturers recommendations (Molecular Probes, 
Eugene, OR, USA). GAPDH levels were used to correct for the amount of template 
added to the PCR mix. For control - and papain-injected knee joints the mRNA levels 
in the non-treated group were stated as 100%. Each PCR was performed in triplicate 
and results were averaged.
S tatistical a n a ly s is
Results were analyzed via a Students t-test. Results were considered significant at 
p<0.05.
r e s u l t s
Im m u n o h isto ch em istr y
The expression of TGF-ß isoforms was studied in papain-injected joints and 
compared to normal knee joints, using immunohistochemical methods on 
cryosections of whole knee joints.
In the periosteum of normal knee joints, hardly any expression of TGF-ß1 and TGF- 
ß3 was observed. After injection of papain the expression of both TGF-ß isoforms 
was enhanced in the periosteum, where the expression of TGF-ß3 seemed more 
intense than TGF-ß1 expression (figure 1a-d, see Ch. 9). The expression was present 
at locations known to develop osteophytes. TGF-ß2 expression was not detected in 
normal periosteum or in periosteum after papain injection. So, TGF-ß1 and -ß3 seem 
to be upregulated after papain injection at locations in the periosteum linked to 
osteophyte formation.
Besides expression in the periosteum, also chondrocytes in the articular cartilage 
expressed TGF-ß1 and -ß3 isoforms. The expression was mostly confined to the non­
calcified layer of the cartilage. As in the periosteum, this expression was upregulated 
after papain injection compared to non-injected left knee joints (figure 1e-h, see Ch. 
9). Also in the cartilage the staining for TGF-ß3 seemed more intense than TGF-ß1 
staining. Again no staining for TGF-ß2 was observed. Negative controls, such as
65
CHAPTER 5
substitution of the primary Ab with chicken IgY's or goat IgG's, did not result in a 
color reaction (figure 1i+j, see Ch. 9).
The results show that TGF-ß1 and TGF-ß3 isoforms are expressed in periosteum and 
in articular cartilage and are upregulated after papain injection. Next, we tried to 
quantify TGF-ß1 and -ß3 levels in knee joints and studied the effect of papain 
injection.
Q u an tifica tio n  o f  TGF-ß1 a n d  TG F-ß3 iso fo r m s
The effect of papain injection on TGF-ß1 and TGF-ß3 protein levels in knee joints 
was compared to non-injected knee joints via ELISA. TGF-ß1 was detected in 2 hour 
patellae wash-outs from control left knee joints (table 1). Part of this released TGF-ß 
is probably the result from the patella isolation procedure itself. Nevertheless, 
injection of papain increased TGF-ß1 protein expression significantly from 10 pg/ml 
in control patellae to 30 pg/ml (p<0.05). TGF-ß3 protein was also detected in wash­
outs from control patellae (200 pg/ml, table 1). Injection of papain increased the 
expression of TGF-ß3 2 fold in 2 hour wash-outs (p<0.001). Approximately 20 times 
more TGF-ß3 than TGF-ß1 was detected, which supports the observation from the 
immunohistochemistry experiment that murine knee joints seem to contain more 
TGF-ß3 than TGF-ß1. The upregulation of TGF-ß1 and - ß3 protein was also found in 
10 hour wash-outs with similar results (results not shown). We proceeded to study 
the effect of TGF-ß inhibition during experimental OA on these joint structures. We 
made use of solRII, the extracellular part of the TGF-ß-RII, as a specific TGF-ß 
inhibitor. SolRII has a high affinity for TGF-ß1 and -ß3 and only low affinity for TGF- 
ß2.
T a b l e  1. Q u a n tific atio n  o f  TGF-ß1 a n d  T G F-ß 3  is o f o r m s  a.
T G F - ß 1  b T G F - ß 3  b
C o n t r o l 8.95 ± 7.35 184.66 ± 28.17
P a p a i n 33.36 ± 18.07* 387.83 ± 65.25**
a R ig h t  k n e e  jo in t s  w e r e  in je c t e d  w ith  1 U p a p a in  s o l u t io n . T h e  n o n -in je c t e d  l e f t  k n e e  jo in t s  s e v e r e d  a s  
in t e r n a l  c o n t r o l s .
b 3 d a y s  a f t e r  p a p a in  in je c t io n , p a t e l l a e  w ith  s u r r o u n d in g  t is s u e  w e r e  is o l a t e d  a n d  t r a n s f e r r e d  t o  R PM I  
m e d iu m  s u p p l e m e n t e d  w ith  0.1%  B S A . W a s h -o u t s  o f  2 h o u r s  w e r e  a n a l y z e d  f o r  t h e  p r e s e n c e  o f  T G F -ß 1  a n d  - 
ß3 v ia  E L IS A . T h e  c o n c e n t r a t io n  o f  T G F -ß  is s h o w n . R e s u l t s  a r e  t h e  m e a n  ± S D  o f  6 p a t e l l a e  w a s h o u t s  p e r  
g r o u p .
* p <0.05, ** p <0.001
S D S -P A G E a n d  Wes ter n b lo ttin g  o f  so lR II pro d u ced  b y  p . pa sto r is
Before using solRII to inhibit TGF-ß in vivo we characterized the recombinant solRII 
as produced by P. pastoris. Therefore, purified solRII was analyzed via SDS-PAGE 
and Western blot analysis. Recombinant solRII showed a pattern of protein bands 
ranging from about 25-40 kDa (results not shown). The different bands are the result 
of heterogeneous glycosylation 19. The Ab used did not cross react with BSA. Our 
recombinant solRII was estimated to be >95% pure.
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N eu tr alizin g  a c t iv it y  o f  so lR II
We proceeded to determine the blocking activity of freshly prepared solRII with an 
ELISA. To fully neutralize TGF-ß, an 4000 fold excess of solRII was required (results 
not shown). SolRII in excess of 2000 and 1000 fold prevented detection of TGF-ß in 
the order of 84% and 68%, respectively.
To apply the TGF-ß inhibitor in vivo, we first checked the stability of the solRII in 
osmotic pumps, implanted i.p. in mice. Therefore, after 7 and 14 days the remainder 
of the protein was flushed from the retrieved osmotic pumps. Comparable 
concentrations of freshly and retrieved solRII were equally effective in blocking TGF- 
ß, indicating no loss of blocking activity of the retrieved solRII protein (results not 
shown). This implies that during the complete period, active solRII was administered.
Osteo ph y tes
To determine the role of endogenous TGF-ß in osteophyte formation we treated mice 
with solRII during experimental OA. Papain injection in the knee joint was used to 
cause the formation of osteophytes at specific locations. Osteophytes developed on 
the femur close to the medial collateral ligament and on the tibia between the 
articular cartilage and where the growth plate meets the joint space. Early 
osteophytes consisted of large round chondrocytes, which stained with Saf-O, and 
had not undergone the process of endochondral ossification yet (figure 2a+e). 
Autoradiographic analysis showed that these chondrocytes had incorporated 
radioactive sulfate in high amounts, suggesting a very active cell metabolism (figure 
2b+f).
F ig u re  2. R e d u c e d  o s t e o p h y t e  
f o r m a t io n  a f t e r  s o l RII
TREATMENT DURING PAPAIN-INDUCED
O A . F r o n t a l  s e c t io n s  o f  w h o l e  
KNEE jo in t s  WERE MADE AND 
s t a in e d  w ith  S a f -O  (A ,C ,E ,G ).  
P r o t e o g l y c a n  s y n t h e s is  w a s  
v is u a l iz e d  v ia  t h e  in c o r p o r a t io n  
o f  35S - s u l f a t e  a n d  H & E  st a in in g  
(B ,D ,F ,H ). A) o s t e o p h y t e  o n  tibia  
in s o l v e n t  t r e a t e d  a n im a l . B) 
a u t o r a d io g r a p h y  o f  A . N o t e  
in t e n s e  35S  in c o r p o r a t io n  a t  
lo c a t io n  o f  o s t e o p h y t e . C) F o r  
c o m p a r is o n , s a m e  r e g io n  a s  A  in 
s o l RII t r e a t e d  a n im a l . D) 
A u t o r a d io g r a p h y  o f  C . e) 
o s t e o p h y t e  o n  f e m u r  in s o l v e n t  
t r e a t e d  a n im a l . F) a u t o ­
r a d io g r a p h y  o f  E. N o t e  in t e n s e  
35S  in c o r p o r a t io n  a t  l o c a t io n  o f  
o s t e o p h y t e . G) F o r  c o m p a r is o n , 
s a m e  r e g io n  a s  E  in s o l RII 
t r e a t e d  a n im a l . H) A u t o ­
r a d io g r a p h y  o f  G . O s t e o p h y t e s  
ARE in d ic a t e d  BY ARROWHEADS. 
O r ig in a l  m a g n if ic a t io n  100 x
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Treatment with recombinant solRII reduced the average size of the osteophytes 
located on the femur significantly (p<0.02) from 9616 |jm2 in the solvent treated 
animals to 2746 ^m2 in the solRII treated mice (figure 3). On the tibia, the average
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F ig u re  3. M e a s u r e m e n t  o f  o s t e o p h y t e  
s iz e . T h e  s u r f a c e  a r e a  o f  o s t e o p h y t e s  w a s  
d e t e r m in e d . F r o m  e a c h  m ic e  (n =8 p e r  
t r e a t m e n t ), f iv e  s e m i-s e r ia l  t is s u e  s e c t io n s  
f r o m  t h e  k n e e  jo in t  w e r e  m e a s u r e d  a n d  t h e
AVERAGE WAS TAKEN. THE 8 VALUES OBTAINED 
PER TREATMENT WERE AVERAGED AND ANALYZED 
VIA A STUDENTS T-TEST (* = P<0.05 AND ** P= 
0.001).
tibia femur
size of the osteophytes was reduced from 9849 |om2 in solvent treated mice to 2653 
|j,m2 in solRII treated animals (p=0.007). Autoradiographic analysis showed a less 
active cell metabolism in the solRII group than in the solvent treated group. These 
results strongly implicate endogenous TGF-ß as an important factor in osteophyte 
development.
Ca r tila g e
The role of endogenous TGF-ß on articular cartilage PG content after papain injection 
was studied using recombinant solRII. Inhibition of TGF-ß activity for 7 days with 
solRII decreased PG staining in 5 out of 6 cartilage compartments compared to 
treatment with solvent (figure 4c+d, e+f and figure 5). The effect of TGF-ß inhibition 
was most striking in patella - and femoral cartilage. In these cartilage compartments 
a significant reduction (p<0.001) in relative PG content of respectively 43% and 38% 
was observed (4c+d and figure 5). Also the lateral femur and lateral tibia, as well as 
the medial femur showed a significant decrease in PG content (p<0.05). No 
significant effects after 7 days of solRII treatment were observed in medial tibia 
cartilage. However, after 14 days of treatment with solRII, the cartilage PG content 
of the medial tibia was significantly less than in the solvent treated animals (p<0.05) 
(figure 4g+h). The other cartilage compartments did not significantly differ between 
treatments at day 14 (results not shown). After 21 days of treatment with solRII, the 
overall PG content of the articular cartilage of the tibia/femur plateau was 
significantly lower than in the control treated mice (p<0.001)(results not shown).
Treatment with solvent, compared to animals receiving an empty pump, had no 
significant effects on PG content in any of the cartilage surfaces on day 7, 14 or 21 
(data not shown). The control left knee joints of mice receiving solRII for 7, 14 or 21 
days were indistinguishable from left knee joints of solvent treated animals (figure 
4a+b), indicating that systemic treatment with solRII itself did not induce 
pathological effects in the knee joint.
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Besides a decrease in PG content, solRII treatment also had an effect on the 
thickness of uncalcified cartilage (figure 4c+d). Measurements of patellar cartilage 
revealed a significant decrease in surface area between solvent and solRII treated 
animals, 22610 and 16351 |im2 respectively and p<0.001 (table 2). The femoral 
uncalcified cartilage also showed a significant decrease (p<0.05) after solRII 
treatment, 22463 versus 26077 |im2 in solvent treated animals. These findings 
further imply a role for endogenous TGF-ß in cartilage maintenance.
F ig u re  4. R e d u c e d  c a r t il a g e  p r o t e o g l y c a n  c o n t e n t  a f t e r  s o l RII t r e a t m e n t  d u r in g  p a p a in - in d u c e d  OA . 
S y s t e m ic  a d m in is t r a t io n  o f  s o l RII f o r  7 o r  14 d a y s  in d u c e s  c h a n g e s  in p a t e l l a -f e m o r a l  c a r t il a g e  (A -D ) a n d
LATERAL FEMORAL-TIBIA CARTILAGE (E -H ) AFTER PAPAIN INJECTION. SAF-O  STAINED FRONTAL SECTIONS OF MURINE KNEE
jo in t s . C o n t r o l  l e f t  k n e e  jo in t  o f  s o l v e n t  t r e a t e d  a n im a l  A )  a n d  o f  s o l RII t r e a t e d  a n im a l  B). C a r t il a g e  o f  
s o l v e n t  t r e a t e d  a n im a l  C ) a n d  o f  s o l RII t r e a t e d  a n im a l  D). N o t e  t h e  d e c r e a s e d  st a in in g  in t e n s it y  o f  th e
CARTILAGE AND THE DECREASE IN CARTILAGE THICKNESS. CARTILAGE OF SOLVENT TREATED ANIMAL E) AND OF SOLRII 
TREATED ANIMAL F). AGAIN DECREASED STAINING INTENSITY IS OBSERVED. DAY 14 OF SOLVENT TREATED ANIMAL G ) AND
s o l RII t r e a t e d  a n im a l  H). P= p a t e l l a , F= f e m u r , T= tibia  a n d  j s = jo in t  s p a c e . O r ig in a l  m a g n if ic a t io n  100x  
In s e r t e d  f ig u r e  s h o w s  P G  c o n t e n t  o f  t h e  m e d ia l  tibia  a t  d a y  14 a s  p e r c e n t a g e  o f  n o r m a l  c a r t i l a g e . W hite 
b a r : s o l v e n t  t r e a t e d , b l a c k  b a r : s o l RII t r e a t e d , * = p  < 0.05).
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Taken together, inhibition of endogenous TGF-ß activity resulted in a decreased PG 
content and decreased cartilage thickness, indicating a pivotal protective role for 
endogenous TGF-ß in cartilage.
Figure 5. M e a su re m e n t o f  c a r t i la g e
PROTEOGLYCAN CONTENT. FOR EACH KNEE JOINT 
(N=8 PER t r e a t m e n t ), THE PROTEOGLYCAN 
CONTENT OF SIX NON-CALCIFIED ARTICULAR 
CARTILAGE SURFACES WAS DETERMINED. LOSS OF 
SAF-O  STAINING OF THE ARTICULAR CARTILAGE
w a s  m e a s u r e d  in t h r e e  s e m i-s e r ia l  t is s u e
SECTIONS AND VALUES WERE AVERAGED. THE 8 
VALUES OBTAINED PER COMPARTMENT WERE 
AVERAGED AND DIFFERENCES ANALYZED VIA A 
STUDENT T-TEST. PAT. = PATELLA, FEM. = FEMUR, 
TIB. = TIBIA, LAT. = LATERAL AND MED. = MEDIAL.
W h ite  b a r : s o l v e n t  t r e a t e d , b l a c k  b a r : 
s o l RII t r e a t e d . * = p <0.05 a n d  ** p = <0.001.
M M P &  A D A M -TS  &  T IM P m RNA expr essio n
Inhibition of endogenous TGF-ß during experimental OA reduces articular cartilage PG 
content. To gain a better understanding how TGF-ß inhibition leads to enhanced PG 
loss, we investigated the effect of solRII on the expression of cartilage degrading 
proteinases MMP-3, -13 and -14, ADAMTS-4 and -5 or inhibitors of degradation TIMP- 
1 and -3.
Treatment with solRII had no significant effect on the MMP-3 expression in patellae 
of non-injected knee joints. However, after papain injection, solRII treatment 
resulted in a ~4 fold upregulation of MMP-3 mRNA (table 3). Although no effect of 
solRII was seen on MMP-13 expression in control knee joints, treatment with solRII 
after papain injection resulted in a ~4 fold upregulation of MMP-13 mRNA (table 3). 
We could not identify significant effects of solRII treatment on MMP-14, ADAMTS-4 
and -5 or on TIMP-1 and TIMP-3 mRNA expression in patellae from normal and 
papain-injected joints (results not shown).
We used stimulation with IL-1 as a validation of the method used to determine the 
upregulation of MMP mRNA levels. As expected, treatment with IL-1 upregulated 
MMP-3 and -13 mRNA expression significantly in both non-injected and papain 
injected knee joints (results not shown). These results indicate the ability of isolated 
patella-tissue to respond to stimuli as IL-1.
From these data we conclude that the observed enhanced PG loss in articular 
cartilage after solRII treatment is probably the result of upregulated MMP-3 and -13 
expression.
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T a b l e  2. R e d u c e d  c a r t il a g e  t h ic k n e s s  a f t e r  s o l RII t r e a t m e n t  a t  d a y  7 a.
P a t e l l a F e m u r
S o l v e n t 2 2 6 1 0 ± 750 26077 ± 690
S o l RII 16351 ± 875* 22463 ± 748**
a O s m o t ic  p u m p s  f il l e d  w ith  s o l RII o r  s o l v e n t  w e r e  im p l a n t e d  i.p . in m ic e  (n =8/t r e a t m e n t ). N e x t  d a y , r ig h t  k n e e
JOINTS WERE INJECTED WITH 1 U PAPAIN SOLUTION. A T  DAY 7, KNEE JOINTS WERE DISSECTED, FRONTAL SECTIONS OF
w h o l e  k n e e  jo in t s  w e r e  m a d e  a n d  s t a in e d  w ith  SAF-O . F o r  e a c h  k n e e  jo in t , t h e  s u r f a c e  a r e a  o f  t h e  n o n ­
c a l c if ie d  LAYER OF ARTICULAR CARTILAGE FROM THE PATELLA-FEMUR JUNCTION WAS DETERMINED IN 3 SEMI-SERIAL TISSUE 
s e c t io n s . T h e  8 v a l u e s  o b t a in e d  p e r  c o m p a r t m e n t  w e r e  a v e r a g e d  a n d  a n a l y z e d  v ia  a  s t u d e n t s  t-t e s t . S h o w n  is 
A REPRESENTATIVE EXPERIMENT OF THREE ± SD . * P<0.05, ** P< 0.001 .
T a b l e  3. E x p r e s s io n  l e v e l s  o f  M M P-3 a n d  M M P-13 m R N A  a f t e r  s o l RII t r e a t m e n t  a .
M M P-3 b M M P-13 b
l e f t  jo in t  (- p a p a in ) 33 ± 20 87 ± 35
r ig h t  jo in t  (+ p a p a in ) 4 0 4 ± 162 3 8 2 ± 103
a R ig h t  k n e e  jo in t s  w e r e  in je c t e d  w ith  1 U p a p a in  s o lu t io n  a n d  l e f t  k n e e  jo in t s  s e r v e d  a s  in t e r n a l  c o n t r o l s . 
A f t e r  3 d a y s , p a t e l l a e  w ith  s u r r o u n d in g  t is s u e  w e r e  is o l a t e d  a n d  t r a n s f e r r e d  t o  R P M I m e d iu m  s u p p l e m e n t e d  
w ith  s o l RII (10 ^g /m l ).
b M M P -3  a n d  - 1 3  R T - P C R  p r o d u c t s  w e r e  q u a n t if ie d  u s in g  P ic o G r e e n . G A P D H  l e v e l s  w e r e  u s e d  t o  c o r r e c t
FOR THE AMOUNT OF TEMPLATE USED. FOR LEFT - AND PAPAIN-INJECTED KNEE JOINTS THE M R N A  LEVELS OF THE NON­
TREATED PATELLAE WERE STATED AS 100% . EACH P C R  WAS PERFORMED IN TRIPLICATE AND RESULTS WERE AVERAGED.
R e s u l t s  w e r e  a n a l y z e d  v ia  a  S t u d e n t s  t -t e s t . S h o w n  is t h e  m e a n  ± SD .
d i s c u s s i o n
Our experiments identified for the first time the role of endogenous TGF-ß during 
experimental OA. Via administration of the soluble TGF-ß-RII we inhibited 
endogenous TGF-ß. This enabled us to study the impact of neutralization TGF-ß on 
osteophyte formation and articular cartilage degradation during experimental OA. 
Blocking of endogenous TGF-ß in the knee joint resulted in an almost complete 
inhibition of osteophyte formation. Furthermore, systemic delivery of solRII not only 
decreased articular cartilage PG content, but also resulted in cartilage loss, probably 
via the upregulation of MMP expression.
We chose the extracellular part of TGF-ß-RII as a TGF-ß antagonist because it has a 
very high affinity for TGF-ß1 and -ß3 24,25, which are both abundantly present in the 
joint 12,26,27. Moreover, because of its small size of 25 kDa, solRII can penetrate 
cartilage and directly affect chondrocytes 28. Chondrocytes are difficult cells to target 
due to the dense network of collagen fibrils and PG's that make up articular cartilage 
and render it virtually impenetrable for large molecules such as antibodies.
The solRII we produced via the P. pastoris expression system is a biologically active 
protein. A 4000 fold excess of recombinant solRII to TGF-ß was able to completely
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neutralize TGF-ß activity. This is well in range with other studies in which 1,600 to
20,000 fold excess of solRII was needed to fully inhibit TGF-ß activity 25,29. The solRII 
obtained from the osmotic pumps retrieved from the mice after implantation, showed 
no loss of blocking activity compared to freshly produced solRII. This indicates that 
during the complete duration of the experiment we were able to inhibit TGF-ß 
activity.
One of the main characteristics of OA is the formation of new cartilage and bone on 
the joint edges, so called osteophytes. Osteophytes are the principal cause of pain in 
OA patients and therefore an unwanted feature of the disease. Osteophytes are 
believed to originate from the periosteum. Periosteal cells have the potential to 
undergo chondrogenesis and osteogenesis in  vivo and in  vitro 30-32. In developing 
osteophytes, not only TGF-ß mRNA is strongly expressed, but also TGF-ß-R 
expression can be found 12,14. Chondrogenesis of periosteal cells can be enhanced by 
TGF-ß in a dose dependent manner 33-35. We previously showed that already one day 
after i.a. injection of TGF-ß, increased PG synthesis was observed in periosteal cells 
at sites that later show massive osteophyte development 14. However, these studies 
did not proof a role of endogenous TGF-ß during osteophyte formation. In this study 
we show expression of TGF-ß1 and -ß3 in periosteum after papain injection. Blocking 
of TGF-ß1 and -ß3 activity by use of the solRII resulted in a dramatic reduction in 
osteophyte formation. So, here we show for the first time that endogenous TGF-ß is 
essential in osteophyte formation during experimental OA.
One of the first signs of OA is the loss of PG's from the articular cartilage, which 
ultimately leads to cartilage loss. Several lines of evidence suggest an important role 
for TGF-ß in cartilage maintenance. We and others showed that TGF-ß can increase 
PG synthesis in normal and OA-chondrocytes in vivo and in vitro 14,15,36. Furthermore, 
local administration of TGF-ß can suppress IL-1 induced matrix degradation 17,37, 
probably via downregulation MMPs 38,39 and/or increasing the level of TIMPs 38,40. 
TGF-ß also inhibits terminal differentiation of chondrocytes (hypertrophy), which has 
been shown to occur during OA. Serra et al have shown that blocking of TGF-ß 
signaling in transgenic mice expressing a truncated, kinase defective TGF-ß-RII in 
skeletal tissue, results in hypertrophic chondrocytes leading to OA changes in these 
mice 41. Recently it was shown that in Smad-3 deficient mice, articular chondrocytes 
undergo abnormal terminal hypertrophic differentiation, which leads to OA 42. These 
studies demonstrate that loss of TGF-ß responsiveness in the articular cartilage can 
lead to OA changes.
Since TGF-ß has an important regulatory function in articular cartilage, we studied 
effects of solRII treatment on articular chondrocytes. First we determined the 
expression of TGF-ß isoforms during papain-induced OA. The results show that TGF- 
ß1 and -ß3 protein expression occurs in chondrocytes of normal articular cartilage, 
which is upregulated after i.a. papain injection. In contrast, we were unable to detect 
TGF-ß2 in normal knee joints or during papain-induced OA. So, TGF-ß1 and -ß3 are 
likely to play a role in cartilage matrix during experimental OA. Next, we showed that 
inhibition of endogenous TGF-ß in articular cartilage leads to a decreased PG content 
in nearly all articular cartilage compartments. The loss of PG's could either be due to 
impaired synthesis of PG's, enhanced breakdown or poor retention of PG's in the
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cartilage. These results are in line with our earlier studies that show that exogenous 
TGF-ß increases PG synthesis and content 14,15. Our present results illustrate that the 
solRII is able to penetrate the cartilage and affect chondrocyte metabolism, leading 
to reduced PG content. In conclusion, endogenous TGF-ß is a necessary agent to 
protect articular cartilage from PG loss.
Besides effects on PG content, TGF-ß deprivation also appeared to increase cartilage 
loss. We found that the thickness of cartilage was decreased after blocking TGF-ß. 
Increased cartilage loss might be related to a decreased resistance to mechanical 
loading. Since inhibition of endogenous TGF-ß decreased PG content, and because 
PG's are important molecules responsible for the resistance of articular cartilage 43-45, 
loss of PG's may lead to loss of cartilage. Therefore, endogenous TGF-ß appears 
important in the prevention of cartilage loss.
We found that inhibition of endogenous TGF-ß leads to enhanced cartilage PG loss. 
This can either be the result of upregulation of cartilage degrading proteases or 
downregulation of the natural inhibitors of these enzymes. In order to clarify the 
mechanistics of TGF-ß inhibition on articular cartilage, the mRNA levels of several 
MMPs, ADAMTS and TIMPs in the knee joint were determined after exposure to 
solRII. Our results suggest that inhibition of endogenous TGF-ß via solRII enhances 
cartilage PG loss via upregulation of MMP-3 and MMP-13. We observed only a small 
stimulation on ADAMTS-4 and -5 mRNA expression after solRII treatment. The 
expression levels of TIMP-1 and -3 were unchanged after solRII and IL-1 treatment. 
So, endogenous TGF-ß suppresses the expression of several MMPs, like MMP-3 and - 
13.
In summary, inhibition of endogenous TGF-ß leads to an increased loss of PGs from 
the cartilage and enhances cartilage loss during experimental OA, most likely through 
the upregulation of MMPs. This indicates a protective role for endogenous TGF-ß on 
cartilage. Moreover, with the aid of the soluble form of the TGF-ß-RII as a TGF-ß 
antagonist, we identified endogenous TGF-ß as the main contributor to osteophyte 
development during experimental OA.
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CHAPTER 6
a b s t r a c t
Ob je c t iv e . T o  assess if  various b io log ical responses to  
Transform ing G row th FACTOR-ß (TG F-ß) in chondrocytes
ARE DIFFERENTIALLY REGULATED BY S mAD6 AND S mAD7.
De s ig n . Adenoviral overexpression of Smad6 o r  -7 mRNA
IN A CHONDROCYTE CELL LINE WAS DETERMINED VIA SEMI­
QUANTITATIVE RT-PCR AND PROTEIN OVEREXPRESSION WAS 
STUDIED BY IMMUNOCYTOCHEMISTRY. FURTHERMORE, THE EFFECT 
OF S mAD6 AND - 7  OVEREXPRESSION ON TGF-ß-INDUCED PAI-1 
AND AGGRECAN MRNA UPREGULATION WAS STUDIED VIA 
QUANTITATIVE RT-PCR. THE EFFECT OF SMAD6 AND - 7  
OVEREXPRESSION ON TGF-ß-INDUCED CHONDROCYTE 
PROLIFERATION WAS STUDIED VIA DNA QUANTIFICATION, WHEREAS 
TGF-ß-INDUCED PROTEOGLYCAN (PG) SYNTHESIS WAS STUDIED BY 
35S-sulfate  INCORPORATION.
R e s u lt s . Adenoviral tran sfectio n  of chondrocytes w ith
S mAD6 AND - 7  RESULTED IN STRONG UPREGULATION OF S mAD6 
AND -7 MRNA LEVELS, RESPECTIVELY. IMMUNOCYTOCHEMISTRY 
SHOWED OVEREXPRESSION OF S mAD6 AND - 7  PROTEINS IN BOTH 
THE NUCLEUS AND CYTOPLASM. S mAD6 OVEREXPRESSION 
SIGNIFICANTLY INHIBITED TGF-ß-STIMULATED CHONDROCYTE 
PROLIFERATION, ALTHOUGH PROLIFERATION WAS NOT COMPLETELY 
ABOLISHED. S mAD7 OVEREXPRESSION HOWEVER, COMPLETELY 
ANTAGONIZED THE TGF-ß EFFECT ON PROLIFERATION. S mAD6 
OVEREXPRESSION HAD NO EFFECT ON TGF-ß-INDUCED PAI-1 
EXPRESSION, WHILE OVEREXPRESSION OF SMAD7 COMPLETELY 
BLOCKED THIS TGF-ß EFFECT. ADDITIONALLY, OVEREXPRESSION OF 
S mAD7, BUT NOT S mAD6, TOTALLY PREVENTED TGF-ß-INDUCED 
PG SYNTHESIS ON THE MRNA- AND PROTEIN LEVEL.
Co n clu sio n s. Adenoviral tran sfectio n  of chondrocytes
WITH S mAD6 AND - 7  RESULTED IN STRONG UPREGULATION OF
S mad6 and - 7  mRNA - and protein  lev els . F urtherm ore,
OVEREXPRESSION OF S mAD7 IN CHONDROCYTES TOTALLY INHIBITED 
IMPORTANT TGF-ß-MEDIATED BIOLOGICAL RESPONSES SUCH AS 
PROLIFERATION AND PG SYNTHESIS, WHILE OVEREXPRESSED S mAD6 
HAD NO OR ONLY A PARTIAL INHIBITORY EFFECT ON TGF-ß  
ACTIVITY. W e conclude that in chondrocytes d istin ct  TGF-ß  
ACTIVITIES ARE DIFFERENTIALLY REGULATED BY S mAD6 AND S mAD7.
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ADENOVIRAL OVEREXPRESSION OF SMAD? AND SMAD6
i n t r o d u c t i o n
Osteoarthritis (OA) is a joint disease affecting up to 70% of the adult population and 
has as main characteristic the destruction of articular cartilage. OA is generally 
considered to be a chondrocyte disease. Although the exact etiology of OA is 
unknown, a role for TGF-ß has been implicated since high concentrations of active 
TGF-ß are found in the synovial fluid of OA patients 1,2 and TGF-ß protein is 
expressed by osteoarthritic chondrocytes 3. Moreover, loss of responsiveness to TGF- 
ß in transgenic mice leads to OA 4,s. We have previously shown that in aging mice, 
chondrocytes become non-responsive to protective TGF-ß functions, another 
indication that loss of TGF-ß responsiveness may be involved in the initiation of OA 6.
TGF-ß is a secreted signaling molecule that is involved in a wide variety of cellular 
responses including proliferation, differentiation, regulation of cell metabolism and 
extracellular matrix formation. Also for chondrocytes TGF-ß is an important anabolic 
factor. In cultured chondrocytes the synthesis of important extracellular matrix 
components such as aggrecan and collagen type II is increased in response to TGF-ß 
7-11, although it has also been reported that TGF-ß can inhibit collagen type II 
synthesis 12. Additionally, TGF-ß inhibits matrix degradation via upregulation of 
inhibitors of matrix degrading enzymes 13,14. Furthermore, TGF-ß is not only a strong 
stimulator of chondrocyte proliferation 15,16 but is also an important regulator of 
chondrocyte differentiation 17-19. Also in vivo TGF-ß is crucial to maintain normal 
chondrocyte differentiation state and metabolism. This is reflected by the elevated 
incidence of OA in several transgenic mouse strains with abrogated TGF-ß signaling 
in chondrocytes 5'6. Additionally, it has been shown that during experimental OA 
articular chondrocytes show a dramatic decrease in the expression of TGF-betaRII, 
which may lead to TGF-beta unresponsiveness during OA 20. Furthermore, we have 
previously shown that TGF-ß is a very potent stimulator of chondrocyte PG synthesis 
in vivo21,22 and that inhibition of endogenous TGF-ß during experimental OA leads to 
enhanced cartilage PG loss 23.
Members of the TGF-ß superfamily to which TGF-ß and Bone Morphogenetic Proteins 
(BMPs) belong, induce the formation of a heterotetra meric complex of the specific 
serine/threonine kinase receptors. Signaling by the TGF-ß family is initiated by the 
phosphorylation of type I receptors by type II receptors. The signal is further 
transduced via phosphorylation of intracellular mediators; so-called receptor 
associated Smad proteins (R-Smads) 24. TGF-ß signaling is mediated by Smad-2 and 
-3, whereas BMPs signal via Smad-1, -5 and -8. Phosphorylated R-Smads from both 
TGF-ß and BMP pathways form a complex with Smad4, a common mediator or Co- 
Smad. The R-Smad/Co-Smad complex propagates the signal to the nucleus, 
eventually resulting in the activation or silencing of TGF-ß responsive genes 25.
The TGF-ß family signaling pathway initiated by R-Smads and Co-Smads can be 
opposed by inhibitory Smads (I-Smads): Smad6 and -7 26-28. I-Smads act by stably 
interacting with activated type I receptors, thus preventing the phosphorylation of R- 
Smads 26,29. Smad6 preferential mode of action is competing with Smad4 for complex 
formation with phosphorylated Smad1 29.
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Smad7 is thought to be an antagonist of both TGF-ß and BMP activity, whereas 
Smad6 is considered to be a BMP inhibitor only. However, results are controversial 
and indicate that TGF-ß activity is differentially regulated and seems to depend on 
the TGF-ß response and cell type studied. Studies have shown that Smad7, but not 
Smad6, not only inhibits specific TGF-ß responses in epithelial lung - and renal tubule 
cells but also antagonizes TGF-ß-induced lung morphogenesis and lung fibrosis 30-33. 
On the other hand, although Smad6 is often considered to be primarily a BMP 
antagonist, inhibition of TGF-ß activity by Smad6 has been described. For instance, 
TGF-ß induced proliferation of pancreatic cancer - and epithelial cells could be 
inhibited by Smad6 34,35. Also TGF-ß-mediated expression of PAI-1 and adipocyte 
differentiation could be antagonized by Smad6 35-37. Taken together, negative 
regulation of TGF-ß activity by Smad6 and -7 is not only cell type specific but also 
depends on the TGF-ß response studied. Until now it is unknown how Smad6 and -7 
regulate TGF-ß-mediated responses in chondrocytes.
In this study we investigated if Smad6 and Smad7 are able to antagonize important 
TGF-ß-mediated biological responses in chondrocytes such as, chondrocyte 
proliferation and PG synthesis. We used adenoviral overexpression of Smad6 and 
Smad7 in a murine chondrocyte cell line to specifically inhibit TGF-ß signaling. 
Overexpression of Smad7 totally inhibited TGF-ß-mediated proliferation and PG 
synthesis (protein - and mRNA levels). Smad6 significantly inhibited, but did not 
completely prevent, TGF-ß-induced proliferation in chondrocytes. On the other hand, 
Smad6 had no effect on TGF-ß-induced PG synthesis. So, Smad6 is at best a weak 
TGF-ß antagonist in chondrocytes, whereas we identified Smad7 as a very efficient 
inhibitor of TGF-ß activity in chondrocytes. We conclude that in chondrocytes TGF-ß 
activity is differentially antagonized by Smad6 and -7 depending on the TGF-ß 
response studied.
m a t e r i a l s  & m e t h o d s
Cell C u ltu r e
Minc lung epithelial cells (MLEC) were cultured in monolayer at 37°C and 5% CO2 in 
Dulbecco's modified Eagle's medium (DMEM)/glutamax: 4500 mg/l glucose, 
pyridoxine and sodium pyrovate (Life Technologies BV, Breda, The Netherlands) 
supplemented with 10% fetal calf serum (FCS) (ICN Biomedicals BV, Zoetermeer, 
The Netherlands), penicillin (500 U/ml)/streptomycin sulfate (500 |ig/ml) (Life 
Technologies BV, Breda) and geneticin sulfate (250 |ig/ml) (Life Technologies BV, 
Breda, The Netherlands). Cells were passaged for no more than 15 times.
H1 chondrocytes were cultured in monolayer in DMEM/nut mix F12 (HAM) (Life 
Technologies BV, Breda, The Netherlands) supplemented with 10% FCS and 
penicillin/streptomycin sulfate at 37°C and 5% CO2. Generation of this immortalized 
murine cell line is described elsewhere 7. Cells were passaged for a maximum of 20 
times.
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A d en o vir al Vec to r s
Recombinant adenoviruses expressing full length Smad6 (Ad-Smad6) and Smad7 
(Ad-Smad7) were generated as described elsewhere 38. Adenoviruses were amplified 
and purified as described previously 39. As controls, a recombinant adenovirus 
expressing Luciferase (Ad-Luc) or an adenovirus lacking an expression cassette (Ad- 
DL70-3) were used. Cells were transfected with a multiplicity of infection (MOI) of 1, 
10 or 100. All adenoviruses used had a comparable concentration of plaque forming 
units ((pfu) range = 1.0 - 2.1 -1010/ml); moreover, the concentration of virus 
particles (virions) was also similar for the different viruses used (range = 0.9 -  1.5 
■1012/ml). All transgenes were controlled by the CMV promoter.
M LE C a s s a y a n d  tr an sfectio n
The ability of Smad6 and Smad7 in inhibiting TGF-ßi activity was tested using the 
MLEC assay. This assay is based on the induction of plasminogen activator inhibitor-1 
(PAI-1) promoter/luciferase construct by TGF-ß, resulting in a dose dependent 
increase in luciferase activity 40. MLEC were transfected with Ad-Smad6, Ad-Smad7 
or Ad-DL70-3 with a MOI of 1, 10 or 100 in DMEM without FCS for 2 hours at 37°C, 
5% CO2. Mock-transfected cells were used as a control. After 2 hours, transfection 
medium was replaced with DMEM/glutamax supplemented with 10% FCS, 
penicillin/streptomycin and geneticin. Next, cells were incubated for 5 hours before 
TGF-ß1 (R&D Systems, Europe Ltd, Abingdon, UK) was added to the transfected cells 
in a final concentration of 1.56 ng/ml and cells were incubated for another 16 hours 
at 37°C, 5% CO2. Then, Bright-Glo luciferase assay reagent was added (Promega, 
Leiden, The Netherlands). Luciferase activity was measured using a Fluorstar Galaxy 
(BMG LabTechnologies GmbH, Offenburg, Germany) in the excitation option using 
the following program: 1 cycle, 0.5s integration time and positioning delay of 0.1s. 
The effect of transfection with Ad-Smad6, Ad-Smad7 or Ad-DL70-3 on the TGF-ß- 
induced luciferase activity was calculated from TGF-ß1 standards added to mock 
transfected cells. Experiments were performed at least two times and each standard 
or sample was tested in quadruplicate. Results were analyzed via ANOVA.
Tr a n sfectio n  o f  ch o n d r o cytes
H1 chondrocytes were transfected with Ad-Smad6, Ad-Smad7, Ad-Luc or were mock 
transfected in DMEM/HamsF12 without FCS for 2 hours (M0I=10). After washing 
with physiological salt, DMEM/HamsF12 with 10% FCS was added and cells were 
stimulated with or without TGF-ß1 (end concentration 10 ng/ml) for the desired 
amount of time.
m RNA iso la tio n  a n d  R T-r eactio n
Cytoplasmic RNA was isolated using the RNeasy mini kit according to the 
manufacturers protocol (Qiagen, Valencia, USA). Isolated RNA was treated with 
DNasel (Life Technologies BV, Breda, The Netherlands) to remove any contaminating 
DNA. Next, 0.5 |ig RNA was reverse transcribed with 200 U Molony-murine leukemia 
virus reverse transcriptase (Life Technologies BV, Breda, The Netherlands) in 50 mM 
Tris pH 8.3, 75 mM KCl, 3 mM MgCh, 10 mM dithiothreitol, 0.5 mM dNTPs, 20 U 
RNasin (Promega, Leiden, The Netherlands) and 0.5 |ig oligo(DT)15 (Eurogentec, 
Liege, Belgium). The mixture was incubated at 39°C for 60 minutes, heated to 95°C 
for 10 minutes and then cooled to 4°C.
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Sem i-quan tita  tiv ea n d  quan tita  tiv e  R T-PC R
Since TGF-ß is a strong stimulator of Smad7 expression in several cell types, we 
studied the effect of TGF-ß1 on endogenous mRNA levels of Smad6 and Smad7 in 
chondrocytes. Furthermore, overexpression of Smad6 and -7 mRNA after adenoviral 
transfection was determined via semi-quantitative RT-PCR. The house keeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used to correct for the 
amount of template used. RT-PCR was performed with the following primers: 
GAPDH: 5'-AACTCCCTCAAGATTGTCAGCA-3' and 3'-ATGTCGTTGTCCCACCACCT-5', 
resulting in a 553 bp product; Smad6: 5'-GTCAGCATTTTCTACGACCTA-3' and 3'- 
AGTCGAACACCTTGATgGaGT-5', resulting in a 262 bp product; Smad7: 5'- 
TCCAGATACCCAATGGATTTTC-3' and 3'-AGCTGACTCTTGTTGTCCGAAT-5', resulting 
in a 293 bp product. RT-PCR was performed at a final concentration of 50 mM KCl, 
20 mM Tris pH 8.4, 1.5 mM MgCl2, 200 |iM dNTPs, 0.4 |iM of each primer and 40 
U/ml Taq-polymerase (Life Technologies BV, Breda, The Netherlands). The mixture 
was overlaid with mineral oil and amplified in a PTC-200 thermal cycler (MJ 
Research, Peltier Thermal Cycler). The PCR protocol started with 1 minute 
denaturation at 92°C, followed by annealing at 60°C for 1 minute and 1 minute 
extension at 72°C. Semi-quantitative PCR was performed as described elsewhere 41. 
A factor 1.8 per PCR cycle was taken to calculate the difference in mRNA expression. 
It was determined that the PCR reaction performed linearly at the point when the 
PCR product was first detected. Experiments were performed at least two times.
The effect of luciferase, Smad6 and -7 overexpression on TGF-ß-induced PAI-1 and 
aggrecan mRNA overexpression was studied using quantitative RT-PCR with the 
following primer sets as designed using Primer Express (Applied Biosystems 
Nieuwerkerk a/d IJssel, The Netherlands): GAPDH: 5'-GGCAAATTCAACGGCACA-3' 
and 5'-GTTAGTGGGGTCTCGCTCCTG-3', aggrecan: 5'-AGGCATGGTGCTTTGACAGTG- 
3' and 5'-TCTACCCCAACCAAACCGG-3', and PAI-1: 5'-ACGTCGTGGAACTGCCCTAC-3' 
and 5'-CAGCGATGAACATGCTGAGG-3'. Quantitative RT-PCR was performed with 
SYBR Green PCR master mix according to the manufacturers recommendations. 
Amplification and detection were performed with a ABI Prism 7000 Sequence 
detection system (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) 
using the following conditions: 94°C (15 s) and 60°C (1 min) for 40 cycles. Threshold 
levels (CT values) were determined using Sequence Detection System software 
(Applied Biosystems). The amplification efficiency was determined in a 10 fold 
standard dilution range and for this 10 fold dilution was shown to be 3,25 for PAI-1, 
3,214 for GAPDH and 3,028 for Aggrecan. Quantitative RT-PCR was performed in 
duplo and for each experimental group the CT of GAPDH was subtracted from the CT 
of PAI-1 and Aggrecan. The average delta CT of the duplo's was taken and up - or 
down regulation of PAI-1 and aggrecan after stimulation with TGF-ß1 compared to 
unstimulated cells was determined (expressed as percentage). The experiment was 
repeated three times and the values from mock transfected cells + TGF-ß1 was 
stated as 100%. The values of the other experimental groups is shown as a relative 
percentage.
Im m u n o cyto ch em istr y  o f  Sm ad 6  a n d  Sm ad7
H1 chondrocytes were cultured in 4 well Lab-Tek II chamber slides (Nalge Nunc 
International, Naperville, IL, USA) in a concentration of 2-105 cells/well for 16 hours 
at 37°C, 5% CO2 to allow attachment. Then, chondrocytes were transfected with
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MOI = 10 with Ad-Smad6, Ad-Smad7, Ad-Luc or were mock transfected for 2 hours 
at 37°C, 5% C02, after which the transfection medium was replaced with normal 
culture medium. Cells were cultured for an additional 48 hours before cells were 
fixed in 2% paraformaldehyde, 4% sucrose for 5 minutes at room temperature (RT). 
Subsequently, cells were permeabilized with 0.2% Triton-X-100 in PBS during 30 
minutes. After extensive washing with PBS, endogenous peroxide was inactivated 
with 1% H202 in methanol for 30 minutes followed by washing with PBS. Slides were 
incubated with rabbit anti-Smad6 antibody (Ab) (Zymed Laboratories, San Francisco, 
USA), goat anti-Smad7 Ab (Santa Cruz Biotechnology, Heidelberg, Germany) or as a 
control with rabbit or goat IgG's, respectively, in a concentration of 1 |ig/ml in 3% 
bovine serum albumin (BSA)/PBS for 2 hours at RT. After washing with PBS, slides 
were incubated with the biotin labeled secondary horse anti-rabbit for the anti- 
Smad6 Ab or rabbit anti-goat for the anti-Smad7 Ab in a concentration of 1 |ig/ml in 
3% BSA/PBS for 1-2 hours at RT. Subsequently, a biotin-streptavidin detection 
system (Vectra elite kit, Vector Laboratories. Inc, Burlingham, CA) was used 
according to the manufacturers recommendations. Bound complexes were visualized 
via reaction with 3',3'diaminobenzidine (DAB; Sigma Chemicals Co, St. Louis, MO, 
USA) and H202. Cells were briefly counterstained with haematoxylin and mounted 
with permount.
Pr o teo g lycan  sy n th esis a n d  Ch o n d r o cyte  pr o lifer a tio n
The effect of adenoviral overexpression of Ad-Smad6, Ad-Smad7, Ad-Luc or mock 
transfected cells on TGF-ß1-induced proteoglycan synthesis (35S042- incorporation) 
and chondrocyte proliferation (DNA content) was studied. After 48 hours cells were 
pulse labeled with 35S0 4 2- (20 |iCi/well) for 3 hours at 37°C, 5% CO2 . Next, a papain- 
carrier solution was added to break down extracellular matrix (60°C, 2 hours): 1 mg 
papain, 50 |ig chondroitin sulfate, 0.2 M NaCl, 0.1 M NaAc, 10 mM cystein- 
hydrochlorid and 50 mM Na2EDTA per ml water. Incubation was followed by storage 
o/n at -20°C. Subsequently, 600 |il sample solution was added to an equal amount of 
cetylpyridiumchlorid (CPC) to precipitate glycosaminoglycans and incubated for 2 
hours at 37°C followed by centrifugation at 12000 rpm for 10 minutes. The pellet 
was washed three times with 0.05% CPC followed by centrifugation after each wash 
step. The pellet was reconstituted in 0.5 ml lumasolve (Lumac-LSC B.V., Groningen 
The Netherlands) and incubated for 1 hour at 60°C, after which the pellet was 
resuspended thoroughly and 10 ml Lipoluma (Lumac-LSC B.V.) was added. 
Incorporated 35S0 4 2- was counted using a liquid scintillation counter. Each sample 
was tested in triplicate.
Chondrocyte proliferation was studied via measurement of DNA content. Double 
stranded DNA was selectively stained with the fluorescent dye PicoGreen according 
to the manufacturers manual (Molecular Probes, Oregon, USA). The DNA content 
was taken as an indirect measure for cell number. After o/n storage at -20°C as 
described above, a 100 |il sample was taken to measure the DNA content of each 
sample. To each sample an equal amount of PicoGreen reagent was added. A 
standard curve was used to quantify DNA concentrations in the samples. 
Fluorescence was measured using the Fluorstar Galaxy with the following program: 
excitation filter 485-P, emission filter 520-P, 1 cycle and 10 flashes. Gain was 
adjusted to the highest concentration in the standard curve. Results were analyzed 
via ANOVA. From the paired results from 35S042- incorporation and DNA
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quantification the 35SÜ42" incorporation per cell was calculated. Experiments were 
performed at least two times. Triplicates were averaged and differences were 
analyzed via ANOVA.
R ESU LTS
M LE C a s s a y
To determine if adenoviral overexpression of Smad6 and -7 resulted in blockage of 
TGF-ßi activity, we made use of the MLEC reporter assay for TGF-ß. As can be seen 
in figure 1, transfection with Ad-DL70-3 at MOI 1 and 10 reduced luciferase activity 
by 11% and 19%, respectively. At higher MOI, luciferase activity was even reduced 
by 25%. These inhibitory effects on TGF-ß1 activity are probably due to an aspecific 
virus effect. Transfection of Ad-Smad6 at MOI 1 and 100 significantly inhibited TGF- 
ß1 activity compared to the effect of Ad-DL70-3 but TGF-ß1 activity was not 
completely abolished by Smad6 overexpression. In contrast to Ad-DL70-3 and Ad- 
Smad6, Ad-Smad7 at an MOI of 1 already blocked 84% of the luciferase activity 
induced by 1.56 ng/ml TGF-ß1 . At higher MOI the TGF-ßrinduced luciferase activity 
was totally inhibited by Smad7 overexpression. The observation that Ad-Smad7 
values are even below background levels is probably due to the inhibition of 
endogenous TGF-ß produced by MLEC or TGF-ß present in FCS. The results indicate 
that already at low MOI, Smad7 totally inhibits the TGF-ßrinduced stimulation of the 
PAI-1 promoter and the subsequent production of luciferase. In contrast, only a 
partial inhibition of TGF-ß1 activity by Smad6 overexpression was observed.
F ig u re  1. S m a d 6 a n d  S m a d 7 e f f e c t s  o n
T G F -ß  INDUCED PAI-1 PROMOTER DRIVEN 
LUCIFERASE ACTIVITY IN M L E C . M L E C  WERE 
TRANSFECTED WITH A D -D L70 -3 , A D -S mAD6 
OR A d - S m a d 7 a t  M OI 1, 10 a n d  100 in 
SERUM FREE D M E M  FOR 2 HOURS. NEXT, 
MEDIUM WAS REPLACED WITH D M EM /10%  
F C S . A f t e r  a n o t h e r  5 h o u r s  1 .56 n g /m l  
T G F - ß WAS ADDED. AFTER 16 HOURS 
INCUBATION LUCIFERASE ACTIVITY WAS 
MEASURED VIA THE BRIGHT-GlO LUCIFERASE 
ASSAY REAGENT. THE EFFECT OF ADENOVIRAL 
TRANSFECTION WAS CALCULATED FROM T G F -ß  
STANDARDS ADDED TO MOCK TRANSFECTED
c e l l s . S t a n d a r d s  a n d  s a m p l e s  w e r e
TESTED IN QUADRUPLICATE AND RESULTS WERE 
AVERAGED AND ANALYZED VIA A N O V A .
S m ad 6 & S m ad7  expr essio n  in  ch o n d ro cytes
Sem i-q u an titativeRT-PCR
I-Smads have been described to be part of an auto-inhibitory feedback loop for TGF- 
ß. Therefore, the effect of exogenously added TGF-ß1 on endogenous expression 
levels of Smad-6 and -7 mRNAs was determined. Cultured chondrocytes express 
Smad-6 and Smad-7 mRNA (results not shown). TGF-ß1 stimulation (48 h) 
upregulated endogenous Smad-7 mRNA in chondrocytes in the order of 3.2 fold. We 
did not observe a detectable upregulation of endogenous Smad-6 mRNA levels by 
TGF-ß1 in chondrocytes after 48 hours (results not shown).
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Because adenoviral transfection of cells with a MOI of 100 resulted in a strong virus 
effect we used a MOI of 10 in all further experiments in order to minimize this effect. 
Transfection of chondrocytes with Ad-Smad-6 resulted in an upregulation of Smad-6 
mRNA levels in the order of 8 PCR cycles compared to mock transfected, Ad-Luc and 
Ad-Smad-7 transfected cells (results not shown). The addition of TGF-ß1 had no 
additional effect on Smad-6 mRNA overexpression. Smad-7 mRNA levels were 
upregulated 9 cycles in Ad-Smad-7 transfected cells compared to mock, Ad-Luc and 
Ad-Smad-6 transfected cells (results not shown). The addition of TGF-ß1 did not 
affect the adenovirally mediated Smad-7 mRNA overexpression.
I mmunocytochemistry
We studied whether the strong mRNA overexpression of Smad6 and Smad7 after 
adenoviral transfection resulted in enhanced Smad6 and Smad7 protein expression. 
Overexpression of Smad6 and Smad7 protein was investigated in transfected 
chondrocytes after 48 hours using specific anti-Smad Ab. Figure 2 shows high 
expression of Smad6 in Ad-Smad6 transfected cells, but not after transfection of Ad- 
Smad7, Ad-Luc or mock treated cells (see Ch. 9). Similarly, high Smad7 expression 
was detected in Ad-Smad7 transfected chondrocytes but not after Ad-Smad6, Ad-Luc 
transfection or mock transfection. Transfection efficiency of chondrocytes with Ad- 
Smad6 and -7 was in the order of 70 -  80%, resulting in similar staining intensities 
of Smad6 and -7 (figure 2A+B, see Ch. 9). Although I-Smads are endogenous 
proteins only little staining was found in control transfected cells, indicating that 
endogenous protein levels of Smad6 and -7 are relatively low and that adenoviral 
transfection leads to Smad6 and -7 protein expression in the cytoplasm and nucleus. 
For both I-Smads staining seemed absent from certain cytoplasmic vesicles of 
unknown origin. I-Smad staining of the nucleus was predominantly peri-nuclear. 
Moreover, I-Smads seemed absent from certain regions of the nucleus, possibly 
representing the nucleoli. Substitution of the primary Ab with control IgG did not 
result in any staining, indicating the specificity of the Abs used (data not shown). 
Taken together, transfection of chondrocytes with Ad-Smad6 and -7 leads to 
pronounced overexpression of Smad6 and Smad7 protein, respectively.
SMAD6 & SMAD7 BOTH INHIBITTGF-ß in d u ced  ch o n d r o cyte pr o lifer a tio n
Since TGF-ß is a potent inducer of chondrocyte proliferation, we studied if 
overexpressing I-Smads could prevent this effect. Proliferation was monitored by 
measuring the increase in DNA content, an indirect measure of cell number. As figure
3 shows, treatment with TGF-ß1 in mock transfected cells increased cell number by 
41% compared to untreated cells. Overexpression of luciferase already caused a 
drop in cell number in comparison to mock treatment. Despite this aspecific virus­
effect in the Ad-Luc group, TGF-ß1 still significantly increased cell number as 
compared to unstimulated Ad-Luc transfected chondrocytes (compare white bars 
with black ones). In contrast, when comparing TGF-ß1-treated with non-treated 
chondrocytes our results indicate that Smad6 overexpression significantly inhibited 
but not completely abolished cell proliferation. Smad7 overexpression on the other 
hand totally inhibited TGF-ßrinduced chondrocyte proliferation (figure 3).
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F ig u re  3. S m a d 6 a n d  S m a d 7 b l o c k  T G F -ß -
INDUCED CHONDROCYTE PROLIFERATION. H1 
CHONDROCYTES WERE TRANSFECTED AT MOI 10 
w ith  A d - L u c , A d - S m a d 6 o r  -7 o r  w e r e  m o c k  
t r a n s f e c t e d  in D M E M /F 1 2 , 0% F C S . A f t e r  2 
HOURS, MEDIUM WAS CHANGED TO D M E M /F 1 2  + 
10% F C S . A f t e r  a n o t h e r  5 h o u r s  10 n g /m l
T G F -ß  WAS ADDED AND CELLS WERE INCUBATED
f o r  48  h o u r s . C h o n d r o c y t e  p r o l if e r a t io n
WAS STUDIED VIA MEASUREMENT OF D N A  CONTENT 
VIA STAINING WITH PICOGREEN AS MEASURED
u s in g  t h e  F l u o r s t a r  G a l a x y . T h e  D N A
CONTENT WAS TAKEN AS AN INDIRECT MEASURE 
FOR CELL NUMBER. GAIN WAS ADJUSTED TO THE 
HIGHEST CONCENTRATION IN THE STANDARD
c u r v e . R e s u l t s  w e r e  a n a l y z e d  via  A N O V A . *
= SIGNIFICANTLY MORE PROLIFERATION THAN IN 
NON-STIMULATED (- T G F -ß )  GROUP.
Sm ad7  b lo ck s  TGF-ß u pr eg u lated  a g g r eca n  a n d  PA I-1  ex pr essio n
We studied the effect of Ad-Smad6 and -7 transfection on TGF-ß-induced 
upregulation of aggrecan mRNA levels, the most abundant PG in articular cartilage. 
The addition of TGF-ß1 to mock transfected cells upregulated aggrecan mRNA 2.9 
PCR cycles compared to non-TGF-ß treated cells. In Ad-Luc transfected cells a slight 
inhibition of aggrecan mRNA expression was observed but this was not significant. 
Also Ad-Smad6 did not significantly inhibit this TGF-ß1-induced upregulation (table 
1). In contrast, transfection of Ad-Smad7 completely prevented the upregulation of 
aggrecan mRNA induced by TGF-ß1.
T a b le  1. Smad7 inhibits TGF-ß induced u p re g u la t io n  o f  PAI-1 and a g g re c a n  mRNA
T r e a t m e n t a A g g r e c a n p a i -1
A v e r a g e  b SD A v e r a g e  b SD
A d - L u c 35.7 0.65 32.3 2.36
A d - S m a d 6 38.0 1.74 33.4 1.70
A d - S m a d 7 99.9 6.33 88.4 2.63
a H1 CHONDROCYTES WERE TRANSFECTED WITH ADENOVIRUSES (M 0I= 10) EXPRESSING LUCIFERASE, S m AD6, S mAD7 OR
WERE MOCK TRANSFECTED. THE NEXT DAY, CELLS WERE STIMULATED WITH T G F -ß  (10 NG/ML) OR NOT STIMULATED FOR 4
h o u r s . b V ia q u a n t it a t iv e  P C R  G A P D H , PAI-1 a n d  a g g r e c a n  m R N A  l e v e l s  w e r e  d e t e r m in e d . G A P D H  l e v e l s
WERE USED TO CORRECT FOR THE AMOUNT OF TEMPLATE USED. THE UPREGULATION FOR PAI-1 OR AGGRECAN M R N A  AFTER 
T G F -ß  STIMULATION VERSUS NON-STIMULATED CELLS WAS DETERMINED. THE UPREGULATION OF PAI-1 AND AGGRECAN
m R N A  b y  T G F -ß  in m o c k  t r a n s f e c t e d  c e l l s  w a s  s t a t e d  a s  100% . T h e  r e l a t iv e  inhibition  o f  T G F -ß  a c t iv it y  in
PERCENTAGES IS SHOWN.
We also studied PAI-1 mRNA expression in response to TGF-ß. The addition of TGF- 
ß1 to mock transfected cells resulted in upregulation of PAI-1 mRNA levels 1.9 PCR 
cycles compared to non-treated cells. Table 1 shows that in Ad-Luc and Smad6 
treated cells a mild inhibitory effect of the transfection itself could be observed but 
this effect was not significant. In contrast, Ad-Smad7 overexpression almost 
completely abolished the TGF-ß1-mediated upregulation of PAI-1 expression.
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Sm ad7  pr ev en ts  TGF-ß INDUCED P G  SYNTHESIS
Because TGF-ß upregulated aggrecan on the mRNA level, we set out to investigate if 
overexpression of Smad6 or Smad7 regulated TGF-ß-induced PG synthesis. Figure 4 
shows that after mock transfection, TGF-ß1 enhanced chondrocyte PG synthesis by 
31% after 48 hours. Overexpression of luciferase via transfection with Ad-Luc had no 
effect on the PG synthesis induced by TGF-ß1 compared to mock treated cells (41%). 
Similarly, overexpression of Smad6 showed no effect on TGF-ßrinduced PG synthesis 
compared to luciferase transfection (40%). In contrast, overexpression of Smad7 
completely prevented TGF-ßrinduced PG synthesis, indicating that Smad7 but not 
Smad6 is a potent inhibitor of TGF-ßrinduced PG synthesis in chondrocytes.
F ig u re  4 . S m a d 7 inhibits  TGF-ß-INDUCED P G  
SYNTHESIS. H1 CHONDROCYTES WERE 
TRANSFECTED AT M OI 10 WITH AD-LUC, AD- 
SMAD6 OR -7 OR WERE MOCK TRANSFECTED IN
D M E M /F 1 , 0% F C S .  A f t e r  2 h o u r s , m ed iu m  
WAS CHANGED t o  D M E M /F 1 2  + 10% F C S .  
A f t e r  a n o t h e r  5 h o u r s  10 n g /m l  T G F -ß  w a s
ADDED AND CELLS WERE INCUBATED FOR 48 
HOURS, PULSE LABELING WITH 35SO 42- (20 
JlCl/WELL), FOLLOWED BY INCUBATION WITH 
PAPAIN-CARRIER SOLUTION. G lYCOS-
AMINOGLYCANS WERE PRECIPITATED AND 
INCORPORATED 35SO 42- WAS COUNTED USING A 
LIQUID SCINTILLATION COUNTER. FROM THE PAIRED 
RESULTS FROM 35SO 42- INCORPORATION AND 
PROLIFERATION THE 35SO 42- INC. PER CELL WAS 
CALCULATED. TRIPLICATES WERE AVERAGED AND 
DIFFERENCES WERE ANALYZED VIA A N O V A .
d i s c u s s i o n
OA is a joint disease with as major characteristic the destruction of articular cartilage. 
OA is regarded as a chondrocyte disease. An important anabolic factor acting on 
chondrocytes is TGF-ß. Recently, Smad6 and -7 have been described as novel 
intracellular regulators of TGF-ß activity. However, the regulatory effect of these I- 
Smads on TGF-ß-induced responses in chondrocytes is unknown. Here, we 
investigated if adenoviral overexpression of Smad6 or Smad7 results in inhibition of 
several TGF-ß1-mediated responses in chondrocytes. Our results show that Smad6 
only weakly inhibited TGF-ßrinduced cell proliferation, whereas Smad7 totally 
blocked TGF-ßrinduced chondrocyte proliferation and PG synthesis in chondrocytes.
Although Smad6 and -7 are described as negative regulators of TGF-ß activity, 
published results indicate that TGF-ß-induced biologic responses are not only 
differentially regulated by I-Smads but are also cell type specific 30'32-36'42. The 
regulation of TGF-ß activity in chondrocytes by I-Smads has never been studied. 
Therefore, we set out to investigate if TGF-ßi-induced responses such as 
chondrocyte proliferation and chondrocyte PG synthesis could be regulated by Smad6 
and/or Smad7.
First, we investigated the efficiency of Smad6 and -7 overexpression in inhibiting 
TGF-ßi responses in a MLEC bioassay, based on the PAI-1 promoter driven 
production of luciferase. Smad7 showed to be very potent in inhibiting TGF-ß1- 
induced activation of the PAI-1 promoter. Already at low MOI TGF-ß1 activity could
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be almost completely inhibited by Smad7. Also Smad6 overexpression had an 
inhibitory effect on TGF-ßi activity, however, the observed inhibitory effect was only 
partial. These results show that Smad7 is a very potent antagonist of TGF-ß1, 
whereas Smad6 is a partial or weak inhibitor of TGF-ß1 activation in MLEC.
We proceeded to use Smad6 and Smad7 overexpression to study regulation of TGF-ß 
signaling in chondrocytes. First, we determined if adenoviral transfection resulted in 
overexpression of I-Smad mRNA and protein levels. Our results show that mRNA 
levels are indeed strongly upregulated after transfection. Moreover, this mRNA 
overexpression resulted in pronounced overexpression of both I-Smad proteins 
throughout the chondrocyte. It has been reported that I-Smads are predominantly 
localized in the nucleus in the absence of TGF-ß, whereas upon receptor activation I- 
Smads translocate to the cytoplasm 30. On the other hand, also perinuclear and 
cytoplasmic staining for I-Smads have been described 42. Our results indicate that 
Smad6 as well as Smad7 were localized throughout the cytoplasm and were only 
absent from certain cytoplasmic vesicles. Nuclear staining for Smad6 and Smad7 was 
also observed, although certain nuclear regions, probably representing nucleoli, were 
not or only weakly stained. Although we detected endogenous I-Smad mRNA levels, 
only very light staining for endogenous I-Smads could be visualized. Since the used 
Ab's crossreact with murine Smad6 and Smad7 the endogenous protein levels for 
Smad6 and -7 are probably low in H1 chondrocytes but protein levels are very high 
after adenoviral transfection.
It has been well described that chondrocytes respond to TGF-ß stimulation by 
increasing proliferation and PG synthesis. It is unknown however, if these biological 
TGF-ß effects can be regulated by Smad6 or -7. To better understand TGF-ß 
regulation in chondrocytes we made use of adenoviral overexpression of Smad6 and 
-7 and studied if Smad6 and -7 are capable of inhibiting different TGF-ß1 -mediated 
responses. As our results show, Smad7 not only completely blocked TGF-ßrinduced 
chondrocyte proliferation but also totally inhibited TGF-ßrinduced PG synthesis (35S- 
sulfate incorporation + aggrecan mRNA levels). Moreover, TGF-ßrinduced PAI-1 
expression could be totally blocked by Smad7 overexpression.
Regulatory activity of Smad6 showed to be dependent on the TGF-ß response 
studied. Whereas TGF-ßrinduced chondrocyte proliferation could be partially 
inhibited by Smad6, we observed no inhibition at all on TGF-ß1-mediated PG 
synthesis on mRNA or protein level. Also the upregulation of PAI-1 mRNA by TGF-ß1 
could not be antagonized by Smad6. Since both the mRNA -  and protein levels of 
Smad6 and -7 after adenoviral overexpression are comparable, the observed 
differences in TGF-ß1 blockage between Smad6 and -7 are most likely not due to a 
difference in amount of the different I-Smads. In fact, the small differences found on 
mRNA and protein levels could easily be explained by differences in primer - and 
antibody affinities.
Our results demonstrate that Smad6 is a poor inhibitor of TGF-ß1 activity in 
chondrocytes. Since TGF-ß can induce the expression of BMPs, it is tempting to 
speculate that the effects observed for Smad6 are due to inhibition of endogenous 
BMP rather than inhibition of exogenous TGF-ß activity. This would imply that 
endogenous BMPs do not contribute to stimulation of PG synthesis in H1
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chondrocytes. Alternatively, since Smad6 had a significant effect on proliferation, 
endogenous BMPs may play a role in chondrocyte cell growth. On the other hand, 
Ota et al have recently shown that TGF-ß can signal via different type I receptors 
depending on the cell type studied 43. In endothelial cells TGF-ß could bind to ALK-1, 
a type I receptor that normally transduces signals via the BMP-activated 
Smad1/Smad5. This ALK-1-mediated transcriptional regulation induced by TGF-ß 
resulted in completely different cell activation compared to signal transduction 
mediated by the common TGF-ß receptor ALK-5. Possibly, in chondrocytes TGF-ß 
signaling is also mediated by different type I receptors leading to activation of 
different sets of R-Smads that in turn are differentially regulated by I-Smads. So, 
regulation of proliferation might be mediated by both ALK-1 and -5, whereas PG 
synthesis is controlled by ALK-5 only.
In conclusion, our results show that Smad7 is a potent antagonist of various TGF-ß 
responses in chondrocytes. Smad6 was able to antagonize TGF-ß activity in some but 
not in all responses studied. Our results suggest that distinct TGF-ß responses in 
chondrocytes are differentially regulated by I-Smads.
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CHAPTER 7
ABSTRACT
O b j e c t iv e . O s te o a r th r it is  (O A ) is  a  jo in t  disease
CHARACTERIZED BY OSTEOPHYTE DEVELOPMENT, FIBROSIS AND 
ARTICULAR CARTILAGE DAMAGE. EXOGENOUS ADDITION OF
T ran sform in g  G row th  FACTOR-ßs (T G F-ß s) and  Bo n e  
MORPHOGENETIC PROTEINS (BM PS) SUGGEST A ROLE FOR THESE 
GROWTH FACTORS IN THE PATHOGENESIS OF OA. IN THIS STUDY 
WE AIMED TO ELUCIDATE THE ROLE OF ENDOGENOUS T G F -ß  AND 
BMP DURING EXPERIMENTAL OA.
Ma t e r ia l s  &  Me t h o d s . W e u tilize d  ad en o v ira l
OVEREXPRESSION OF T G F -ß  AND BMP ANTAGONISTS TO BLOCK 
GROWTH FACTOR SIGNALING. W E USED AN ADENOVIRUS 
EXPRESSING A SECRETED, PAN-SPECIFIC T G F -ß  ANTAGONIST 
CALLED MLAP1. I n a d d it io n , w e  u sed  in tr a c ellu la r  
INHIBITORY S mAD6 AS A BMP ANTAGONIST AND S mAD7 AS A 
TG F-ß /B M P in h ib it o r . I n jectio n  o f  papain in to  m urin e kn ee
JOINTS WAS USED AS AN O A MODEL, WHICH RESULTED IN THE 
DEVELOPMENT OF OSTEOPHYTES, SYNOVIAL THICKENING AND 
ARTICULAR CARTILAGE PROTEOGLYCAN (PG ) LOSS.
R e s u l t s . In t r a - a r t ic u la r  ( i.a .)  papain in jectio n  caused
INCREASED PROTEIN EXPRESSION OF SEVERAL T G F-ß  AND BMP 
ISOFORMS IN SYNOVIUM AND CARTILAGE. ADENOVIRAL 
TRANSFECTION OF THE JOINT RESULTED IN STRONG EXPRESSION OF 
THE TRANSGENES IN THE SYNOVIAL LINING. OVEREXPRESSION OF
mLAP1, S mad6 and  - 7  a ll  led  t o  a  sig n ific a n t  r ed u ctio n  in
OSTEOPHYTE FORMATION COMPARED TO CONTROLS. S mAD6 AND -  
7 OVEREXPRESSION ALSO SIGNIFICANTLY DECREASED SYNOVIAL 
THICKENING. FURTHERMORE, THE SECRETED T G F -ß  INHIBITOR
MLAP1 in c r ea sed  a r t ic u la r  c a r t ila g e  PG l o s s .
C o n c l u s io n . O u r  re s u lt s  point to w a rd s  a  p ivo ta l ro le
FOR ENDOGENOUS T G F -ß  IN THE DEVELOPMENT OF OSTEOPHYTES 
AND SYNOVIAL THICKENING, IMPLYING ENDOGENOUS T G F-ß  IN THE 
PATHOGENESIS OF OA. IN CONTRAST, ENDOGENOUS T G F-ß  
PREVENTS CARTILAGE DAMAGE, SIGNIFYING THE PROTECTIVE ROLE 
FOR T G F -ß  ON ARTICULAR CARTILAGE. MOREOVER, IN THIS STUDY 
WE IDENTIFIED FOR THE FIRST TIME THAT ENDOGENOUS BMPS ARE 
INVOLVED IN OSTEOPHYTE FORMATION AND SYNOVIAL THICKENING 
DURING EXPERIMENTAL DEGENERATIVE JOINT DISEASE.
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in t r o d u c t io n
OA is in general a joint disease of unknown origin with a very high prevalence in the 
adult population. Major characteristics of OA are the formation of new bone tissue on 
the joint edges (osteophytes), fibrosis of the synovial lining and PG depletion of the 
articular cartilage. Excessive growth factor levels have been implicated in the 
pathogenesis of OA 1-3. In this study we investigated the function of endogenous 
TGF-ß and BMPs released during experimental OA.
TGF-ßs and BMPs all belong to the TGF-ß superfamily. Both TGF-ßs and BMPs play 
important roles in embryonal development, cell growth and differentiation and 
regulation of matrix synthesis. For the subfamily of BMPs more than 10 proteins have 
been reported, originally described as factors that can induce cartilage and bone 
formation in ectopic skeletal sites 4. So far, three highly homologous mammalian 
isoforms have been described for TGF-ß: TGF-ß1, -ß2 and -ß3. When produced, all 
TGF-ß isoforms are secreted as a latent pro-peptide. For TGF-ß to be biologically 
active the pro-portion, also called Latency Associated Peptide (LAP), has to be 
released 5.
Excessive TGF-ß and BMP levels have shown to be involved in OA pathogenesis. We 
have previously shown that multiple i.a. injections of TGF-ß or BMP-2 induced 
considerable osteophyte formation in the murine knee joint 6-8. Furthermore, i.a. 
injection of these growth factors proteins not only identified TGF-ß as a major 
fibrogenetic agent but we also observed BMP-2-induced fibrosis of the synovium 6. 
Also cartilage changes resembling OA are induced after high dose exposure of 
articular cartilage to TGF-ß 7'9.
On the other hand, TGF-ß and BMPs are the most potent anabolic factors to act on 
chondrocytes 6,1°. A single i.a. injection of TGF-ß resulted in long-lasting enhanced 
articular cartilage PG synthesis and content, while BMP-2 injection caused a very 
rapid and strong stimulation of PG synthesis in articular cartilage 6. Additionally, 
abrogation of the TGF-ß signaling pathway in transgenic mice resulted in OA-changes 
of the cartilage 11,12. These results are strongly in favor of a protective and regulatory 
function of TGF-ß and BMP on articular cartilage. Therefore, these growth factors are 
of high therapeutic relevance and application of TGF-ß and BMP may aid cartilage 
repair.
Despite the clear link between growth factors and OA, little is known about the role of 
endogenously released TGF-ß and BMPs during OA. Therefore, we set out to 
determine the function of endogenous TGF-ß and BMP during experimental OA by 
using specific inhibitors.
Since the dissociation of LAP from TGF-ß is a reversible action and because LAP of one 
TGF-ß isoform can block activity of all three TGF-ß isoforms with an affinity in the low 
nanomolar range, LAP is a very potent TGF-ß inhibitor 13,14. Moreover, since LAP is a 
soluble protein of only 27 kDa it can also penetrate the dense structure of articular 
cartilage and directly affect chondrocytes 15.
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Members of the TGF-ß superfamily signal via two types of serine/threonine receptors 
(types RI and RII). After activation by the type RII, the type RI transmits the signal 
to Receptor-associated Smad proteins (R-Smads); Smad2 and -3 for TGF-ß and 
Smad1, -5 and -8 for BMPs. Phosphorylated R-Smads form a complex with the 
Common (Co)-mediator Smad4. This R-Smad/Co-Smad complex then enters the 
nucleus and regulates the transcription of TGF-ß/BMP responsive genes 16,17.
The Inhibitory (I-) Smads, Smad6 and Smad7, are components of the inhibitory 
feedback regulation of the TGF-ß/BMP signaling pathways. Both Smad6 and -7 act 
by binding to activated type RI, thereby preventing the activation of R-Smads. For 
Smad6 also a competition with Smad4 for binding to Smad1 has been described 18. 
Furthermore, Smad6 and -7 may enhance the degradation of TGF-ß-R complexes 
19,20. I-Smads are strongly induced by the growth factors they ultimately inhibit, 
suggesting a role in negative feedback regulation. BMP induces the expression of 
Smad6 18,21,22, whereas TGF-ß stimulates Smad7 expression 23-25. Smad6 
preferentially inhibits BMP signaling 18,21,22, although in vitro some TGF-ß inhibitory 
effect has been shown 26-28. Smad7 has shown to be a very potent TGF-ß 23-25 and 
BMP antagonist 26,29.
Our results show for the first time that not only TGF-ßs, but also BMPs are key 
factors involved in osteophyte development and synovial thickening during papain- 
induced OA-like changes. Moreover, the scavenging mLAP1 increased cartilage PG 
loss demonstrating that endogenous TGF-ß protects against cartilage damage. We 
conclude that in addition to TGF-ß also BMPs, released during experimental 
degenerative joint disease, cause osteophyte formation and synovial thickening of 
the joint.
M A TER IA L & M ETH O D S
A d en o vira l Vec t o r s
Recombinant adenoviruses expressing full length Smad6 (Ad-Smad6) and Smad7 
(Ad-Smad7) were generated as described elsewhere 30 and were generously 
provided by Dr. P. ten Dijke.
We generated an adenovirus expressing the murine form of LAP1 (Ad-mLAP1) as 
follows. A mouse cDNA library was used as a template for PCR. PCR reaction was 
performed using Pwo proofreading DNA polymerase (Roche, Almere, The 
Netherlands) and the following oligonucleotides:
5'-GTCGACGCCACCATGCCGCCCTCGGGGCTGCGGCTA-3' and 
5'-TCTAGATCAGTGCCGTGAGCTGTGCAGGTGCTGGGC-3'.
The PCR product corresponds to the signal sequence and the entire LAP portion of 
the murine TGF-ß1 gene. The blunt-ended PCR product was cloned in the PCR-Script 
plasmid according to the manufacturers protocol (Stratagene, Amsterdam, The 
Netherlands). Via restriction sites for Sali and XbaI, introduced via the 
oligonucleotides, mLAP1 was cloned in the pShuttle-CMV plasmid. The sequence of 
the open reading frame was confirmed via automated sequencing. The mLAP1- 
adenovirus was further generated as described elsewhere 31.
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As controls a recombinant adenovirus expressing Luciferase (Ad-Luc) or an 
adenovirus lacking an expression cassette (Ad-DL70-3) were used. Adenoviruses 
were amplified and purified as described previously 32. All adenoviruses used had a 
comparable concentration of pfu (range = 1.0 - 2.1 -1010/ml); moreover, the 
concentration of virus particles (virions) was also similar for the different viruses 
used (range = 0.9 -  1.5 -1012/ml).
Ce ll  C u ltu r e
Mink lung epithelial cells (MLEC) were cultured in monolayer at 37°C and 5% CO2 in 
DMEM/glutamax: 4500 mg/l glucose, pyridoxine and sodium pyrovate (Life 
Technologies BV, Breda, The Netherlands) supplemented with 10% fetal calf serum 
(FCS) (iCN Biomedicals BV, Zoetermeer, The Netherlands), penicillin (500 
U/ml)/streptomycin sulfate (500 |ig/ml)/geneticin sulfate (250 |ig/ml) (Life 
Technologies BV). Cells were passaged for no more than 15 times.
M L E C a s s a y  AND M LEC  tra n sfectio n
The bioactivity of secreted mLAP1 and the intracellularly expressed Smad6 and 
Smad7 in inhibiting TGF-ß activity was tested using the MLEC TGF-ß bioassay. This 
assay is based on the induction of plasminogen activator inhibitor-1 (PAI-1) promoter 
by TGF-ß, resulting in a dose dependent increase in luciferase activity 33. First we 
compared the efficacy of mLAP1 TGF-ß inhibition with Smad6 and Smad7. MLEC 
were transfected with Ad-mLAP1, Ad-Smad6, Ad-Smad7 or Ad-DL70-3 with a MOi of 
1, 10 or 100 in DMEM without FCS for 2 hours at 37°C, 5% CO2. Mock-transfected 
cells were used as a control. After 2 hours, transfection medium was replaced with 
culture medium. Next, after 5 hours TGF-ß1 or TGF-ß3 (R&D Systems, Europe Ltd, 
Abingdon, UK) was added (final concentration of 1.56 ng/ml) and cells were 
incubated overnight (o/n). Luciferase activity was measured using Bright-Glo 
luciferase assay reagent (Promega, Leiden, The Netherlands) and a Fluorstar Galaxy 
(BMG LabTechnologies GmbH, Offenburg, Germany). The effect of adenoviral 
transfection on the TGF-ß-induced luciferase activity was calculated from TGF-ß 
standards added to mock transfected cells. Each standard or sample was tested in 
quadruplicate. Results were analyzed via ANOVA.
To study if mLAP1 was indeed secreted in the culture medium we performed transfer 
experiments. MLEC were transfected with Ad-mLAP1 (MOi 0.1, 0.01 and 0.001) or as 
a control with the non-secreted TGF-ß inhibitor Ad-Smad7 (MOi 0.1) as described 
above. The next day, conditioned medium was transferred to fresh untransfected 
MLEC and after 4 hours TGF-ß1, -ß2 or -ß3 was added in a final concentration of 
1.56 ng/ml and cells were incubated o/n. Subsequently, luciferase activity was 
measured as described above.
To confirm that the transferred TGF-ß neutralizing activity was indeed mLAP1 we 
performed blocking studies. MLEC were mock transfected or were transfected with 
Ad-Smad7 or -mLAP1 (MOi 0.1) and transfer was performed as described above 
with the addition that anti-LAP1 (R&D Systems) or control IgG's were added in a 
final concentration of 1 |ig/ml. The next day luciferase activity was measured.
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A n im a ls
Male C57Bl/6 mice aged 12 weeks were used. Animals were kept in filter top cages 
with a woodchip bedding under standard pathogen free conditions. They were fed a 
standard diet and tap water adlibitum.
Pa p a in  in d u c ed  OA -l ik e  ch a n g es
The effect of adenoviral overexpression of Smad6, -7 and mLAP1 was studied in the 
papain model of degenerative joint disease, which induces OA characteristics, such 
as osteophyte formation, fibrosis and PG depletion of articular cartilage 34. The 
papain model was initiated by injection of 1 U papain solution (Sigma Chemicals Co, 
St. Louis, MO, USA) into the right knee joints of mice, the left knee joints served as 
internal controls.
I m m u n o h isto c h em istr y
The expression of BMP-2, -4 and -6 was studied in naive joints and in papain-injected 
joints. Papain was i.a. injected and 3 days later knee joints were isolated.
Adenoviral overexpression of Smad6, -7 and mLAP1 was determined after i.a. 
injection of 1-107 pfu of Ad-Smad6, -7, Ad-mLAP1 or Ad-Luc as a control. Knee joints 
were isolated 1, 3 or 7 days later.
Knee joints were decalcified for 14 days in EDTA/PVP and subsequently stored at - 
20°C as previously described 35. Next, cryosections of total knee joints were 
prepared. Before use, sections were airdried for 30 min and freshly prepared 
paraformaldehyde (4%, 5 min) was used to fixate the sections. 
immunohistochemistry was performed on cryosections with specific Ab against the 
different TGF-ß or BMP isoforms (R&D Systems) or Smad6 (Zymed Laboratories inc, 
San Francisco, USA), Smad7 (Santa Cruz Biotechnology inc, Santa Cruz, USA) and 
human LAP1 (R&D Systems). The human LAP1-Ab has shown to cross-react with 
mouse LAP1. As a negative control, the primary Ab was replaced with chicken IgY's 
or goat IgG's. Biotin labeled secondary Ab were used (Vector Laboratories. inc, 
Burlingham, CA), followed by a biotin-streptavidine detection system (Vector 
Laboratories). Bound complexes were visualized via reaction with 
3',3'diaminobenzidine (Sigma Chemicals Co) and H2O2. Sections were briefly 
counterstained with haematoxylin and mounted with permount.
IMAGEANALYSIS OF HISTOLOGY
Total knee joint sections were stained with Safranin-O (Saf-O) and fast green. The 
surface area of the osteophytes and the PG content of the articular cartilage was 
measured by a blinded observer as described previously 36. Briefly, the microscopic 
image of the osteophyte or articular cartilage was captured on a computer screen 
using a digital camera. The size of the osteophytes was determined by manual 
selection of the surface area of the osteophyte in 5 semi-serial sections per knee. 
Measurements of 8 knees per group were averaged. The PG content of articular 
cartilage was measured by selection of non-calcified layer of both the lateral- and 
medial sides of the tibia and femoral condyles and determining the amount of blue 
light passing through the tissue section. Three sections per knee were measured and 
values were averaged.
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Synovial thickness was also measured by a blinded observer by determining the 
width of the medial side of the joint from bone edge to joint capsule in 5 semi-serial 
sections per knee joint and the average was taken. The width of the joint space itself 
was subtracted from the total width. Measurements of 8 knees per group were 
averaged. in all measurements the Ad-Luciferase group was stated as being 100%. 
Results were statistically analyzed using ANOVA.
R E S U L T S
BM P-2, - 4 an d  - 6  ex p r es s io n  is in c r e a s e d  d u r in g  ex p er im en ta l  OA
Papain injection caused the formation of osteophytes on the joint edges and 
thickening of the synovium. Furthermore, injection of papain resulted in PG depletion 
of the non-calcified layer of articular cartilage. We have previously shown that papain 
injection caused an upregulation of TGF-ß1 and -ß3 in articular cartilage and 
periosteum, whereas we could not identify expression of TGF-ß2 36. Here, we 
investigated expression of BMP-2, -4 and -6 in articular cartilage and synovium in 
naïve and OA joints.
The number of chondrocytes expressing BMP-2 and -4 in cartilage after papain 
injection was comparable to naive joints (figure 1, compare A+C with E, see Ch. 9). 
However, chondrocytes expressing BMP-2 or -4 during OA showed more abundant 
and intense staining than chondrocytes in naive knee joints. in contrast to the 
expression in cartilage, the expression of both BMP-2 and -4 in synovium during 
experimental OA was dramatically increased compared to expression in naive 
synovium (figure 1, compare B+D with F, see Ch. 9).
We observed no effect on BMP-6 expression in cartilage after papain injection. 
Strongest BMP-6 expression was localized to hypertrophic chondrocytes in the 
calcified cartilage in both naïve and OA joints (figure 1 G+i, see Ch. 9). Contrary to 
BMP-2 and -4, BMP-6 expression was almost completely absent in synovium from OA 
and naive joints (figure 1 H+J, see Ch. 9).
Ch a ra cteriza  tio n  o f  t h e in h ib it o r s
The TGF-ß-blocking capacity of Ad-mLAP1 was determined and compared to Smad6 
and Smad7 activities in the MLEC TGF-ß bioassay. As shown in figure 2A, both 
Smad7 and mLAP1 are very efficient inhibitors of TGF-ß1 in this bioassay, since 
already at MOi = 1 approximately 75% of the TGF-ß activity is blocked. At higher 
MOi, TGF-ß activity is totally prevented. The negative values probably represent the 
inhibition of endogenously produced TGF-ß by MLEC. in contrast, Smad6 only blocks 
TGF-ß activity at very high MOi and is therefore not as potent a TGF-ß inhibitor as 
Smad7 and mLAP1.
Since several TGF-ß isoforms are upregulated during experimental OA, we tested the 
neutralizing capacity of mLAP1 on TGF-ß1, -ß2 and -ß3 isoforms. To test this, 
conditioned medium from transfected MLEC was transferred to fresh untransfected 
MLEC and TGF-ß was added. As a control, conditioned medium from cells transfected 
with the intracellular inhibitor Smad7 was also transferred. Figure 2B shows that 
transferred mLAP1 is able to block all three TGF-ß isoforms when a MOi of 1 is used.
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F ig u re  2A. C h a r a c t er iz a t io n  o f  a d e n o v ir a l l y  
p r o d u c e d  mL A P I .  mL A P I in h ibits T G F-ß  a c t iv it y  in 
M L E C . M L E C  w e r e  t r a n s f e c t e d  w ith  A d-D L70-3, - 
S mad6, -7 o r  - mL A P I a t  MOI 1, 10 and  lo o  in DM EM  
f o r  2 h o u r s . Ne x t , m edium  w a s  r e p l a c e d  w ith  
DM EM /10%  F C S . A f t e r  5 h o u r s  1.56 n g/ml T G F-ß  w a s
ADDED AND 16 HOURS LATER LUCIFERASE ACTIVITY WAS
m e a s u r e d . T h e  e f f e c t  o f  a d e n o v ir a l  t r a n s f e c t io n  w a s  
c a l c u l a t e d  fr o m  T G F-ß  STANDARDS a d d ed  to  m o c k  
t r a n s f e c t e d  c e l l s . T h e  r e l a t iv e  p e r c e n t a g e  o f
STIMULATION OF THE PAI-1 PROMOTER IS SHOWN. STANDARDS 
AND SAMPLES WERE TESTED IN QUADRUPLICATE AND RESULTS 
WERE AVERAGED AND ANALYZED VIA A N O V A .
When using a lower MOI the results seem to indicate that mLAP1 most potently blocks 
TGF-ß3, followed by TGF-ß2 and -ß1, which is in accordance with previously described 
binding affinities of human LAP1 for the different TGF-ß isoforms. Moreover, this 
transfer experiment shows that mLAP1 is a secreted factor, since the TGF-ß 
neutralizing activity of mLAP1 can be transferred to fresh cells as opposed to transfer 
of medium of MLEC transfected with intracellular Smad7 .
B) Ad-mLAP1 blocks all TGF-ß isoforms □  TGF-beta1
■  TGF-beta2
■  TGF-beta3
F ig u re  2B . C h a r a c t er iz a t io n  o f  a d e n o v ir a l l y  
p r o d u c e d  mLA P 1 . mLAP1 in h ibits  T G F-ß  a c t iv it y  in 
M L E C . mLAP1 b l o c k s  a l l  T G F-ß  is o fo r m s  and  its 
e f f e c t  is t r a n s f e r a b l e . M L E C  w e r e  t r a n s f e c t e d  w ith  
A d- S m ad7 o r  - mLAP1 w ith  an MOI a s  in d ic a t e d . T he
NEXT DAY MEDIUM FROM THESE CELLS WAS TRANSFERRED TO 
FRESH UNTRANSFECTED M L E C  AND T G F-ß  (1.56 NG/ML) 
WAS ADDED AND 16 HOURS LATER LUCIFERASE ACTIVITY WAS 
MEASURED.
mLAPI MOI mLAPI MOI mLAPI MOI 
0.001 0.01 0.1
To proof that the transferred TGF-ß inhibiting substance is really mLAP1, we added a 
neutralizing antibody against LAP1 to the transferred medium. Figure 2C 
demonstrates that conditioned medium transferred from cells transfected with the 
intracellular TGF-ß inhibitor Smad7 (or mock transfected cells) does not contain a 
TGF-ß antagonist, since all exogenously added TGF-ß is recovered. On the other 
hand, transfer of conditioned medium from cells transfected with mLAP1 contains 
TGF-ß neutralizing activity that can be completely blocked by anti-mLAP1 Ab but not 
by the IgG control. This experiment shows that adenovirally-produced mLAP1 is the 
TGF-ß inhibitor that is transferred.
F ig u re  2C . C h a r a c t er iz a t io n  o f  a d e n o v ir a l l y  
p r o d u c e d  mLA P 1 . a n ti-LA P  1 A b b l o c k s  mLAP1 a c t iv it y . 
M L E C  w e r e  m o c k  t r a n s f e c t e d  o r  t r a n s f e c t e d  w ith  A d- 
S mad7 o r  - mLAP1 w ith  MOI 0.1. T h e  n e x t  d a y  m edium
FROM THESE CELLS WAS TRANSFERRED TO FRESH
u n t r a n s f e c t e d  M L E C  and  T G F-ß  (1.56 ng/m l) and  a- 
LAP1 A b (1 jig /m l) o r  c o n t r o l  Ig G  w a s  a d d e d . A f t e r  o/n 
in cu batio n  l u c if e r a s e  a c t iv it y  w a s  m e a s u r e d .
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Taken together, these data indicate that our adenovirally-produced mLAPI is a very 
potent, soluble and pan-specific TGF-ß inhibitor. Smad7 is also a potent TGF-ß 
antagonist, whereas Smad6 is only a weak inhibitor of TGF-ß in the MLEC assay.
Ex p r es s io n  o f  t r a n sg en esin  vivo
We investigated the transfection efficiency of the adenoviruses in vivo. Therefore, 
adenoviruses were i.a. injected and transgene expression on day 1, 3 and 7 was 
studied. As figure 3 shows, transfection with Ad-Smad6 and -7 and subsequent 
staining with anti-Smad6 or anti-Smad7 Ab, respectively, showed considerable 
overexpression of Smad6 and -7 in the synovial lining, near the menisci and around 
the anterior cruciate ligament (ACL) (figure 3A and B and results not shown). As a 
control, transfection with Ad-Smad7 and subsequent staining with anti-Smad6 Ab, or 
vise versa, transfection with Ad-Smad6 and staining with anti-Smad7 Ab did not 
result in any staining in the lining, demonstrating the specificity of the antibodies 
used (figure 3C and D, respectively). Besides the I-Smad overexpression in the 
lining, we also observed strong endogenous staining of both I-Smads in hypertrophic 
chondrocytes present in articular cartilage and the growth plates (results not shown).
F ig u re  3. O v e r e x p r e s s io n  o f  
t r a n s g e n e s  in t h e  sy n o v ia l  
lin in g . A d e n o v ir u s e s  e x p r e s s ­
ing  L u c if e r a s e , S mad6, -7 o r  
mLAP1 w e r e  in je c t e d  i.a . at  
1 1 0 7 p f u . S u b s e q u e n t l y , k n e e  
jo in t s  w e r e  is o l a t e d , 
d e c a l c if ie d  and  c r y o s e c t io n s
WERE PREPARED. IMMUNOHISTO­
CHEMISTRY o f  S mad6 a f t e r  A d- 
S mad6 A ) o r  A d- S mad7 C )  
in jec t io n . Im m u n o h isto ch em ­
is t r y  o f  S mad7 a f t e r  A d- S mad7
B ) o r  A d- S mad6 D) in jec t io n . 
Im m u n o h isto c h em ist r y  o f  LAP1  
a f t e r  in jec t io n  o f  A d-mLAP1 E )  
o r  A d-L u c  F). O r ig in a l  
m a g n ifica -tio n  250  x .
Transfection of the joint with our Ad-mLAP1 virus also resulted in abundant 
overexpression of mLAPI in the synovium, near the menisci and around the anterior 
cruciate ligament (ACL) (figure 3E and results not shown). In control transfected 
joints using Ad-Luciferase no expression of mLAPI was observed (figure 3F).
For all transgenes we observed a relative rapid decrease of staining intensity on day 
3 (decrease ~70%) and hardly any staining was found on day 7 (results not shown).
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Our results show that by using adenoviruses we are able to reach high transgene 
expression that lasts at least 3 days as detected by immunohistochemistry.
Ost eo p h y tes
We sought to determine the role of endogenous TGF-ß and BMP on osteophyte 
formation during experimental OA by adenoviral overexpression of growth factor 
inhibitors in the synovial lining. I.a. injection of papain induced osteophyte formation 
on three specific locations. Osteophytes formed on the femur between the articular 
cartilage opposing the patella and where the growth plate meets the joint space 
(both lateral and medial) and where the other end of the semi-circular growth plate 
meets the joint space (medial) close to were the medial collateral ligament is 
attached. Osteophyte formation was strongly diminished after transfection with 
mLAP1, Ad-Smad6 and -7 compared to Ad-Luc (figure 4A).
F ig u re  4A. R e d u c e d  o s t e o p h y t e  fo rm a tio n  a f t e r  a d e n o v ir a l  t r a n s f e c t io n  w ith  A) A d- L u c , B) - mL A P I ,  C) - 
S mad6 o r  D) - S mad7 d u r in g  pa pa in- in d u c ed  O A -l ik e  c h a n g e s . A d e n o v ir u s e s  w e r e  ia . In j e c t e d  1 d a y  p r io r  t o
INDUCTION OF O A . AFTER 7 DAYS WHOLE KNEE JOINTS WERE ISOLATED AND SUBSEQUENTLY FRONTAL SECTIONS OF WHOLE 
KNEE JOINTS WERE MADE AND STAINED WITH SAF-O . OSTEOPHYTES ARE MARKED BY WHITE ARROWS. C= CARTILAGE, F = 
CORTICAL BONE OF FEMUR, GD = GROWTH DISK AND JS IS JOINT SPACE. ORIGINAL MAGNIFICATION 100 X.
Quantification of osteophyte size in the three locations is shown in figure 4B. 
Transfection with mLAP1 reduced osteophyte size in all three locations. This effect 
was significant on the medial side of the joint with a reduction of 40% and 60% in 
the two locations. On the lateral femur, mLAP1 reduced osteophyte size by 20% but 
this effect did not reach statistical significance. Transfection with Ad-Smad6 and -7 
significantly reduced osteophyte size in all locations studied with a maximum 
reduction of ~50% and ~60% for Smad6 and Smad7, respectively, as compared to 
Ad-Luc treatment. Overall, osteophyte size was reduced by about 50% by the 
intracellular inhibitors Smad6 and -7. These results strongly point to TGF-ß and BMPs 
as major contributors to the formation of osteophytes.
S yn o vial th ic k n ess
Adenoviral overexpression of TGF-ß/BMP inhibitors was used to study the effect of 
TGF-ß/BMP inhibition on synovial thickening. Inhibition of endogenous BMPs by 
Smad6 and TGF-ß/BMPs by Smad-7 resulted in a significant decrease in synovial
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thickness of 42% and 50%, respectively as compared to the Ad-Luc group (figure 
5A+B). We also observed a 25% reduction in synovial thickness after mLAP1 
treatment compared to Ad-Luc, however this effect did not reach statistical 
significance (p=0.075). These data point to TGF-ß and BMPs as important mediators 
involved in synovial thickening during experimental OA.
F ig u re  4 B . Q u a n tifica tio n  o f  o s t e o p h y t e  
s iz e  a f t e r  t r a n s f e c t io n  w ith  A d-L u c , - 
mL A P I ,  - S mad6 o r  - S mad7. T h e  s u r f a c e  
a r e a  o f  o s t e o p h y t e s  w a s  d e t e r m in e d . F rom  
ea c h  m ice  (n=8 p e r  t r e a t m e n t ), f iv e  s em i­
s e r ia l  t is s u e  s e c t io n s  fr o m  t h e  k n e e  jo in t
WERE MEASURED AND THE AVERAGE WAS TAKEN.
T h e  8 v a l u e s  o b ta in ed  p e r  t r ea t m e n t  w e r e  
a v e r a g e d  and  a n a ly z ed  via  A N O V A  (* = 
p <0.05).
Pro teo g lyca n  co n ten t
Transfection of the synovial lining with the secreted inhibitor Ad-mLAP1 resulted in 
significantly increased PG loss from the articular cartilage in the four cartilage 
surfaces studied compared to Ad-Luc treatment (figure 6A+B). The PG content in the 
lateral femur was reduced in the order of 16%, whereas the medial tibia was most 
affected (25%). The cartilage surfaces on medial side contained approximately 20% 
less PGs than the Ad-Luc control group after Ad-mLAP1 transfection. So, endogenous 
TGF-ß protects cartilage from PG loss during experimental OA. Overexpression of 
Smad6 and -7 is restricted to the lining and did not affect the PG content of the 
articular cartilage compared to controls (figure 6B).
F ig u re  5A. R e d u c e d  sy n o v ia l
THICKENING AFTER AD-MLAP1
t r a n s f e c t io n  d u r in g  pa pa in - in d u ced  OA- 
lik e  c h a n g e s . A d e n o v ir u s e s  w e r e  i.a .
INJECTED 1 DAY PRIOR TO INDUCTION OF OA.
A f t e r  7 d a y s  w h o l e  k n e e  jo in ts  w e r e  
is o l a t e d  and  s u b s e q u e n t l y  fr o n t a l  
s e c t io n s  o f  w h o l e  k n e e  jo in ts  w e r e  
m ade  and  sta in ed  w ith  S a f -O. S yn o viu m  
o f  A d-L u c  A), A d-mLAP1 B), A d- S mad6
C) and  A d- S m ad7 D) t r e a t e d  a n im a l . 
O rig in a l  m a g n ifica tio n  100 x .
We have clearly demonstrated before that injection of TGF-ßs and BMP-2 protein in 
knee joints induces the formation of osteophytes 6,s. Moreover, both growth factors 
induced fibrosis of the synovial lining. Although suggestive, these results give no 
information about the endogenous role for these growth factors during OA. In this 
study we investigated the roles of endogenously produced BMPs and TGF-ß in the 
pathogenesis of papain-induced OA-like changes. We focussed on OA-characteristics 
such as osteophyte formation, synovial thickening and cartilage PG depletion.
d i s c u s s i o n
Osteophyte size
120 -i 
2  100 -
80
9- 60 -
o 40
20 I
□  Ad-Luc □  Ad-mLAP1
□  Ad-Smad6 BAd-Smad7
lateral femur medial femur (1) medial femur (2)
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Adenovirally produced Smad-7 and mLAPI were used to block TGF-ß activity. In 
addition, BMP activity was blocked by adenoviral overexpression of the intracellular 
BMP antagonists Smad6 and Smad-7. With the aid of these antagonists, endogenous 
TGF-ß and BMPs were identified as crucial factors involved in the induction of OA-like 
pathology, such as osteophyte formation and synovial thickening.
Synovial thickness
100 -
60 -
40
F ig u re  5B . Q u a n tifica tio n  o f  sy n o v ia l
THICKENING AFTER TRANSFECTION WITH AD-
L u c , -mLA P 1 , - S mad6 o r  - S mad7. F o r
EACH KNEE JOINT (N=8 PER TREATMENT),
s y n o v ia l  t h ic k n e s s  w a s  d et er m in ed  in 3 
s e m i-s e r ia l  t is s u e  s e c t io n s  and  v a l u e s
WERE AVERAGED. THE 8 VALUES OBTAINED 
PER COMPARTMENT WERE AVERAGED AND
d if f e r e n c e s  a n a ly z e d  via  A N O V A . * = 
p <0.05.
Ad-Luc Ad-mLAP1 Ad-Smad6 Ad-Smad7
Smad7 overexpression strongly reduced osteophyte development and synovial 
thickening, stressing the pivotal role of TGF-ß and/or BMPs in these OA- 
characteristics. The observation that endogenous TGF-ß is a major factor involved in 
osteophyte formation is in line with data showing that blocking of TGF-ß1 and -ß3 
during experimental OA by systemic delivery of the scavenging extracellular part of 
the TGF-RII reduced osteophyte formation 36.
Strikingly, the effect of BMP inhibition by Smad6 is comparable to TGF-ß/BMP 
blocking by Smad7, emphasizing the important role of BMPs during osteophyte 
development and synovial thickening. So, we show for the first time the involvement 
of endogenous BMPs in osteophyte development and the induction/progression of 
synovial fibrosis. Our data provide evidence for a pathogenic role of BMPs towards 
osteophyte development and synovial thickening during papain-induced degenerative 
joint disease.
Osteophytes are thought to be formed via the process of endochondral ossification 
and thus involve chondrogenesis and subsequent ossification. Osteophytes are 
believed to originate from periosteal cells that have the potential to undergo 
chondrogenesis 37. Both TGF-ß and BMPs have shown to be able to induce 
chondrogenesis of periosteal cells 38,39. However, contrary to BMP, TGF-ß induces the 
expression of TGF-ß and BMPs in periosteal cells 39,40. TGF-ß also appears necessary 
to maintain BMP-R mRNA expression 38. Additionally, in our OA models TGF-ß 
expression in cartilage and periosteum precedes BMP expression (own observation). 
Taken together, these findings are suggestive for an initiating role for TGF-ß in 
osteophyte formation. So, TGF-ß does not only induce chondrogenesis by itself but 
TGF-ß may also induce BMPs and BMP-R expression, causing further outgrowth of 
osteophytes. So, TGF-ß acts upstream of BMP, hence, inhibition of BMP by Smad6 or 
inhibition of TGF-ß by Smad7 overexpression has similar effects on the development 
of osteophytes.
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F ig u re  6A. R e d u c e d  c a r t il a g e  
P G  c o n t e n t  a f t e r  A d-mLAP1  
t r a n s f e c t io n  d u rin g  pa pa in - 
in d u c ed  O A -l ik e  c h a n g e s . 
A d e n o v ir u s e s  w e r e  i.a . in je c t e d  1 
d ay  p r io r  t o  in d u ctio n  o f  O a . 
A f t e r  7 d a y s  k n e e  jo in t s  w e r e  
is o l a t e d  and  f r o n t a l  s e c t io n s  o f  
w h o l e  k n e e  jo in t s  w e r e  m ade and  
s t a in ed  w ith  S a f -O. La t e r a l  
tibia/f e m o r a l  c o n d y l e  o f  A d-L u c  A) 
o r  A d-mLAP1 C) t r e a t e d  a n im a ls . 
Med ia l  tib ia/fe m o r a l  c o n d y l e  o f  
A d-L u c  B) o r  A d-mLAP1 D) t r e a t e d  
a n im a ls . O r ig in a l  m a g n . 100 x .
Three different TGF-ß isoforms exist (TGF-ß1, -ß2 and -ß3) and TGF-ß1 and TGF-ß3 
are expressed during experimental OA 36. Consequently, to study the net result of all 
TGF-ß isoforms a pan-specific TGF-ß antagonist is crucial. Therefore, we generated 
the mLAP1 adenovirus. The advantage of secreted mLAP1 over Smad7 lies herein 
that mLAP1 enabled us to block TGF-ß activity in articular cartilage in addition to 
inhibiting TGF-ß effects in synovial lining cells. The results from mLAP1 are in line 
with the Smad7 overexpression data and also identify TGF-ß as a causative factor in 
osteophyte development and synovial fibrosis. The somewhat smaller effect of 
mLAP1 compared to Smad7 is probably because mLAP1 is distributed throughout the 
entire joint instead of the lining only. However, in contrast to Smad7, expression of 
mLAP1 induced a strong increase in cartilage PG loss, showing TGF-ß to be a key 
protective factor for articular cartilage. These data are in line with data showing that 
blocking of TGF-ß1 and -ß3 using a soluble type II receptor also increased significant 
PG loss from articular cartilage during experimental OA 36. So, endogenous TGF-ß is 
a necessary agent to protect articular cartilage from PG loss.
F ig u re  6 B. Q ua n tifica tio n  o f  c a r t il a g e  
P G  c o n t e n t  a f t e r  t r a n s f e c t io n  w ith  A d- 
L u c , -mL A P I , - S mad6 o r  - S mad7. F o r  
ea c h  k n e e  jo in t  (n=8 p e r  t r e a t m e n t ), t h e  
P G  c o n t e n t  o f  t h e  non-c a l c if ie d  
a r t ic u l a r  c a r t il a g e  o f  t h e  l a t e r a l  and  
m ed ia l  tib ia /fe m o r a l  c o n d y l e  w a s  
d e t e r m in e d . L o s s  o f  S a f -O sta in in g  o f  t h e  
a r t ic u l a r  c a r t il a g e  w a s  m e a s u r e d  in 3 
s e m i-s e r ia l  t is s u e  s e c t io n s  and  v a l u e s  
w e r e  a v e r a g e d . T h e  8 v a l u e s  o b ta in ed  
p e r  c o m p a r t m en t  w e r e  a v e r a g e d  and  
d if f e r e n c e s  a n a ly z e d  via  A N O V A . * = 
p <0.05.
TGF-ßs and BMPs are among the most potent inducers of cartilage PG synthesis 
known. We have previously demonstrated that during joint pathology local 
administration of TGF-ß, but not BMPs, results in inhibition of the destructive effect 
of IL-1 on cartilage 41. However, some evidence from in vitro experiments exists 
showing antagonistic activity of BMPs on IL-1 effects 42. Because of these 
characteristics the therapeutic potential for cartilage repair of these growth factors is 
extremely high. This potential is however limited because of the adverse side effects 
endogenous growth factors have, such as osteophyte formation and fibrosis, as we
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show in this study. In order to be therapeutically effective TGF-ß and BMPs need to 
be specifically targeted to the cartilage. Our study suggests that by creating a TGF- 
ß/BMP unresponsive joint lining by Smad6 and/or -7 overexpression, the local 
application of growth factors to stimulate cartilage repair might be feasible.
In conclusion, for the first time we identified endogenous BMPs as strong stimulators 
of osteophyte formation and synovial thickening during degenerative joint disease. 
Moreover, via the use of adenoviral overexpression of TGF-ß inhibitors we identified 
endogenous TGF-ß as a major inducer of osteophyte development and synovial 
thickening, whereas TGF-ß has a positive role on articular cartilage maintenance 
during experimentally induced cartilage damage.
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c h a p te r  8
SU M M A R Y
Osteoarthritis (OA) is the most common rheumatologic disorder reported in man and 
has as main characteristics the destruction of articular cartilage, fibrosis of the 
synovial lining and the formation of osteophytes. Growth factors such as 
Transforming Growth Factor-ß (TGF-ß) and Bone Morphogenetic Proteins (BMPs) 
have been implied in the OA process.
OA is in essence a slowly progressive disease and strongly correlated with increased 
age. Therefore, we investigated in c h a p te r  2 if young and old mice behave 
differently in their responses to the important catabolic cytokine Interleukin-1 (IL-1), 
TGF-ß or the combination TGF-ß/IL-1. We showed that although young and old mice 
demonstrate similar responses to TGF-ß and IL-1 on proteoglycan (PG) synthesis and 
nitric oxide (NO) production separately, old mice are no longer able to antagonize IL- 
1 effects by TGF-ß on these parameters the way young animals can. This would 
subsequently result in a shift in the anabolic/catabolic balance to the catabolic side in 
old mice, which could explain both the slowly progressive character of OA and the 
high prevalence of OA in the elderly population.
In c h a p te r  3 we further pursued the interesting finding that IL-1 counteraction by 
TGF-ß is lost in old animals. We hypothesized that this phenomenon was the result of 
altered TGF-ß signaling in such a manner that TGF-ß signaling in old animals was 
less active than in young animals. Therefore, we looked at expression levels of 
various TGF-ß signaling mediators in young and old mice and also studied the effect 
of IL-1 exposure on these mediators. On the one hand, the articular cartilage was 
studied for expression of activating TGF-ß mediators such as TGF-ß receptors, 
receptor-associated and common-mediator Smads by immunohistochemistry. 
Alternatively, the expression of inhibitory Smads was also studied. Surprisingly, in 
stead of a less active TGF-ß signaling pathway in old mice, our results indicate that 
old mice expressed significantly more receptors and less inhibitory Smads. On the 
other hand, exposure to IL-1 did induce a 50% drop in Smad4 expression in old mice 
only. Although this effect on Smad4 expression was not significant, this is probably 
the result of a rather small group size caused by the availability of a limited number 
of old mice. Taken together, the loss of TGF-ß counteraction of IL-1 effects in old 
animals cannot be explained by a change in the expression of TGF-ß signaling 
mediators. In addition to changed TGF-ß signaling, old mice could of course also 
have altered IL-1 signaling. Indeed IL-1 has shown to induce a more potent and 
prolonged effect on chondrocytes in old than in young animals. Since this is probably 
not due to decreased TGF-ß signaling as we have shown here, an explanation could 
be that old mice have a more active IL-1 signaling as well. Further studies will be 
necessary to determine if the balance is indeed shifted to the IL-1 side in old mice.
Experiments with intra-articular growth factor injections have identified a dualistic 
role for TGF-ß and BMP in the joint. On the one hand, TGF-ß and BMP are one of the 
most potent inducers of cartilage PG and collagen synthesis known and have 
therefore a strong therapeutic potential. On the other hand, they seemed to induce 
pathology such as fibrosis and osteophytes, reminiscent of OA pathology. Although 
suggestive, these experiments give no information about the function of naturally
110
su m m a r y  &  fin a l  re m a r k s
released growth factors during the OA process. To study the role of endogenously 
released TGF-ß during OA we followed the strategy of TGF-ß inhibition. In c h a p te r  4 
we describe the large scale expression, purification and characterization of the 
extracellular domain of the TGF-ß type II receptor (solRII) as produced by 
fermentation of the yeast Pichia pastoris. Purified solRII turned out to be 
approximately 95% pure and about a 1000 fold excess of solRII was necessary to 
fully block TGF-ß activity. The large quantities of solRII obtained via this procedure 
enabled us to study the role of endogenous TGF-ß in articular cartilage and 
osteophyte development during experimental OA as described in c h a p te r  5. In this 
study we demonstrated for the first time that endogenous TGF-ß is a crucial 
protective factor for articular cartilage because blocking of TGF-ß resulted in 
significant loss of articular cartilage PG content and even caused cartilage damage. 
On the other hand, in this chapter we also demonstrated for the first time that 
endogenous TGF-ß is the pivotal factor that induces osteophyte formation during 
experimental OA. We used papain as a model of OA in this study since OA features 
such as PG depletion of the cartilage and osteophyte formation are already present 
at day 7. Since we estimated that large quantities of solRII (10 mg/mouse) were 
necessary, the papain model, because of the rapid induction of OA features, seemed 
most suitable to study the natural role of TGF-ß during OA. However, it can be 
debated to what extend this model represents the physiological OA process. 
Therefore, similar studies in the joint instability OA model as induced by the injection 
of bacterial collagenase can be very useful to get a better understanding of the 
function of endogenous TGF-ß in other OA models. Since this model is based on a 
completely different process to induce OA pathology it can be assumed that TGF-ß 
levels and possibly also the function of TGF-ß is different in the collagenase-induced 
than in the papain-induced OA model. However, these studies will require large 
quantities of solRII since the induction of pathology in this model takes several 
weeks.
Although a powerful tool, the strategy of using solRII to study the function of 
endogenous TGF-ß also has serious drawbacks. Not only is the production of solRII 
very time-consuming, the production of solRII has to be performed in batch mode 
that could possibly introduce differences in experimental outcome. Needless to say, 
each batch was carefully examined regarding purity, protein concentration and TGF-ß 
blocking capacity before use in vivo. Furthermore, administration of solRII protein 
requires the implantation of mini osmotic pumps intra-peritonealy, a procedure that 
obviously does not contribute to the well-being of the mice.
Therefore, we pursued a different strategy to inhibit TGF-ß and BMP signaling; the 
use of adenoviruses. Adenoviruses are tools that enable us to efficiently overexpress 
different transgenes in different cell types in vitro and in vivo. In c h a p te r  6 we 
investigated if important chondrocyte responses to TGF-ß such as proliferation and 
PG synthesis can be differentially regulated by adenoviral overexpression of the 
intracellular TGF-ß and BMP inhibitors, Smad6 and Smad7. Although both Smad6 and 
Smad7 are originally described as TGF-ß antagonists, the current general conception 
is that Smad6 is preferentially a BMP antagonist, whereas Smad7 inhibits both TGF-ß 
and BMP activity. In our opinion published results are however contradictory and the 
experimental outcome certainly seems to depend on the cell type and TGF-ß
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response studied. Moreover, the negative regulation of various TGF-ß responses by 
these inhibitory signaling mediators has never been studied in chondrocytes. We 
identified Smad7 as a very powerful TGF-ß antagonist, totally blocking every TGF-ß 
response studied. On the other hand, Smad6 could significantly inhibit chondrocyte 
proliferation but this effect was only partial. Other TGF-ß responses seemed not to 
be regulated by Smad6. Since TGF-ß can induce the expression of BMPs, it is 
tempting to speculate that the effects observed for Smad6 are resulting from the 
inhibition of endogenous BMPs instead of blocking the TGF-ß added to the cells. This 
assumption would imply that in chondrocytes Smad6 acts as a BMP antagonist and 
Smad7 as a TGF-ß inhibitor.
We proceeded to apply adenoviral overexpression of growth factor inhibitors to study 
the role of endogenous TGF-ß and BMP during experimental OA. We used the 
extracellular pan-specific TGF-ß inhibitor mLAP1 and the intracellular TGF-ß 
antagonists Smad6 and -7 to block BMP and TGF-ß+BMP, respectively, during 
papain-induced OA as is described in c h a p te r  7. Because mLAP1 is a small 
secretory protein, not only TGF-ß activity in the synovial lining but also TGF-ß activity 
in articular cartilage can be targeted. On the other hand, since Smads are 
intracellular proteins only TGF-ß activity in the lining will be inhibited. The data 
obtained with overexpression of mLAP1 substantiated results from solRII 
experiments; endogenous TGF-ß is essential to protect articular cartilage from PG 
loss and damage, whereas endogenous TGF-ß is also a pivotal mediator that 
stimulates osteophyte formation. Overexpression of the TGF-ß/BMP inhibitor Smad7 
during experimental OA resulted in almost complete prevention of papain-induced 
synovial thickening and osteophyte formation, again stressing the importance of 
TGF-ß in these processes. Rather unexpectedly, overexpression of the preferential 
BMP antagonist Smad6, displayed essentially the same characteristics as Smad7 
treatment, pointing to an important role for BMPs in the process of synovial 
thickening and osteophyte development. Since Smad6 is not specific for BMP but also 
to some extend inhibits TGF-ß activity the role of endogenous BMP has to be further 
studied. A likely candidate to determine the role of endogenous BMP during OA is the 
specific BMP inhibitor noggin. Therefore, we generated an adenovirus expressing the 
murine form of noggin. Experiments with this specific BMP inhibitor are in progress 
during the writing of this chapter.
In conclusion, we identified that naturally released growth factors during the OA 
process are essential to protect articular cartilage from PG loss and damage. 
Together with the findings that exogenous addition of TGF-ß and BMP stimulate 
cartilage PG synthesis and increase PG content, these factors are of great therapeutic 
potential. However, studies with growth factor supplementation and the blocking 
studies described in this thesis clearly point out that TGF-ß and BMP are the main 
contributors to synovial hyperplasia and osteophyte development, thus limiting their 
therapeutic potential. So, for TGF-ß or BMP to be of real therapeutic use these 
factors will have to be targeted to the articular cartilage. We are currently pursuing 
the hypothesis that a TGF-ß/BMP unresponsive synovial lining, caused by adenoviral 
overexpression of Smad6 or Smad7, enables the targeting of growth factors 
specifically to the articular cartilage. This would fully reinstate the therapeutic 
potential of these growth factors.
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FIN A L R EM A R K S
This thesis provides information that TGF-ß during OA is necessary to protect 
cartilage from damage (The Good), whereas on the other hand it induces fibrosis 
(The Bad) and osteophyte formation (The Ugly). We further provide evidence that 
targeting of growth factors to the cartilage via the generation of a TGF-ß- 
unresponsive lining is feasable. This provides the foundation necessary to apply 
growth factor supplementation during OA as a therapeutic means to stimulate 
cartilage repair, although some hurdles have to be taken still.
First and foremost, TGF-ß has the uncanning characteristic of behaving differently 
depending on a large variety of parameters which are as diverse as the cell type, 
culture conditions or organ systems studied. Even in a single isolated cell type such 
as the chondrocyte, TGF-ß can act completely differently depending on e.g. the 
differentiation state of the cell or the concentration of TGF-ß used. Taken together: 
TGF-ß is a difficult cytokine to work with! Fortunately, not only TGF-ß itself, but also 
its receptors and intracellular mediators have been very highly conserved throughout 
evolution. Hopefully this makes the eventual extrapolation from mice studies to the 
human situation somewhat easier.
The OA-characteristics studied here, involve different cell types such as 
chondrocytes, fibroblasts and osteoblasts. It would be interesting to determine the 
dose-dependency of TGF-ß on the induction of each different OA-feature as induced 
by this variety of cells. Such knowledge would enable better dosage of growth 
factors and/or inhibitors during OA to optimally induce the cartilage repair process.
Then there is the problem that OA is unlikely to be caused by a single factor. Thus, 
most likely a large variety of different OA-types exists with e.g. a slowly progressive 
age-dependent variety on the one hand and a rapidly progressive sports injury- 
dependent variety on the other. It remains to be seen if TGF-ß (and BMPs) have 
similar roles in these types of OA as shown here in our enzymatically-induced form of 
OA. The outcome will certainly depend on the concentrations of growth factors 
released during the OA process.
Future research should therefore also focus on OA-models that are physiologically 
more relevant such as the STR/ort mouse, transaction of the ACL or naturally 
occuring OA in old mice. In order to study the function of growth factors in OA in 
these models however, tools have to be developed that enable us to express 
transgenes or deliver proteins for extended periods of time, since these OA- 
processes develop much slower than the induced OA-models.
Although these obstacles have to be overcome still, it is clear from this thesis that 
growth factors are a necessity for stimulating matrix synthesis, inhibiting matrix 
degradation and controlling the chondrocyte differentiation state. In short, growth 
factors such as TGF-ß and BMPs have the potential to provide the means to achieve 
normal cartilage homeostasis during OA.
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N ED ER LA N D SE SA M EN V A TTIN G
Osteoarthritis (OA) is de meest voorkomende gewrichtsziekte in de mens en 
sommige studies laten zelfs zien dat 70% van de mensen ouder dan 65 jaar 
kenmerken vertoont van OA. OA heeft als belangrijkste karakteristieken de afbraak 
van het articulaire kraakbeen, fibrose van de synoviale lining en de vorming van 
osteofyten. In de gewrichtsvloeistof van OA-patiënten zijn grote hoeveelheden 
groeifactoren zoals Transforming Growth Factor-ß (TGF-ß) en Bone Morphogenetic 
Proteins (BMPs) gevonden. Bovendien vertonen chondrocyten van OA-patiënten een 
verhoogde expressie van deze groeifactoren. Mede hierdoor wordt gedacht dat TGF- 
ß en BMPs een belangrijke rol spelen tijdens OA.
OA is in feite een langzaam voortschrijdende ziekte en is sterk leeftijds- 
afhankelijkheid. Onze hypothese was daarom dat in oude dieren de balans tussen 
katabole/anabole factoren op het kraakbeen verschoven was naar de katabole kant. 
Daarom hebben we in h o o fd s tu k  2 bestudeerd of er een verschil bestaat tussen 
jonge en oude dieren in de respons op het katabole cytokine Interleukine-1 (IL-1), 
de anabole groeifactor TGF-ß of de combinatie van de twee. Het bleek dat jonge en 
oude dieren feitelijk geen verschillen laten zien in de effecten van IL-1 en TGF-ß 
apart. Echter, oude dieren bleken niet meer in staat om de katabole effecten van IL- 
1 op proteoglycaan (PG) synthese en nitriet oxide (NO) productie te blokkeren door 
middel van TGF-ß zoals het geval was in jonge muizen. Dit betekend dat hierdoor de 
balans tussen IL-1/TGF-ß zal doorslaan naar de katabole kant. Op deze manier kan 
zowel het langzaam voortschrijdende karakter en de sterke leeftijdsafhankelijkheid 
van OA verklaard worden.
De interessante bevinding dat oude dieren IL-1 effecten niet meer kunnen 
blokkerend door middel van TGF-ß is verder uitgediept in h o o fd s tu k  3. In dit 
hoofdstuk was onze hypothese dat dit fenomeen veroorzaakt werd door een 
verstoorde TGF-ß signalering dat leidt tot een verminderd actieve TGF-ß signaal 
transduktie. De expressie van belangrijke TGF-ß signaleringsmediatoren in jonge en 
oude muizen en het effect van IL-1 hierop is bestudeerd. Enerzijds is de activerende 
zijde van de signaalstransduktie bestudeerd zoals TGF-ß receptoren I en II en de 
activerende Smads2, -3 en -4. Bovendien is ook de inhiberende kant van de TGF-ß 
signaalstransduktie in kaart gebracht door middel van het bestuderen van de 
expressieprofielen van Smad6 en -7. De uitkomst van deze studie was verrassend 
omdat oude dieren meer TGF-ß receptoren en minder inhiberende Smads tot 
expressie brengen. Alhoewel de expressie van Smad4 niet significant veranderd was 
door leeftijd of IL-1 behandeling werd wel een 50% afname gevonden na IL-1 
behandeling in oude dieren. Het gebruik van grotere groepen muizen zou de rol van 
Smad4 duidelijk kunnen maken, echter vanwege de zeldzaamheid van oude dieren 
waren we hierin beperkt. Dus in plaats van een minder actieve TGF-ß 
signaaloverdracht lijken oude muizen juist een actievere signaaloverdracht te 
hebben. Concluderend kan gesteld worden dat het verlies van TGF-ß blokkering van 
IL-1 effecten niet verklaart kan worden door een verminderd actieve TGF-ß 
signaalstransduktie in oude dieren.
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De injectie van groeifactoren in het kniegewricht van muizen hebben een dualistische 
rol van deze groeifactoren duidelijk gemaakt. Aan de ene kant blijken TGF-ß en BMPs 
erg potent in het induceren van de PG en collageen synthese. Anderzijds induceren 
ze pathologie zoals fibrose en osteofyten die vergelijkbaar is met OA pathologie. Een 
sterke relatie van TGF-ß en BMPs met OA is hiermee aangetoond. Echter het is 
volstrekt onbekend wat de rol is van natuurlijk voorkomend TGF-ß en BMP tijdens 
OA. Om deze natuurlijke rol te bestuderen zijn potente en specifieke remmers van 
deze factoren noodzakelijk. In h o o fd s tu k  4 beschrijven we de expressie, 
opzuivering en karakterisatie van een van deze remmers: het recombinante 
oplosbare type II receptor eiwit (solRII) zoals gemaakt op grote schaal door 
fermentatie van de gist Pichia pastoris. Het opgezuiverde solRII bleek ongeveer 95% 
zuiver te zijn en een duizend keer overmaat solRII was nodig om TGF-ß effecten 
volledig te blokkeren. Door de grote hoeveelheden solRII die op deze wijze 
verkregen zijn waren we in staat om het natuurlijk vrijkomende TGF-ß tijdens 
experimentele OA te blokkeren zoals beschreven is in h o o fd s tu k  5. In deze studie 
tonen we voor de eerste keer aan dat het natuurlijk vrijgekomen TGF-ß tijdens OA 
essentieel is om PG verlies en kraakbeenschade te voorkomen en dat endogeen TGF- 
ß dus een beschermende rol heeft op het kraakbeen. Bovendien tonen we hier voor 
het eerst aan dat endogeen TGF-ß tijdens experimentele OA een zeer belangrijke 
factor is die osteofyten induceert en dus dat TGF-ß betrokken is bij het veroorzaken 
van OA pathologie.
Ondanks dat het toedienen van solRII eiwit een krachtige manier is om TGF-ß 
activiteit te blokkeren kleven er een aantal belangrijke nadelen aan deze strategie. 
Ten eerste is de productie van solRII erg tijdsintensief en wordt gedaan in batches 
dat kan leiden tot verschillen in experimentele resultaten. Bovendien is voor het 
toedienen van solRII de implantatie van osmotische pompjes noodzakelijk wat 
vanzelfsprekend niet ten goede komt aan de gezondheid van de muizen.
Daarom hebben we in h o o fd s tu k  6 een andere strategie gevolgd, namelijk het 
gebruik van adenovirussen. Door middel van adenovirussen zijn we instaat heel 
efficiënt verschillende transgenen tot overexpressie te brengen in verschillende 
celtypen, zowel in vitro als in vivo. In dit hoofdstuk hebben we onderzocht of 
belangrijke effecten van TGF-ß op chondrocyten, zoals de stimulatie van PG synthese 
en proliferatie, gereguleerd kunnen worden door overexpressie van Smad6 en 
Smad7. Alhoewel, Smad6 oorspronkelijk beschreven is als een TGF-ß remmer, 
beschrijft recentere literatuur Smad6 steeds meer als specifieke BMP remmer. In 
onze opinie zijn de gepubliceerde resultaten op zijn minst controversieel en hangt de 
uitkomst van de experimenten zeker af van het bestudeerde celtype en respons. 
Bovendien is de regulatie van TGF-ß door deze remmers nog nooit onderzocht in 
chondrocyten. Onze resultaten laten zien dat Smad7 erg potent is in het remmen van 
een variëteit van TGF-ß responsen. Contrasterend, Smad6 liet allen een partieel 
effect zien op chondrocyte proliferatie, terwijl andere responsen niet gereguleerd 
werden door Smad6. Aangezien TGF-ß de expressie van BMPs kan induceren is het 
mogelijk dat het effect van Smad6 op proliferatie komt door de indirecte remming 
van BMPs in plaats van directe remming van TGF-ß effecten. Dit zou beteken dat in 
chondrocyten Smad6 een BMP remmer is terwijl Smad7 een TGF-ß antagonist is.
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Vervolgens hebben we de strategie van adenovirale overexpressie van groeifactor 
remmers toegepast tijdens experimentele OA zoals beschreven in h o o fd s tu k  7. De 
oplosbare TGF-ß remmer mLAP1 maakt het mogelijk om TGF-ß activiteit in het 
synovium en het articulaire kraakbeen te remmen. De intracellulaire remmers Smad6 
(BMP) en Smad7 (TGF-ß/BMP) maken alleen remming van TGF-ß/BMP in het 
synovium mogelijk. De resultaten van mLAP1 versterken de data verkregen met de 
solRII; TGF-ß is essentieel voor bescherming van het kraakbeen tegen PG verlies 
terwijl endogeen TGF-ß ook verantwoordelijk is voor OA-gemedieerde fibrose en 
osteofytvorming. Smad7 overexpressie resulteerde in een bijna volledige blokkering 
van de osteofytvorming en fibrose geïnduceerd door de injectie van het papaine. Een 
onverwachte uitkomst was dat overexpressie van Smad6 grotendeels tot hetzelfde 
resultaat leidde, wat duidt op een cruciale rol van BMPs in de processen van 
osteofytvorming en fibrose. Omdat niet uitgesloten is dat Smad6 ook TGF-ß activiteit 
remt moet de rol van endogeen BMP nader onderzocht worden met behulp van 
specifieke BMP remmers zoals Noggin. Een adenovirus coderend voor Noggin is 
ontworpen en ontwikkeld door ons en experimenten om de endogene rol van BMPs 
tijdens experimentele OA aan te tonen zijn momenteel onderweg.
Concluderend kan gesteld worden dat endogene groeifactoren geproduceerd tijdens 
experimentele OA essentieel zijn om het kraakbeen te beschermen tegen PG verlies 
en schade. Bovendien leidt het injecteren van deze groeifactoren tot een verhoogde 
synthese van PGs en collagenen in het kraakbeen. Hierdoor zijn TGF-ß and BMPs van 
grote therapeutische waarde. Echter, tegelijkertijd zijn deze endogene groeifactoren 
verantwoordelijk voor de inductie van OA pathologie zoals fibrose en osteofytvorming 
wat de therapeutische waarde sterk beperkt. Om TGF-ß en BMP als medicijn toe te 
kunnen passen moeten de groeifactoren specifiek naar het kraakbeen getargeted 
worden. Momenteel proberen we aan te tonen dat door het ongevoelig maken van 
de synoviale lining voor TGF-ß, door middel van adenovirale overexpressie van 
Smad7, het mogelijk wordt TGF-ß/BMP naar het kraakbeen te "geleiden" wat de 
therapeutische waarde van deze groeifactoren herstelt.
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DAN KW OORD
En dan nu het belangrijkste stukje van het proefschrift wat dan ook meestal als 
eerste gelezen wordt: het dankwoord. Het werk dat beschreven staat in de hier 
voorafgaande bladzijden is zeker niet alleen mijn werk, maar in tegendeel, het werk 
van velen en die wil ik hier graag bedanken. Dit is misschien ook de juiste plek om 
mijn diepste verontschuldiging aan te bieden aan iedereen die in de loop van mijn 
Lab Reuma carriere de dupe is geworden van onbezonnen acties van mijn kant die 
resulteerden in het zeer nat worden door het onrechtmatig gebruik van spuitflessen, 
blauwe plekken door (te hard) gooien met waterflesjes, hartverzakkingen door 
booby-traps met droog-ijs bommen, irritaties door het pesten met propjes en 
ijsblokjes en waarschijnlijk nog heeeel veel meer. Sorrie.
Op de eerste plaats wil ik Peter bedanken. Alhoewel het ontwerpen van de "tools" 
heel wat meer tijd vergde dan we zelf hadden ingeschat hebben we de schade in de 
laatste twee jaar denk ik behoorlijk ingehaald. De manier waarop jij een 
onderzoekslijn kan handhaven zonder daarbij de inbreng van anderen te beknotten 
verdient bewondering. Ook de bijzonder snelle wijze (vaak dezelfde dag) waarop jij 
mijn abstracts en manuscripten corrigeerde heb ik erg gewaardeerd, het hield de 
vaart er goed in. Ik heb veel van je geleerd en heb onze samenwerking als bijzonder 
prettig ervaren en hoop dat dat wederzijds is.
Verder wil ik natuurlijk Wim bedanken. Ondanks weinig tijd zag je altijd kans om 
mijn manuscripten te voorzien van een kort en krachtig commentaar dat altijd erg 
nuttig bleek. Jouw objectieve en kritische blik dwong mij goed na te denken over de 
uit te dragen boodschap en daardoor kregen de manuscripten net dat beetje extra.
En vooral ook Elly, mijn charmante assistente. Ik had het geluk dat ik vanaf dag 1 
met jou mocht samenwerken. Overmoeibaar heb je run na run met die stinkende 
"pruttelpot" afgewerkt, eiwit opgezuiverd, dedialyseerd en geconcentreerd, blotjes 
gedraaid, ge-PCR-ed, histologie gesneden en geplakt en nog veel, heel veel meer. 
Onmisbaar was je ook bij het inzetten van de dierexperimenten waarvoor we al dat 
kostbare "tattie" hadden opgezuiverd. Door jou gingen de experimenten gewoon 
door zodat ik me volledig kon wijden aan het schrijven. Maar vooral ook buiten het 
werk heb ik jouw vriendschap erg op prijs gesteld. Elly, heel erg bedankt en ik zal je 
missen.
Henk jij was er altijd om bij de opzet van de dierexperimenten nog eens even de 
puntjes op de i te zetten en kritisch naar de resultaten te kijken. Zo geduldig als jij 
zijn er maar weinig met histologie. Maar ook de diepgaande, of juist niet diepgaande, 
discussies gevoerd tijdens de borrels zal ik missen.
Mijn ex-roomies, Arjen en Karin. Behalve dat het erg gezellig is konden we op onze 
kamer lekker zaniken over het ons aangedane leed tijdens het aio-schap. Het luchtte 
toch altijd weer lekker op.
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Ik zal het vrijdagmiddag-lunchen met de dames missen (broodje kroket anyone?). 
Miranda, Esmeralda, Fieke, Marije, Marleen en Karin bedankt voor de gezelligheid, de 
roddels en vriendschap.
Niet te vergeten, de Die-hard kern die zich vormde tijdens de borrels en dagjes-uit. 
Vaak een wisselende samenstelling maar altijd erg gezellig tot vaak in de late 
uurtjes. Arjen & Astrid, Henk, Liduine, Elly, Andrew, Ruben en later Fieke en verder 
iedereen die zich verder verbonden voelt tot de die-hard clan: dank je wel, ik heb me 
kostelijk vermaakt.
De oude rotten in het vak met wie ik congressen over de hele wereld heb mogen 
bezoeken (een van de voorrechten van de wetenschap). Wim, PL en PK, Leo, Fons, 
Henk en Erik. Het was leuk, altijd leerzaam en zeker een voorrecht om met jullie op 
stap te mogen.
Ook mijn studenten, Robin, Joost en Rob, wil ik bedanken voor hun inzet. Ik ben blij 
dat jullie alle drie verder zijn gegaan in de wetenschap en hoop dat ik daar iets mee 
van doen had.
De mensen van het dierenlab bedank ik voor hun hulp tijdens het uitvoeren van de 
dierexperimenten.
En in volstrekt willekeurig volgorde alle andere (ex-) collega's van Lab Reuma die 
hun steentje hebben bijgedragen aan dit proefschrift. Het lab is ondertussen te groot 
om iedereen persoonlijk te noemen maar jullie inzet, collegialiteit en vriendschap is 
enorm gewaardeerd. Marianne, Onno, Alfons, Brigit, Moniek, Annet, Nozomi, Tim, 
Audrey, Twan, Mieke, Reinout, Muriël, Joyce, Esther, Natasja en wie ik vergeten 
mocht zijn allemaal bedankt.
Mijn ouders dank ik voor hun rotsvaste geloof in mijn kunnen en hun liefde. Het gaf 
me het zelfvertrouwen, nodig om te worden wie ik nu ben.
Mijn "schoonouders", vrienden en familie voor hun steun, vriendschap en wijze raad. 
En natuurlijk Heleen. Zonder jou ... niets.
Alwin
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1998 tot december 2002 is hij werkzaam geweest als AIO op wat toen lab reuma 
heette maar nu ondertussen geëvolueerd is tot Experimental Rheumatology and 
Advanced Therapeutics. Vervolgens is hij in 2003 ook op deze afdeling werkzaam 
geweest als junioronderzoeker. De resultaten van het onderzoek gedaan tijdens deze 
periodes staan beschreven in dit proefschrift. Tijdens deze aanstelling(en) heeft hij 
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FIGURE 1. E x p r e s s io n  o f  TGF-ß signaling  m ediato rs in a r ticu la r  c a r t ila g e . R ep r es e n t a t iv e
IMMUNOHISTOCHEMICAL PICTURES OF THE VARIOUS SIGNALING MEDIATORS ARE SHOWN. WHERE 
APPROPRIATE, DIFFERENCES IN EXPRESSION LEVELS BETWEEN YOUNG/OLD OR -IL-1/+IL-1 ARE SHOWN.
Right knee jo in ts  o f young (3 months, n=14) and o ld  (2 y e a rs , n=14) mice w ere  in jected  w ith IL-1 
(10 NG/ML) AND LEFT KNEE JOINTS SERVED AS INTERNAL CONTROLS. 24 HOURS LATER KNEE JOINTS WERE 
ISOLATED AND PREPARED FOR HISTOLOGY. VARIOUS TGF-ß SIGNALING MEDIATORS WERE DETECTED VIA 
IMMUNOHISTOCHEMISTRY ON TOTAL KNEE JOINT SECTIONS. A) TGF-ß-RI, YOUNG MOUSE, WITH IL-1. B) 
TGF-ß -RI, OLD MOUSE, WITH IL-1. C ) TGF-ß-RII, YOUNG MOUSE, WITH IL-1. D) TGF-ß-RII, OLD MOUSE, NO 
IL-1. E) Smad2, o ld  mouse, with IL-1. F) Smad3, young mouse, no IL-1. g ) Smad4, o ld  mouse, no IL- 
1. H) Smad4, o ld  mouse, with IL-1. I) Smad4, young mouse, with IL-1. J )  Smad6, o ld  mouse, with IL- 
1. k ) SMAD7, YOUNG MOUSE, NO IL-1. L) SMAD7, OLD MOUSE, NO IL-1. ORIGINAL MAGNIFICATION 200X.
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FIGURE 1 Im m u n o h is t o c h em is t r y  o f  T G F-ß  is o f o r m s  o f  n o rm a l  a n d  pa pa in - in j e c t e d  k n e e  jo in t s
(DAY 7). R ig h t  KNEE JOINTS WERE INJECTED WITH PAPAIN SOLUTION. THE NON-INJECTED LEFT KNEE JOINTS 
SEVERED AS INTERNAL CONTROLS. T G F-ß  EXPRESSION IN PERIOSTEUM A-D AND CARTILAGE E-H. TG F-ß1  
e x p r e s s io n  in n o rm a l KNEE jo in t  A) AND AFTER PAPAIN INJECTION B). T G F-ß 3  e x p r e s s io n  in n o rm a l 
KNEE JOINT C ) AND AFTER PAPAIN INJECTION D). TG F-ß1 EXPRESSION IN LEFT KNEE JOINT. E) AND AFTER
papain  in jec t io n  F). T G F-ß 3  e x p r e s s io n  in l e f t  k n e e  jo in t  G ) an d  a f t e r  papain  in jec t io n  H). 
Ne g a t iv e  c o n t r o l  o f  non- in j e c t e d  l e f t  k n e e  jo in t  I) an d  o f  papain  in j e c t e d  jo in t  J). A r r o w h e a d  
p o in t s  t o  s y n o v ia l  l a y e r ; a r r o w  in d ic a t e s  p e r io s t e u m , b r o a d  a r r o w s  po in t  t o  TG F-ß1 p o s it iv e  
c e l l s , j s  = jo in t  s p a c e .
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Colo ur  f ig u r eb elo n g in g  to Ch a pter  6
FIGURE 2. Im m unocytochem ical lo c a liz a t io n  o f  Smad6 and Smad7 a f t e r  a d e n o v ira l  
o v e re x p re ss io n . H1 c h o n d ro c y te s  w e re  c u lt u r e d  in Lab-Tek Il cham ber s l id e s  a t  2 1 0 5 
c e l ls / w e l l .  The next day, c e l l s  w e re  t r a n s f e c t e d  w ith  MOl 10 w ith A d-Luc, Ad-Sm ad6 o r  Ad- 
Smad7 o r  w e re  m ock t r a n s f e c te d . The next day, I-Smad o v e re x p re ss io n  w a s stud ied  using anti-  
Smad6 - o r  anti-Sm ad7 Ab fo llo w e d  by incubation w ith th e  a p p ro p ria te  b io tin -lab eled  se c o n d a ry  
Ab. Ad-Sm ad6 A  and C) and Ad-Smad7 B  and D) t r a n s f e c t e d  c h o n d ro c y te s  incubated  w ith anti- 
Smad6 o r  anti-Sm ad7 Ab, re s p e c t iv e ly . N ote, in ten se  sta in in g  o f  cy to p lasm  and p e r in u c le a r  
sta in in g  o f  th e  n u c le u s . S ta in ing  is a b se n t from  cy to p la sm ic  v e s ic le s  and c e r ta in  re g io n s  o f  th e  
n u c le u s . E ) Ad-Sm ad6 t r a n s f e c t e d  c h o n d ro c y te s  incubated  w ith anti-Sm ad7 Ab. L it t le  Smad7 
sta in in g  is o b se rve d . F) Ad-Smad7 t r a n s f e c t e d  c h o n d ro c y te s  incubated  w ith anti-Sm ad6 Ab. 
Fe w  positive  c e l l s  a r e  sta in ed . A d-Lu c t r a n s f e c t e d  c h o n d ro c y te s  incubated  w ith anti-Sm ad6 G) 
o r  anti-Sm ad7 Ab H). O n ly  fa in t sta in in g  is v is ib le .
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FIGURE 1. Im m u n o h is t o c h em is t r y  o f  BMP-2, -4 AND -6 is o f o r m s  o f  n o rm a l an d  pa pa in -in je c t e d
KNEE JOINTS (DAY 3). RIGHT KNEE JOINTS WERE INJECTED WITH PAPAIN SOLUTION AND NON-INJECTED LEFT 
KNEE JOINTS SEVERED AS INTERNAL CONTROLS. A) BMP-2 EXPRESSION IN CARTILAGE AND B) SYNOVIUM
d u rin g  p a pa in -in d u c ed  OA. C) BMP-4 e x p r e s s io n  in c a r t il a g e  an d  D) syn o viu m  d u r in g  pa pa in - 
in d u c ed  OA. E) BMP-2 e x p r e s s io n  in c a r t il a g e  o f  n o rm a l  k n e e  jo in t . F) BM P-4 e x p r e s s io n  in 
syn o viu m  o f  n o rm a l  k n e e  jo in t  (syn o viu m  b e t w e e n  a r r o w s ). G) BMP-6 e x p r e s s io n  in c a r t il a g e  
an d  H) syn o viu m  d u rin g  pa pa in -in d u c ed  OA. I) BM P-6 e x p r e s s io n  in c a r t il a g e  o f  n o rm a l k n e e  
jo in t . J) Ne g a t iv e  c o n t r o l  o f  O A  k n e e  jo in t . c  = c a r t il a g e , m = m e n is c u s , j s  = jo in t  s p a c e , s  =
SYNOVIUM, BM = BONE MARROW AND B = BONE. ARROWS POINT TO POSITIVE CHONDROCYTES FOR BMP-2
an d  -4 . A r r o w h e a d s  po in t  to  p o s it iv e  h y p e r t r o p h ic  c h o n d r o c y t e s  f o r  BMP-6. O r ig in a l 
m a g n ifica tio n  250 x .
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